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ABSTRACT 
Primary human hepatocytes (PHHs) are currently considered the “gold standard” 
cell model for investigating the liver physiology, toxicity, and lipid homeostasis. 
However, PHHs are scarce and functionally heterogeneous, and when cultured, they 
lose their liver-specific functions relatively fast within a few days. Induced 
pluripotent stem cell-derived hepatocyte-like cells (iPSC-HLCs) provide a relevant 
alternative model for PHHs to study the lipid derangements of the liver. Unlike 
PHHs, the cell source to generate iPSC-HLCs is unlimited and they can be 
advantageously generated from selected individuals with different genetic 
backgrounds. Since lipid defects play central roles in the pathogenesis of several 
common diseases such as non-alcoholic fatty liver disease and atherosclerotic 
cardiovascular disease, iPSC-HLCs could serve as a novel platform for studying the 
basic mechanisms of the lipid metabolism and its dysregulation in a truly patient-
specific manner. Additionally, this cell model could be utilised in drug discovery and 
especially in studying the drug induced hepatotoxicity. To maximise the utilisation 
of HLCs for such valuable purpose, it is critical to characterise their detailed lipid 
profile in relation to the human adult liver cells. 
Lipids are a major class of molecules, which play critical roles in cellular structure, 
function, and signalling. It has been shown that certain fatty acids (FAs) promote 
neuronal and adipocyte differentiation. Therefore, in-depth knowledge of changes 
in lipid and FA profile of the hepatocytes during differentiation and de-
differentiation could assist us to generate matured target cells, which resemble the 
lipid profile of PHHs even closer. In addition, this knowledge can be utilised to 
optimise the culture environment according to the cellular need and subsequently 
prolong the life span and functionality of both the iPSC-HLCs and the PHHs in 
culture.  
Major aims of this thesis were to first study the alterations in the lipid and FA 
profile of the cells during the hepatic differentiation in order to identify the lipid 
species that may play important roles in the differentiation and maturation of 
hepatocytes. For this purpose, detailed lipidomic analysis and gene expression 
profiling of a set of key genes involved in the metabolism of lipids were performed 
at several time points during the entire differentiation process from iPSC to HLCs. 
x 
The second aim was to comprehensively characterise the lipid and FA profile of 
HLCs against current standard hepatic cell models. HLCs were generated by five 
different methods and their lipid profile as well as their ability to synthesise, elongate, 
and desaturate FAs were thoroughly assessed and compared to the profiles of widely 
used hepatocyte models, PHHs and HepG2 cells. In addition, the effect of various 
conditions or stimuli introduced by each method were evaluated on HLCs’ 
phenotype and functionality. The third aim focussed on the mechanisms behind the 
hepatic de-differentiation by studying the alterations in the lipid profile of the PHHs 
during their prolonged two-dimensional (2D) culture. In addition, we complemented 
our results from lipidomics with miRNA analysis to further identify the differentially 
expressed miRNAs that may regulate changes in the lipid profile of PHHs during 
the process of de-differentiation.  
Taken together, our findings illustrate that HLCs differentiated from iPSCs 
provide a relevant and functional cell model to explore human lipid homeostasis at 
both cellular and molecular levels. Additionally, this thesis provides novel findings 
on the possible role of lipids, FAs, and miRNAs in the process of differentiation 
and/or de-differentiation and may be applied in designing culture environments that 
would improve the maturity of HLCs. Since hepatocytes in 2D culture lose their 
metabolic competence and viability relatively fast, this thesis offers some new ideas 
and strategies to improve the culture systems for maintaining hepatocytes in long-
term culture.  
 
xi 
 
TIIVISTELMÄ 
Ihmisen maksasta eristettyjä soluja (PHH) pidetään ns. ”kultaisena standardina” 
maksan fysiologian, toksisuuden ja lipidien homeostaasin tutkimiseksi. Nämä solut 
ovat vaikeasti saatavia sekä toiminnoiltaan heterogeenisiä ja viljeltynä menettävät 
maksalle spesifit toiminnot suhteellisen nopeasti jo muutamassa päivässä. Uudelleen 
ohjelmoiduista kantasoluista (iPS-solut) tuotetut maksasolujen kaltaiset solut (HLC) 
tarjoavat vaihtoehtoisen mallin maksan normaalin ja poikkeavan rasva-
aineenvaihdunnan tutkimiseksi. Näiden kantasoluista tuotettujen maksasolujen 
etuna on rajoittamaton saatavuus sekä mahdollisuus tuottaa niitä eri geenitaustan 
omaavien yksilöiden soluista. Koska rasva-aineenvaihdunnan häiriöillä on keskeinen 
rooli monien yleisten tautien kuten ei-alkoholiperäisen rasvamaksan sekä 
ateroskleroottisen sydän- ja verisuonitaudin patogeneesissä, kantasoluista tuotetut 
maksasolut tarjoavat uuden potilasspesifisen keinon rasva-aineenvaihdunnan ja sen 
häiriöiden perusmekanismien tutkimiseksi. Lisäksi tätä solumallia on mahdollista 
hyödyntää lääkekehityksessä ja erityisesti lääkkeiden aiheuttaman maksatoksisuuden 
tutkimisessa. Jotta näitä maksasoluja voidaan hyödyntää maksimaalisesti, on tärkeää 
selvittää niiden yksityiskohtainen lipidiprofiili ja verrata sitä ihmisen maksasta 
eristettyihin soluihin. 
Rasvat ovat merkittävä molekyyliluokka, ja niillä on tärkeä tehtävä solun 
rakenteessa, toiminnassa ja signaloinnissa. On myös osoitettu, että tietyt rasvahapot 
edistävät hermo- ja rasvasolujen erilaistumista. Siksi maksasolujen lipidi- ja 
rasvahappoprofiilien muutoksien syvällinen tuntemus sekä erilaistumisen 
(differentiaation) että spesifisten ominaisuuksien vähenemisen (dedifferentiaation) 
aikana auttaisi meitä tuottamaan kantasoluista kypsiä maksasoluja, joiden lipidiprofiili 
muistuttaisi maksasta eristettyjen solujen lipidiprofiilia entistä paremmin. Lisäksi 
tämän tiedon avulla viljely-ympäristö voitaisiin optimoida solujen tarpeiden 
mukaiseksi ja sen seurauksena pidentää niiden elinkaarta ja funktionaalisuutta. 
Tämän väitöskirjatyön päätavoitteina oli ensin tutkia lipidi- ja 
rasvahappoprofiilien muutoksia maksasolujen erilaistumisen aikana ja pyrkiä 
tunnistamaan tässä erilaistumisessa ja kypsymisessä tärkeitä lipidejä. Tätä tarkoitusta 
varten tehtiin yksityiskohtainen lipidomiikka-analyysi ja rasva-aineenvaihduntaan 
osallistuvien avaingeenien ilmentymisen profilointi useina eri ajankohtina 
xii 
erilaistumisprosessin aikana. Toinen tavoite oli kuvata kattavasti kantasoluista 
tuotettujen maksasolujen lipidi- ja rasvahappoprofiili ja verrata sitä tämänhetkisiin 
standardimaksasolumalleihin. Maksasolujen tuottamiseen iPS-soluista käytettiin 
viittä eri menetelmää ja näiden maksasolujen lipidiprofiili samoin kuin niiden kyky 
syntetisoida ja prosessoida rasvahappoja tutkittiin perusteellisesti ja verrattiin laajasti 
käytettyihin maksasolumalleihin. Lisäksi tarkasteltiin kunkin menetelmän avulla 
tuotettujen erilaisten kasvatusolosuhteiden vaikutusta solujen ilmiasuun sekä 
toiminnallisuuteen. Kolmas tavoite keskittyi maksasolujen dedifferentiaation, eli 
soluviljelmissä tapahtuvan maksasoluominaisuuksien menettämisen, taustalla olevien 
mekanismien tutkimiseen seuraamalla ihmisen maksasta eristettyjen solujen 
lipidiprofiilin muutoksia soluviljelyn aikana. Lipidomiikka-analyysista saatuja tuloksia 
täydennettiin mikroRNA-analyysillä, jotta voitiin tunnistaa eri tavoin ilmentyneet 
mikroRNA:t, jotka voisivat säädellä tuota prosessia. 
Yhteenvetona voidaan todeta, että iPS-soluista tuotetut maksasolut tarjoavat 
asianmukaisen ja toimivan solumallin ihmisen rasva-aineenvaihdunnan tutkimiseksi 
sekä solu- että molekyylitasolla. Lisäksi tämä tutkimus tarjoaa uusia havaintoja 
lipidien, rasvahappojen ja mikroRNA:n mahdollisesta roolista differentiaatio- ja/tai 
dedifferentiaatioprosessissa, joita voidaan soveltaa kantasoluista tuotettujen 
maksasolujen kypsymistä parantavien viljely-ympäristöjen suunnittelussa. Koska 
maksasolut menettävät soluviljelmissä merkittäviä metabolisia toimintojaan 
suhteellisen nopeasti, tämä tutkimus tarjoaa uusia ideoita ja strategioita 
kasvatusjärjestelmien parantamiseksi maksasolujen pitämiseksi toiminnallisina 
pitkäaikaisissakin soluviljelmissä. 
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1 INTODUCTION 
Liver is the main metabolic and synthetic organ, which regulates many critical 
physiological functions in the human body. Approximately 70% of the liver mass is 
composed of hepatocytes (Blouin et al., 1977), which carry out most of the metabolic 
functions of the liver such as detoxification of a wide variety of molecules, synthesis 
of plasma proteins, regulation of amino acids and carbohydrates, and activation of 
inflammatory and immune responses (Si-Tayeb et al., 2010a). In addition, 
hepatocytes control the energy/fuel homeostasis by regulating the synthesis of 
glucose/glycogen and fatty acids (FAs). Moreover, hepatocytes are the major cells 
for synthesis of many lipids including cholesterol, cholesteryl esters (CEs), 
triacylglycerols (TAGs) and phospholipids (PLs), which are further utilized by 
hepatocytes to assemble and secrete lipoprotein particles to the general circulation 
(Godoy et al., 2013; Gordillo et al., 2015). 
The use of primary hepatocytes as the “gold standard” model system to study the 
liver physiology and drug-induced liver injury has escalated in recent years. However, 
since primary human hepatocytes (PHHs) are obtained from organ donors, they are 
scarce and functionally variable due to genetic variation of the donors. In addition, 
when PHHs are isolated and cultured, they progressively lose their liver-specific 
functions (Elaut et al., 2006; Godoy et al., 2013), which dramatically limits their utility 
especially in the long-term toxicity studies. Due to these limitations, other cell models 
such as human hepatoma cell lines (e.g. HepG2) have been widely used since they 
demonstrate unlimited life span and stable phenotype. However, the key 
morphological and metabolic features are often repressed or absent in hepatoma cell 
lines and they may typically represent a cancer metabolic profile. Therefore, they do 
not faithfully represent the metabolic activities of healthy hepatic cells (Olsavsky et 
al., 2007; Steenbergen et al., 2018). Animal models have also abundantly been used, 
but information gained from animal primary hepatocytes is not fully translatable to 
humans due to significant interspecies variations e.g. in their physiology, gene 
expression profile, lipoprotein distribution and drug metabolism (Kvilekval et al., 
1994; Uhl and Warner, 2015). 
22 
The invention of human induced pluripotent stem cells (hiPSCs) have opened 
new avenues for the research in the field of regenerative medicine (Takahashi et al., 
2007). hiPSCs can be easily reprogrammed from somatic cells, and then 
differentiated into hepatocyte-like cells (HLCs) that functionally resemble PHHs 
(Hu and Li, 2015). Therefore, hiPSC-derived HLCs (iPSC-HLCs) provide a good 
alternative for PHHs as they also circumvent the limited availability of the cells faced 
when working with the PHHs. hiPSC-HLCs could highly benefit us in understanding 
the molecular basis of liver cell differentiation, disease mechanisms, modelling 
inborn errors of hepatic metabolism, and in drug discovery and studying the 
hepatocellular toxicity effects as well as in developing personalised medicine.  
Lipids, as a major class of biological molecules, play critical roles in energy 
storage, structure, function, and signalling (Van Meer et al., 2008). Lipids are the key 
components in plasma and nuclear membrane, endoplasmic reticulum (ER), Golgi 
apparatus, and trafficking vesicles such as endosomes and lysosomes (Muro et al., 
2014). Lipoproteins in circulation are vehicles operating the transfer of lipids 
between the organs and peripheral cells.   
In addition, lipid defects have central role in the pathogenesis of many diseases, 
such as atherosclerotic cardiovascular disease (Meikle et al., 2011; Stübiger et al., 
2012) and non-alcoholic fatty liver disease (Ruhanen et al., 2017; Younossi et al., 
2016), and hiPSC-HLCs offer a relevant platform to investigate the basic 
mechanisms of lipid metabolism and its dysregulation in a patient-specific manner. 
In order to maximise the utilisation of HLCs as a cell model, it is essential to know 
their lipid profile in relation to their native counterparts and the currently used cell 
models, such as PHHs and hepatoma cell lines. Until recently, studying the lipids in 
molecular levels was dramatically hampered due to their complexity and lack of 
suitable analytical technology. However, by the emergence of the advanced lipidomic 
technologies together with the recent cutting-edge computational techniques, today 
it is possible to study the complex cellular lipidome, making this field a promising 
area for biomedical research. The lipidomic data can be further combined with 
genotype/phenotype information on the individual level.  
The main objectives of this dissertation were to generate a functional patient-
specific hepatic cell model suitable for investigating human lipid homeostasis, to 
characterise the lipid and FA profile of generated hepatocytes comprehensively in 
comparison to their native counterparts, and to investigate the role of various 
molecular lipid species and FAs both in the differentiation and in de-differentiation 
of hepatic cells.  
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2 LITERATURE REVIEW 
2.1 Human liver 
Liver is the largest metabolic organ in the human body and regulates more than 500 
various functions including the synthesis and storage of lipids, amino acids, proteins, 
and vitamins as well as the detoxification of a wide variety of molecules (Si-Tayeb et 
al., 2010a) (Gordillo et al., 2015). In addition, liver is responsible for the synthesis 
and transport of cholesterol and triglycerides, the metabolism of urea, and the 
production and secretion of bile. Hepatocytes are the main cell type in the liver and 
are responsible for most of its physiological function (Blouin et al., 1977). The liver 
is traditionally structured in highly organised functional units called lobules which in 
addition to hepatocytes contain many other cell types such as cholangiocytes, 
endothelial cells, pit cells, Kuppfer cells, and stellate cells (Ishibashi et al., 2009; Si-
Tayeb et al., 2010b) (Figure 1). In the lobules, blood from the portal vein and hepatic 
artery flows toward the central vein through sinusoids. On the other hand, the bile 
acid secreted by the hepatocytes flows in the opposite direction than the blood and 
towards the bile ducts (Godoy et al., 2013). In this structure, hepatocytes are 
organised in a highly polarised manner and have sinusoidal and the apical surfaces. 
The sinusoidal surface is faced towards sinusoidal endothelial cells and apical surface 
is faced towards the bile canaliculi (Treyer and Müsch, 2013). This organisation and 
polarization is critical for the proper function of hepatocytes (Gissen and Arias, 
2015).  
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Figure 1.  The structure of the liver lobule and its composing cell types. A) Demonstrates a liver lobule 
including the central vein (CV) and portal triad consist of hepatic artery, portal vein, and 
biliary duct. Hepatocytes are structured as cords separated by sinusoids. B) Demonstrates 
the organised hepatic cells along with the non-parenchymal cells (NPCs) within a liver 
lobule. The sinusoids carry blood from the portal triad towards the central vein while the 
secreted bile moves in the opposite direction in the bile canaliculi towards the bile ducts. 
Image is adapted with permission from Gordillo et al., 2015 (Gordillo et al., 2015). 
2.2 Liver development 
During embryogenesis, the inner cell mass goes through gastrulation and forms three 
germ layers of endoderm, mesoderm, and ectoderm. At this stage, endoderm is a 
single cell layer thick on the ventral site of the developing embryo. The definitive 
endoderm (DE) then forms the primitive gut tube patterned into three progenitor 
domains of foregut, midgut and hindgut (Tremblay and Zaret, 2005). Through 
inductive signals from surrounding tissues, the foregut differentiates into the liver as 
well as many other tissue types such as pancreas, thyroid, lungs, and gastrointestinal 
tract (Wells and Melton, 1999). 
Liver development is tightly regulated by signals and growth factors in both time- 
and concentration-dependent manner (Gordillo et al., 2015; Zaret, 2002) and cell 
signalling during the hepatocyte differentiation process is of utmost importance 
(Vasconcellos et al., 2016). Wnt/β-catenin signalling together with bone 
morphogenic proteins (BMPs) and fibroblast growth factors (FGFs) activate Nodal 
signalling (Haramoto et al., 2004; Lade and Monga, 2011), which is critical for the 
initiation of gastrulation and early endoderm development as well as the segregation 
of endoderm and mesoderm from the bipotential mesendoderm (Vincent et al., 
2003). The first sign of liver formation is seen when the cells in ventral foregut 
endoderm express alpha-fetoprotein (AFP) (Tremblay and Zaret, 2005). The FGFs 
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secreted from early cardiac mesoderm and BMPs secreted from the septum 
transversum mesenchyme (STM) initiate hepatic induction in a concentration-
dependent manner (Calmont et al., 2006; Rossi et al., 2001). FGFs activate 
phospatidylinositide 3-kinase (PI3K) independent MAPK pathway and BMPs 
activate the albumin gene as well as the expression of GATA4 transcription factor 
which all participate in the specification of hepatic endoderm (Rossi et al., 2001; 
Wandzioch and Zaret, 2009). When the ventral foregut endoderm cells commit to 
the hepatic fate, Wnt/β-catenin signalling is repressed to allow the activation of 
hematopoietically-expressed homeobox protein (HHEX), an important 
transcription factor regulating the hepatic commitment and development (Bort et 
al., 2006). The newly committed hepatic endoderm cells then thicken and form the 
liver diverticulum which further proliferates and forms a multilayer of hepatoblasts 
surrounded by a laminin-rich basal membrane. Hepatoblasts then delaminate into 
the STM and proliferate to give rise to the liver bud (Bort et al., 2006). At this stage, 
FGFs, BMPs, and hepatocyte growth factor (HGF) promote the hepatoblast 
migration and hepatic bud growth (Calmont et al., 2006; Medico et al., 2001). 
Hepatoblasts differentiate into hepatocytes and start to polarize and arrange into 
cords lined by bile canaliculi and sinusoidal epithelial cells (Figure 1A).  
A complex transcriptional network and a combination of several growth factors 
secreted from the surrounding cells regulates the maturation of the newly formed 
hepatocytes. Wnt/β-catenin and HGF signalling together with oncostatin M (OSM) 
coordinate the maturation of hepatocytes (Nejak-Bowen and Monga, 2008). In 
addition, the dynamically changing extra cellular matrix (ECM) surrounding the 
hepatoblasts also plays an important role in the hepatic fate determination 
(McClelland et al., 2008).  
In addition to the growth factors, several transcription factors (TFs) regulate the 
liver development. Forkhead box (Fox) A and GATA binding factor (Gata) -4 bind 
to the Albumin enhancer region, which opens the chromatin structure and assists the 
access of the other transcription factors to the promoter site (Kaestner, 2005). Hhex 
is initially involved in the regulation of the hepatic endoderm cell proliferation and 
later it controls the completion of the liver bud morphogenesis as well as the 
hepatocyte maturation (Bort et al., 2006; Hunter et al., 2007; Martinez Barbera et al., 
2000). Hepatocyte nuclear factor 4 alpha (HNF4α) regulates the morphological and 
functional differentiation of hepatocytes as well as the formation of the hepatic 
epithelium (Li et al., 2000; Parviz et al., 2003). HNF4α is shown to be critical in the 
generation of correct liver architecture and its polarised structure (Santangelo et al., 
2011). 
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2.3 Lipid and fatty acid synthesis in hepatocytes 
Hepatocytes can directly uptake lipids in the form of lipoproteins and FAs from their 
culture medium using low-density lipoprotein receptor (LDL-R), LDL receptor–
related protein-1 (LRP-1), and scavenger receptor B1 (SR-B1). Simultaneously, they 
can produce FAs (de-novo lipogenesis) by hydrolysing glucose to acetyl-CoA through 
tricarboxylic acid (TCA) cycle, which links glycolysis to lipogenesis (Figure 2A). 
Concurrently, acetyl-CoA can be synthesised from other precursors than glucose 
such as glutamine (Currie et al., 2013). Acetyl-CoA is then used by a multifunctional 
enzyme called fatty acid synthase (FASN) to synthesize FA 16:0 (palmitic acid) 
(Jensen-Urstad and Semenkovich, 2012). FA 16:0 is then elongated by fatty acid 
elongase (ELOVL) members to generate long-chain FAs (LCFAs, >16 carbon). 
LCFAs are further desaturated by stearoyl-CoA desaturase (SCD) and fatty acid 
desaturase (FADS) to produce diverse spectrum of mono- and poly-unsaturated 
LCFAs. Human cells are not able to produce unsaturated FAs with a double bond 
positioned on their ω-3 and ω-6 acyl chain. Therefore, these essential FAs, alpha-
linolenic acid (18:3 ω-3) and linoleic acid (18:2 ω-6), need to be obtained from the 
diet or the medium in case of cell culture.  
 
Figure 2.  A) Demonstrates a simplified pathway of de-novo synthesis of fatty acids (FAs) as well as 
imported essential polyunsaturated FAs (PUFAs) alongside the responsible genes such as 
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FASN, SCD, ELOVL, FADS regulating the pathway. B) Demonstrates a simplified pathway 
of sphingolipids (SLs) alongside the responsible key genes. 
FAs are further used by the cells to generate different types of lipids. Via the glycerol 
phosphate pathway, FAs are converted into diacylglycerols (DAGs) and 
triacylglycerol (TAGs), which are mainly utilized by cells for energy storage in the 
form of lipid droplets. In addition, the intermediates of the glycerol phosphate 
pathway can be converted into PLs such as PC, PE and PI, which are important for 
membrane functions (Baenke et al., 2013; Ntambi and Miyazaki, 2004). Sterols such 
as cholesterol and cholesteryl esters (CEs) - another important component of the 
cellular membrane- are synthesised from acetyl-CoA (discussed in Liscum 2008 
(Liscum, 2008)). 
Sphingolipids (SLs) form a class of lipids defined by their C18 amino-alcohol 
backbones and are synthesised from non-sphingolipid precursors coupled to serine. 
This basic structure is further modified to produce the immense family of SLs such 
as ceramides (Cer), glycosphingolipids (GSLs) and sphingomyelins (SMs). SLs are 
bioactive molecules in several cellular activities including cell division, 
differentiation, gene expression and apoptosis and are the structural components of 
biological membranes (Gault et al., 2010). In addition, SLs contribute to cell 
signalling and regulation of inflammation (Hannun & Obeid 2008; Maceyka & 
Spiegel 2014). The metabolism of SLs is a complex process with ceramide playing as 
a central key molecule (Delgado et al., 2006) (Figure 2B). Cer synthesis is 
orchestrated by six ceramide synthases (CerS), each of which produces ceramides 
with distinct FA chain lengths (Cingolani et al., 2016; Levy and Futerman, 2010; Park 
et al., 2014). The expression pattern of CerS is cell specific and CerS2 is the dominant 
CerS isoform found in the liver (Laviad et al., 2008; Levy and Futerman, 2010). Cers 
are degraded to sphingosines and free FAs by ceramidases encoded by distinct genes 
like acid ceramidase (ASAH1 and ASAH2).  
SM is metabolised from ceramides by SM synthase (SMS). SM is the most 
abundant SL in human cells and its synchronised breakdown is also an important 
part of membrane homeostasis. Regulated by SMase family (SMPD), SM can be 
degraded to Cer and free phosphorylcholine (Kim et al., 2008). SMase are organised 
into acidic, alkaline, and neutral SMases depending on the pH in which their 
enzymatic activity is optimal.  
Glycosphingolipids are complex carbohydrate-containing SLs and UDP-
glucose:ceramide glucosyltransferase (UGCG) gene encodes the enzyme which 
catalyses the first glycosylation step in GSL biosynthesis (Figure 2B) (Gault et al., 
2010). GSLs are characteristic components of plasma membranes, residing 
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specifically in the membrane microdomains called lipid rafts (Figure 3). The lipid 
rafts are relatively small and specialised regions of the plasma membrane enriched in 
cholesterol and very-long and saturated SLs, unlike the surrounding bulk membrane, 
which is dominated with unsaturated PLs (Ishibashi et al., 2013; Simons and Gerl, 
2010). 
 
 
 
Figure 3.  A simplified model of cell membrane lipid rafts domain. The phospholipids and cholesterol 
are located in both outer and inner leaflets, while sphingolipids such as sphingomyelin (SM) 
and glycerophospholipids (GPLs) are enriched in the outer leaflet of the membrane bilayer. 
The bulk (non-raft) membrane is enriched with unsaturated glycerophospholipids (GPLs) 
such as phosphatidylcholine.  
2.4 Functions of lipids and fatty acids 
Mammalian cells contain more than 1000 of different lipids, mostly comprise of a 
polar head and hydrophobic tails. This complex mixture of lipids execute a wide 
variety of functions in the cells from forming the bilayer matrix and shaping cellular 
and ultimately tissue architecture to storing energy (principally as triacylglycerol and 
steryl esters in the form of lipid droplets) and regulating membrane protein activity, 
mediating membrane trafficking, facilitating signal transduction, and forming the 
basis for creating dynamic subcompartments within membranes (Ekroos, 2012). The 
composition of lipids in different organelles, cell types, and tissues can vary 
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considerably, which suggests that different lipids are required for different functions 
(Muro et al., 2014). In addition, the local concentration of each lipid varies between 
the cells, cellular organelles, and even between the two leaflets of the lipid bilayer, 
which determines their function (Van Meer, 2005). 
Cholesterol is a fundamental structural component in the cell membranes of most 
vertebrates (Ikonen, 2008) and contribute in forming a semipermeable barrier 
between the cellular compartments. Cholesterol also regulates the membrane 
fluidity. In addition, it modulates the membrane proteins function and participates 
in many membrane trafficking and transmembrane signalling processes.  
Sphingolipids are essential constituents of eukaryotic cells. Besides playing 
structural roles in cellular membranes, some of the SLs metabolites, including 
ceramide, are considered as bioactive signalling molecules involved in the regulation 
of cell growth, proliferation, differentiation, senescence, necrosis, and apoptosis. SLs 
dynamically cluster with sterols to form lipid rafts, which function as hubs for 
effective signal transduction and protein sorting (Bartke and Hannun, 2008). 
Interestingly, some SLs such as ceramide and sphingosine 1-phophate (S1P) exhibit 
opposing functions in the regulation of cell survival and death, and therefore the 
relative balance between ceramide/S1P determines the fate of cells in response of 
particular stimuli (Morales et al., 2007).  
Phospholipids play key roles in the structure and function of mammalian cell 
membranes and account for approximately 70% of the total membrane lipid content 
and the PC alone covers approximately 50% of the phospholipids in most eukaryotic 
membranes (Leventis and Grinstein, 2010). As was mentioned above, the 
composition of lipids varies between the two leaflets in Golgi, plasma and endosomal 
membranes, where in the outer leaflet (luminal side) PC, SM, and PE are the 
dominating lipids, whereas in the inner leaflet (cytoplasmic side), PS, PE, and PI are 
abundant (Van Meer et al., 2008). This asymmetric distribution of lipids is important 
for the function of the cellular membrane e.g. in vesicle budding (Marsh, 2007; 
Pomorski and Menon, 2006). In hepatocytes, phospholipids also take part to 
assemble very low density lipoprotein (VLDL) particles, a 30-70 nm diameter 
spherical complexes, with approximately 50% triglycerides, 20% cholesterol, 20% 
phospholipids and 10% protein (with apoB-100 as the major apolipoprotein) 
(Ikonen, 2008).  
Fatty acids are one of the most fundamental classes of biological lipids, which 
serve as the basic building blocks of the complex lipids. In form of triacylglycerol, 
they represent a major form of storage energy containing fatty acyl groups in their 
structure largely in white adipose tissue. Glycerophospholipids provide an essential 
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structural component of membranes, and are able to regulate and modify the 
properties of many proteins through direct covalent linkage. FAs can also be 
metabolized to lipid signalling molecules that perform important role as metabolic 
intermediates used for lipid synthesis and protein modification. In addition, through 
mitochondrial beta-oxidation, FAs can be broken down to generate ATP via 
oxidative phosphorylation (Puzio-Kuter, 2011). Furthermore, FAs can directly 
regulate cellular processes via controlling of gene transcription, or via binding to 
membrane-bound receptors. For example, ω3-unsaturated FAs bind to G protein-
coupled receptor 120 (GPR120) and exert anti-inflammatory effects in macrophages 
(Ichimura et al., 2012; Oh et al., 2010). FAs also regulate the expression of a range 
of genes involved in lipid metabolism. For instance, it has been shown that PUFAs 
interacts directly with nuclear receptors such as peroxisome proliferator activated 
receptors (PPARs). PPARα is the predominant isoform of PPARs in the liver and 
plays a major role in the fatty acid-induced regulation of hepatic gene transcription 
(Montagner et al., 2011).  
2.5 Liver cell models 
Physiologically relevant predictive in vitro hepatocyte models are needed to develop 
and test different drugs and to mimic diseases. There are several cell sources available 
when constructing in vitro human liver cell culture models and depending on the 
study aim, various sources may be utilised in hepatic in vitro research (Figure 4). 
Bellow some of the main cell sources commonly used as in vitro hepatic cell models 
are discussed. 
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Figure 4.  Major cell sources used for generation of human in vitro liver cell models and their 
processing steps. Image is adapted with permission from Zeilinger et al., 2016 (Zeilinger et 
al., 2016).  
2.5.1 Primary human hepatocytes 
Freshly isolated primary hepatocytes are a faithful representative of in vivo-like 
hepatic physiology and currently is considered as the “gold standard” cell model to 
study liver physiology (Kakisaka et al., 2012; Ling et al., 2013; Sahi et al., 2010). PHHs 
express the drug transporter enzymes at considerably higher levels than e.g. many 
hepatoma cell lines (Westerink and Schoonen, 2007). In addition, cultured 
hepatocytes are able to maintain high levels of their functionality in short-term, 
which makes them a well-accepted platform for studying liver-related diseases and 
drug toxicity (Godoy et al., 2013). However, their routine implementation in long-
term studies is hampered by the progressive loss of liver-specific phenotype (Elaut 
et al., 2006). In addition, PHHs are usually obtained from cadaveric donors; 
therefore, they are expensive, limited and hard to access.  
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2.5.2 Hepatoma cell lines 
In order to overcome the limitations of primary human hepatocytes, several human 
hepatoma cell lines such as HepG2, Huh7, Fa2N4, and HepaRG cells have been 
developed and utilised (Godoy et al., 2013). Hepatoma cell lines are abundant, have 
unlimited life span and stable phenotype, and are easy to handle, which explains their 
wide application as in vitro cell models in both academia and industry. However, they 
do not faithfully represent the metabolic activities of healthy hepatic cells and as a 
result have failed to correctly predict many hepatotoxic side-effects of the new drugs 
(Olsavsky et al., 2007). Moreover, most cell lines exhibit low or partial expression of 
key hepatic-specific factors and particularly drug-metabolizing enzymes (i.e. CYPs) 
in comparison to the primary hepatocytes (Donato et al., 2008). Recently, several 
studies have tried to improve the phenotype of hepatoma cell lines. For instance, 
treating proliferating HepaRG cells with differentiating factors such as DMSO have 
shown to improve their drug-metabolizing activities (Kanebratt 2008). However, 
compared with human hepatocytes, the CYP expression in hepatoma cell lines 
remains low and even the most promising cell line is not yet an ideal alternative 
system for human primary hepatocytes (Sivertsson et al., 2010). Additionally, these 
cell models also differ substantially in their potential to secrete apoB-100 and apoA-
I containing nascent lipoproteins (Meex et al., 2011; Sasaki et al., 2017).   
2.5.3 Stem cell-derived hepatocytes 
Hepatic cells have been derived from both human embryonic stem cells (hESCs) 
and hiPSCs in numerous studies and the differentiated hepatic cells derived from 
both cell sources have reported to be morphologically, genetically, and functionally 
identical (Godoy et al., 2013). Stem cell-derived HLCs show very similar 
characteristics to PHHs and are able to circumvent the limited availability of the 
PHHs. HLCs secrete albumin, urea and TAG and to some levels express drug 
transporters and cytochrome P450 enzymes (Kia et al., 2012). HLCs are able to 
produce, secrete, and uptake cholesterol in vitro and robustly express apolipoprotein 
genes, e.g. APOA1, APOA2, APOB-100, APOC, and APOE (Rasmussen, 2015). 
HLCs also respond to statin treatment in vitro by decreasing their cholesterol 
secretion (Krueger et al., 2013). Another advantage of HLCs is that unlike the rodent 
hepatocytes and some human hepatoma cells, they are sensitive to hepatitis C virus 
infection and support viral replication, similar to PHHs (Schwartz et al., 2012). In 
addition, iPSC-derived HLCs can be generated from patients of different genetic 
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backgrounds, a pre-requisite for personalised medicine development. Furthermore, 
generating hiPSC-HLCs in large quantities facilitates the modelling of inborn errors 
of hepatic metabolism, understanding the molecular basis of liver cell differentiation, 
studying disease mechanisms, and discovering novel and safe drugs. iPSC-HLCs 
have been already utilised as cell models to study several liver disease such as hepatitis 
C virus infection (Zhou et al., 2014), liver-stage malaria (Ng et al., 2015), and systemic 
amyloidosis (Leung et al., 2013). In addition, iPSC-HLCs have been used to 
recapitulate the human cholesterol homeostasis (Krueger et al., 2013), the 
pathophysiology of familial hypercholesterolemia (Cayo et al., 2012), and Tangier 
disease, a rare autosomal recessive disorder with almost full absence of HDL (Bi et 
al., 2017). Furthermore, iPSC-HLCs have proven to be of great value in developing 
novel therapeutics (Medine et al., 2013; Szkolnicka et al., 2014). 
2.6 Differentiation of HLCs from pluripotent stem cells 
To date, several protocols for differentiating hepatocytes from hESCs or iPSCs have 
been published (Cameron et al., 2015; Chen et al., 2012; Gerbal-Chaloin et al., 2014; 
Hannan et al., 2013; Hu and Li, 2015; Mallanna and Duncan, 2013; Schwartz et al., 
2014; Si-Tayeb et al., 2010a; Sullivan et al., 2010; Takayama et al., 2012). Nonetheless, 
most can be divided into three-step differentiation protocols proceeding from stem 
cells through DE phase, hepatoblast stage, and finally hepatocyte-like cells using 
various growth factors and cytokines known to be necessary for liver development. 
In addition, protocols for direct reprogramming of somatic cells (human fetal and 
adult fibroblasts) to functional hepatocytes have also been reported (Huang et al., 
2017; Simeonov and Uppal, 2014).  
Activin A is commonly used during the DE induction as it activates the Nodal 
signal necessary for the DE formation (D’Amour et al., 2005; Kubo, 2004). 
Alternatively, Wnt3a is crucial for the specification of cell fates during embryonic 
development (Cohen and Friedman, 2004). CHIR99012 is a small molecule and is 
an inhibitor of human glycogen synthase kinase 3 β (GSK-3β). GSK3 is also 
inhibited in response to Wnts during liver development. It has been shown that 
CHIR99021 enhances cell survival at low density but also induces non-neural 
differentiation (Ying et al., 2008). NaB is an epigenetic modifier, more specifically a 
short chain FA that inhibits histone deacetylases (HDACs), leading to 
hyperacetylation of histones. NaB together with Activin A induces DE formation, 
possibly through promoting epigenetic changes that consequently make cells more 
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prone for Activin A-mediated induction of endoderm-specific genes (Jiang et al., 
2007).  
Bone morphogenic protein 4 (BMP4) and basic fibroblast growth factor (bFGF) 
are used to promote hepatic differentiation from DE cells. Low concentration of 
FGF induces hepatic gene expression through activation of the MAPK pathway. In 
some protocols, DMSO is used instead of FGF and BMP4 to induce hepatic 
differentiation. DMSO has histone deacetylase inhibitor activity and significantly 
increases the expression of BMP2 and BMP4 but decreases the expression of stem 
cell markers such as Oct4 (Behbahan et al., 2011; Choi et al., 2015; Czysz et al., 2015; 
Santos et al., 2003). Finally, for the maturation of hepatocytes, HGF and OSM, and 
dexamethasone are used. OSM suppresses the differentiation towards the 
hematopoietic lineage and promotes the liver progenitor cells to differentiate to 
hepatocytes (Kamiya et al., 1999). The combination of HGF and OSM enhances 
hepatocyte proliferation (Si-Tayeb et al., 2010b) and inhibits the progression of the 
cells into the cholangiocytic lineage by blocking the Notch signalling. 
Dexamethasone reduces hepatocyte growth by suppressing many growth-associated 
molecules in the liver including IL-6. In addition, it induces phenotypic maturation 
of hepatocytes by HNF4 and C/EBP-alpha induction, which are essential 
transcription factors for hepatic differentiation (Michalopoulos et al., 2003). 
2.7 Challenges in using iPSC-derived hepatic cells 
While there are many advantages in using iPSC-derived hepatocytes, there are yet 
some limitations and challenges to overcome. Despite the great advances in hepatic 
differentiation methods, none of the existing protocols is yet producing fully mature 
hepatocytes (Baxter et al., 2015). Additionally, variabilities exist between the iPSC 
lines generated from different donors or in different laboratories (Kim et al., 2011; 
Rouhani et al., 2014). This variation could be due to many reasons including 
differences in epigenetic cell memory (Ruiz et al., 2012), or “lab-specific” gene 
expression patterns (Newman and Cooper, 2010). The variation between the iPSC 
lines could affect the differentiation potential of the cell lines to a certain cell types 
other than hepatocytes. Therefore, more consistent iPS cell cultures are needed in 
order to generate uniform hepatic cells with fully comparable phenotype. Moreover, 
the criteria for characterisation and functional assessment of the HLCs is currently 
varying between the laboratories and needs to be standardised (Gerbal-Chaloin et 
al., 2014). 
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Even in the most efficient hepatic differentiation, residual undifferentiated iPSCs 
might remain in the culture, which brings the risk of tumour formation in case of 
cell transplantation. One solution is sorting the hepatic or hepatic progenitor cells 
using specific cell surface markers such as asialoglycoprotein receptor  (ASGPR) 
(Goldman et al., 2013; Peters et al., 2016). Recently, Kang et al have suggested that 
addition of YM155 – a small molecule- to the cell culture during the differentiation 
could remove the undifferentiated iPSCs and eliminate the risk of teratoma 
formation upon in vivo transplantation (Kang et al., 2017). 
Even though the purified hepatic cells can highly affect the functionality of a cell 
model, an ideal cell model should also include the non-parenchymal cells (NPCs) 
along with the hepatocytes. The interaction between the hepatocytes and NPCs e.g. 
endothelial and Kupffer cells are important particularly when testing unknown 
mechanisms of a disease or potential toxicity of a drug (Godoy et al., 2013). This 
arises another challenge of culturing HLCs in co-culture with NPCs or in 3D format, 
which require development of suitable culture environments and optimal 
biomaterials or hydrogels able to support the growth and differentiation of HLC (see 
chapter 2.8 below). 
2.8 Three-dimensional culture of hepatic cells   
The conventional 2D culture is the most common approach for culturing and 
differentiating the hepatic cells due to its ease of achievement. However, the 2D 
system does not fully support the natural organisation and polarization of hepatic 
cells, which is necessary for their correct organotypic cell differentiation and proper 
function (Gissen and Arias, 2015; Godoy et al., 2013; Schyschka et al., 2013). 
Therefore, the 3D cultivation of hepatocytes has recently gained increasing attention 
and in this concept, various strategies have been utilised to improve the hepatocytes 
maturity, functionality, and life-span by re-establishing the physiological 
microenvironment of the liver including cell-cell contacts and cell-matrix 
interactions.  
A simple approach like the sandwich culture of hepatocytes in type I collagen or 
Matrigel (a mixture of basal membrane components derived from mouse sarcoma) 
have shown to enhance the long-term functionality, drug metabolism activity and 
formation of canalicular networks (Gieseck et al., 2014; Kim and Rajagopalan, 2010; 
Swift et al., 2010). Numerous studies have also reported the 3D culture of hepatic 
cells in various matrixes such as collagen (Gieseck et al., 2014), alginate (Ramasamy 
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et al., 2013), Matrigel (Takayama et al., 2013), heparin (Foster et al., 2015) or 
nanofibrillar cellulose (NFC, commercially available as GrowDexTM) (Malinen et 
al., 2014), leading to improved liver-specific parameters including CYP expression 
and albumin and urea secretion. In addition, some recent reports have utilised 
bioreactors for 3D culture of hepatic cells (Freyer et al., 2016; Heidariyan et al., 
2018). In order to further improve the physiological relevance of the hepatic culture 
environments, different co-culture systems have been also investigated (often in 3D 
format). For instance, several studies have reported successful co-culture of stem 
cell-derived hepatocytes with endothelial cells and mesenchymal stem cells (MSCs) 
(Du et al., 2014; Takebe et al., 2014; Zhong et al., 2015), and fibroblasts (Berger et 
al., 2015; Nagamoto et al., 2012), all of which significantly increased the expression 
of hepatic marker genes and overall hepatic functionality. In a more complex 
approach, a dynamic 3D culture of hepatic cells is created using advanced 
biofabrication techniques or patterned culture of cells combined with microfluidics 
systems to create Liver-On-Chip constructs (Bhise et al., 2016; Ma et al., 2016; 
Skardal et al., 2015). In this system, hepatic cells alone or alongside the NPCs are 
printed (often with a support hydrogel) on a platform connected to a perfusion 
system. 
The 3D structure could also be achieved through a scaffold-free approach based 
on the self-aggregation of the hepatic cells known as spheroids. Spheroids can be 
formed either by seeding the cells in low-attachment culture vessels (Bell et al., 2016) 
or by gravity-enforced cellular assembly in a hanging drop (Messner et al., 2013). In 
this perspective, stem cell-derived liver organoids have been recently developed 
(Kruitwagen et al., 2017; Nantasanti et al., 2015), which provides the 
nonparenchymal cells (NPCs) and essential tight cell-cell interactions for proper 
function of hepatocytes.  
2.9 De-differentiation of hepatic cells 
When primary hepatocytes are isolated and cultivated in culture, a number of liver-
specific phenotypes are progressively lost with time, which is known as “de-
differentiation”. De-differentiation can already be started during the isolation 
procedure in which the polarised and organised cellular structure of the liver is 
disrupted and an ischemia-perfusion injury happens, which triggers both a 
proliferative and inflammatory response. Consequently, liver-enriched transcription 
factors such as CYP enzymes are negatively affected and hepatocytes rapidly 
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deteriorate (Baker et al., 2001; Elaut et al., 2006; Godoy et al., 2009). The de-
differentiation process continues upon the in vitro culture and the hepatic cells are 
not able to recover to a stable state particularly in current suboptimal 2D culture 
environments that lack the significant survival factors (Cohen et al., 2015; Elaut et 
al., 2006; Godoy et al., 2009).  
The de-differentiation limits the usability of primary hepatocytes to typically a 
few days, far from the minimum two-weeks required for long-term toxicity studies 
(Elaut et al., 2006; Gouliarmou et al., 2015). To date, intensive research has been 
conducted to understand the mechanism of de-differentiation. For instance, it has 
been reported that proteins responsible for carbohydrate, amino acid and lipid 
metabolism networks are affected during the de-differentiation (Rowe et al., 2010). 
On the other hand, different approaches have been adopted to prevent or decelerate 
the de-differentiation of primary hepatocytes in culture. Classical approaches have 
tried to mimic the in vivo hepatic environment by using bioreactors, liver spheroids, 
microfabricated co-culture, and 3D sandwich cultures as well as a wide variety of 
soluble differentiating-promoting medium components (Darnell et al., 2012; No et 
al., 2012; Tostões et al., 2012). Although these efforts could delay the de-
differentiation process they are not yet able to counteract it completely. Therefore, 
the ideal hepatocyte-based culture model, which could preserve the long-term 
expression of hepatocellular phenotype, is still lacking. 
2.10 MicroRNAs 
MicroRNAs (miRNAs) are short (approximately 22 nucleotides), non-coding RNA 
molecules acting as post-transcriptional regulators of gene expression by inhibiting 
translation and increasing mRNA degradation (Schmiedel et al., 2015). Single 
miRNAs are able to regulate multiple genes and conversely, individual genes can be 
regulated by multiple miRNAs. To date, more than 1,000 miRNAs have been 
identified in human and approximately 50% of human mRNAs are predicted to be 
miRNA targets (Shomron and Levy, 2009). miRNAs are cell- or tissue-specific and 
are shown to play important roles in e.g. the regulation of cell replication and 
differentiation. miR-122 is abundantly expressed in the liver tissue, composing about 
70% of all hepatic miRNAs (Ørom et al., 2008). miR-122 regulates up to 200 genes 
in the liver (Figure 5) and its knockdown results in the reduction of the biosynthesis 
of hepatic cholesterol (Elmén et al., 2008). 
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miRNAs have been previously shown to play critical roles in the de-
differentiation of PHHs (Fraczek et al., 2013; Lauschke et al., 2016). Emerging 
evidence also shows that miRNAs regulate the lipoprotein formation and secretion 
as well as the lipid synthesis and FA oxidation (Yang et al., 2015). 
 
 
 
 
Figure 5.  MicroRNA-122 signalling. An example of the role of microRNAs in regulation of genes 
involved in the liver function and differentiation. The figure was adapted with permission 
from Vasconcellos et al. (Vasconcellos et al., 2016). 
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3 AIMS OF THIS THESIS 
The objective of this PhD thesis was to establish HLCs as patient-specific cell 
models for studying lipid metabolism and derangements. Therefore, it was crucial to 
investigate the similarities between the lipid profiles of matured HLCs and human 
primary hepatocytes. In addition, considering the important structural and signalling 
function of lipids, we investigated the role of lipids in both hepatic differentiation 
(in iPSC-HLCs) and de-differentiation (in PHHs). The step-by-step aims of this 
dissertation are outlined as follows:  
1. To study the lipid alterations in differentiating HLCs and investigate the 
possible role of lipids in hepatic differentiation and maturation (Study I). 
2. To compare the hepatic differentiation methods and investigate the effect 
of various differentiating conditions and biological stimuli on the phenotype 
of HLCs (Study II). 
3. To comprehensively characterise the lipid and FA profile of HLCs and 
compare it with both PHHs and HepG2 cells (Study II). 
4. To study the lipid alterations in de-differentiating PHHs and investigate the 
possible role of lipids in the de-differentiation process and its mechanism 
(Study III). 
5. To study the alterations in the miRNA profile of de-differentiating PHHs 
and identify the differentially expressed miRNAs that may regulate those 
changes in the lipidome of PHHs (Study III). 
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4 MATERIALS AND METHODS 
4.1 Ethical consideration 
The study and the recruitment of the patients have been approved by the Ethics 
Committee of Pirkanmaa Hospital District (Tampere University Hospital) with the 
approval number: R12123. All recruited participants were adults over 18 years old, 
who had signed an informed consent form after receiving both written and oral 
descriptions of the research.  
4.2 Reprogramming of hiPSC  
Three hiPSC lines (UTA.11104.EURCAs, UTA.10100.EURCAs, and 
UTA.11304.EURCCs) were used in the original publications (Studies I and II) and 
cell lines were derived directly from the fibroblasts of three individuals. The collected 
fibroblasts were induced to pluripotency by Sendai reprogramming kit (CytoTune; 
Life Technologies), based on the protocol described by Takahashi et al. (Ohnuki et 
al., 2009; Takahashi et al., 2007). The induction of cell lines was performed according 
to the manufacturer’s instruction. Induced cells were cultured on mitotically 
inactivated mouse embryonic fibroblast (MEF, Applied StemCell) feeders until 
characterisation.  
4.3 Culture of hiPSC  
hiPSC lines were maintained at +37 °C in 5% CO2 on MEFs in a basic hiPSC culture 
medium containing Knock-Out Dulbecco’s Modified Eagle’s Medium (KO-
DMEM) supplemented with 20% Knock out Serum Replacement (Ko-SR), 0.1 mM 
2-mercaptoethanol (2-ME), 2 mM Glutamax (all from Gibco®), 1% nonessential 
amino acids (NEAA), 50 U/ml penicillin/streptomycin (both from LONZA), and 
4 ng/ml human basic fibroblast growth factor (bFGF, R&D system). 
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Undifferentiated colonies were enzymatically passaged onto fresh feeder layers on 
weekly bases. Cell lines were routinely checked for mycoplasma contamination. 
4.4 Characterization of hiPSC  
All the hiPSC lines were characterised for their pluripotency at both gene and protein 
levels. In addition, their ability to generate derivatives of all three embryonic germ 
layers was evaluated by the formation of embryoid bodies (EBs). Furthermore, 
normal karyotype of the hiPSC lines was confirmed by performing genome-wide 
screening for gross chromosomal abnormalities with KaryoLite BoBs (Product 
number 4501–0010, Perkin Elmer) as described elsewhere (Lund et al., 2012). The 
details of the characterisations have been described before (Manzini et al., 2015). A 
summary of the hiPSC characterisation methods is demonstrated in the Table 1.  
 
Table 1.  An overview of the assays used in this thesis for characterisation of the iPSC lines. 
Methods/assays Markers       
PCR          
 Exogenes         
   OCT4, SOX2, c-MYC, KLF4     
 Endogenes        
   NANOG, REX1, OCT3/4, SOX2, c-MYC   
 Embryoid bodies (EBs)       
  Endoderm        
   SOX17, AFP      
  Mesoderm        
   KDR, ACTC1       
  Ectoderm        
   Nestin, Musashi      
Immunocytochemistry (ICC)       
  Pluripotency markers       
   NANOG, OCT3/4, SSEA4, SOX2, TRA1-60, TRA1-81 
Karyotype analysis        
Abbreviations: OCT, octamer-binding transcription factor; SOX, (sex determining 
region Y)-box; KLF, kruppel-like factor; NANOG, nanog homeobox; REX1, ZFP42 
zinc finger protein; AFP, alpha fetoprotein; KDR, kinase insert domain receptor; 
ACTC1, alpha actin cardiac muscle 1; SSEA, stage-specific embryonic antigen; TRA, 
tumour rejection antigen.   
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4.5 Culture of the human primary hepatocytes 
Cryopreserved PHHs (Lots. Hu8209 & Hu8210) (Studies I, II, and III) were 
purchased from Gibco®. PHHs were cultured in monolayer on collagen-I-coated 
plates (CellAffixTM), with the density of 2.5 × 105 cells/cm2, and maintained in 
William’s E medium (Gibco®) supplemented with cocktail B (CM 4000, Gibco; 
including ITS [insulin, transferrin, selenium], bovine serum albumin (BSA), 
GlutaMAXTM, and linoleic acid) as well as dexamethasone. 
4.6 Culture of HepG2 cells 
Hepatocellular carcinoma cells (HepG2) (Study II) were purchased from ATCC™ 
and were thawed and plated according to the manufacturer’s instructions. HepG2 
cells were cultured in DMEM medium supplemented with 10% FBS (Biosera) and 
50 U/ml penicillin/streptomycin (LONZA). HepG2 cells were passaged on weekly 
bases and normally used at passages 5-10.  
4.7 Hepatic differentiation from hiPSCs 
To generate HLCs, iPSCs were adapted to feeder free condition on pre-coated plates 
either with Geltrex (Gibco®) or Laminin 521 (BioLamina, Lot: 80104) in mTeSRTM 
medium before starting the hepatic differentiation. In this thesis, HLCs have been 
differentiated by five different methods (Studies I and II). Figure 6 demonstrates 
a schematic view of methods used. 
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Figure 6.  A schematic illustration of the five hepatic differentiation methods used in the Studies I 
and II for generating hepatocyte-like cells (HLCs).  
The details of the differentiation methods are described below: 
Method 1 (M1) (Study II) is based on a protocol originally introduced by Si-
Tayeb et al. (Si-Tayeb et al., 2010a). In this protocol, hiPSCs were cultured in 
RPMI+Glutamax (Gibco®) supplemented with 1×B27 (Gibco®), 100 ng Activin A 
(Peprotech), 3 μM CHIR99021 (Stemgent), 1 mM NaB (Sigma) for 1 day and 0.5 
mM for 5-6 days until definitive endoderm (DE) formation. Medium was switched 
to RPMI/B27 supplemented by 20 ng/ml BMP4 and 10 ng/ml of bFGF for hepatic 
induction for 3 days. Then, BMP4 and bFGF were replaced by 20 ng/ml of 
hepatocyte growth factor (HGF) for 5 days. From this stage onward, cells were 
cultured in HBM (cc-3199, Lonza) supplemented with Single Quotes (no epidermal 
growth factor [EGF]) complemented with 40 ng/ml HGF (life technologies) and 20 
ng/ml oncostatin M (OSM, R&D systems) for further maturation. 
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Method 2 (M2) (Studies I and II) is according to a study performed by Hay et 
al. (Hay et al., 2008). The DE stage was similar to M1 except that 75 ng/ml Wnt3 
(R&D systems) was used instead of CHIR99021. The hepatic differentiation was 
initiated by switching the medium to KO-DMEM+20% KO-SR, 1 mM Glutamax, 
1% NEAA, 0.1% β-ME, and 1% DMSO for 7 days. From this point, cells were 
cultured in Leibovitz’s L-15 medium (Invitrogen), supplemented by 8.3% BSA 
(Biosera), 8.3% Tryptose phosphate broth (Sigma-Aldrich), 10 μM Hydrocortisone 
21- hemisuccinate, 1 mM Insulin (both from Sigma-Aldrich), 2 M Glutamax, 25 
ng/ml HGF, and 20 ng/ml OSM. 
Method 3 (M3) (Study II) is an alteration of both M1 and M2 and was described 
by Kajiwara et al. (Kajiwara et al., 2012). After reaching 70% confluency, hiPSCs 
were detached by Versene (Gibco) and re-suspended in RPMI+Glutamax 
supplemented with 1×B27, 100 ng/ml Activin A, 50 ng/ml Wnt3, and 10 μM Rock 
inhibitor and seeded with 5-10 x 104 /cm2 density. Next day Rock inhibitor was 
replaced with 0.5 μM NaB until day 5-6 of differentiation. Hepatic specification stage 
was carried out as in M2 and hepatic maturation stage was carried out according to 
M1, however, EGF was included in HCM, and HGF was reduced to 25 ng/ml. 
Method 4 (M4) (Study II) is similar to M3 except that the plates were coated 
with a mix of Laminin 111/521 (3:1 ratio) instead of GeltrexTM used in other 
methods. 
Method 5 (M5) (Study II) is similar to M3 except that the DE stage in M3 was 
substituted by a commercial kit (STEMdiffTM). The differentiation in DE stage was 
performed according to the manufacturer’s instructions. 
4.8 The characterization of cells during hepatic differentiation 
and maturation 
4.8.1 Morphology 
During the hiPSC-HLCs differentiation, cell growth and morphology were regularly 
monitored using either Nikon Eclips TS100 phase contrast or EVOS FL (Life 
technology) microscope. 
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4.8.2 Real-time quantitative PCR 
Real-time quantitative polymerase chain reaction (qPCR) was used to evaluate the 
stages of differentiation (Studies I and II) or de-differentiation (Study III), 
functionality (Studies I, II, and III), and efficiency of differentiation methods 
(Study II). Total RNA extraction and cDNA synthesis are described in details in the 
original publications. cDNA was multiplied either by Power SYBR Green PCR 
Master Mix (Life Technologies) and gene specific primers or Taqman Fast Advanced 
Master Mix (applied Biosystems) and gene specific TaqMan probes. The qPCR 
reactions were run in triplicates using the 7300 Real-time PCR system (Applied 
Biosystems, Foster City, CA) (Study I) or Real Time PCR Detection System 
(BioRad, CFX384TM Optics Module, Singapore) (Studies II and III). The studied 
genes and respective primers are presented in Tables 2 and 3. 
 
Table 2.  List of the studied genes using SYBR Green-based real-time quantitative PCR 
(qPCR). GAPDH was used as the endogenous control gene. 
Gene Target Forward primer 
5’-3’ 
Reverse primer 
5’-3’ 
Study 
OCT3/4 iPSCs TTGGGCTCGAGAA
GGATGTG 
TCCTCTCGTTGTGC
ATAGTCG 
I, II 
SOX17 Endoderm CCGAGTTGAGCAA
GATGCTG 
TGCATGTGCTGCA
CGCGCA 
I, II 
FOXA2 Endoderm AAGACCTACAGGC
GCAGCT 
CATCTTGTTGGGG
CTCTGC 
I, II, III 
AFP Immature HLCs CGCTGCAAACGAT
GAAGCAG 
AATCTGCAATGAC
AGCCTCAAG 
I, II, III 
ALB Matured HLCs GAAAAGTGGGCAG
CAAATGT 
GGTTCAGGACCAC
GGATAGA 
I, II, III 
GAPDH Housekeeping 
gene 
AGCCACATCGCTC
AGACACC 
GTACTCAGCGCCA
GCATCG 
I, II, III 
Abbreviations: iPSCs, induced pluripotent stem cells; HLCs, hepatocyte-like cells 
 
Table 3.  List of the studied genes using TaqMan-based real-time quantitative PCR (qPCR). 
Both B2M and GAPDH were used as the endogenous control genes. 
Gene 
symbol 
Gene product TaqMan assay 
ID 
Study 
FASN Fatty acid synthase Hs01005622_m1 II, III 
SCD Stearoyl-CoA desaturase Hs01682761_m1 II, III 
FADS1 Fatty Acid Desaturase 1 Hs01096545_m1 II, III 
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FADS2 Fatty Acid Desaturase 2  Hs00927433_m1 II, III 
ELOVL1 Elongation of very-long chain fatty acids 1 Hs00967951_g1 
II, III 
ELOVL2 Elongation of very-long chain fatty acids 2 Hs00214936_m1 
II, III 
ELOVL3 Elongation of very-long chain fatty acids 3 Hs00537016_m1 
II, III 
ELOVL5 Elongation of very-long chain fatty acids 5 Hs01094711_m1 
II, III 
ELOVL6 Elongation of very-long chain fatty acids 6 Hs00907565_m1 
II, III 
ELOVL7 Elongation of very-long chain fatty acids 7 HS00405151_m1 
II, III 
GCK Glucokinase Hs01564555_m1 II, III 
PKLR Liver-type pyruvate kinase Hs00176075_m1 III 
PCK1 Phosphoenolpyruvate carboxykinase Hs00159918_m1 III 
CERS1 Ceramide synthase 1 Hs04195319_s1 I, III 
CERS2 Ceramide synthase 2 Hs00371958_g1 I, III 
CERS3 Ceramide synthase 3 Hs00698859_m1 I 
CERS4 Ceramide synthase 4 Hs00226114_m1 I, III 
CERS5 Ceramide synthase 5 Hs00908759_m1 I, III 
CERS6 Ceramide synthase 6 Hs00826756_m1 I, III 
SGMS1 Sphingomyelin synthase 1 Hs00983630_m1 I, III 
SGMS2 Sphingomyelin synthase 2 Hs00380453_m1 I, III 
UGCG UDP-glucose ceramide glucosyltransferase Hs00234293_m1 
I, III 
SMPD1 Sphingomyelin phosphodiesterase 1 Hs03679347_g1 I, III 
SMPD2 sphingomyelin phosphodiesterase 2 Hs00906924_g1 I 
SMPD3 sphingomyelin phosphodiesterase 3 Hs00920354_m1 I 
SMPD4 sphingomyelin phosphodiesterase 4 Hs04187047_g1 I 
ASAH1 N-acylsphingosine amidohydrolase (acid ceramidase) 1 Hs00602774_m1 
I, III 
ASAH2 N-acylsphingosine amidohydrolase (non-lysosomal ceramidase) 2 Hs01025305_m1 
I, III 
ASAH2B N-acylsphingosine amidohydrolase (non-lysosomal ceramidase) 2B Hs00184096_m1 
I 
APOB apolipoprotein B-100 Hs00181142_m1 I, II 
APOA1 apolipoprotein A-I Hs00985000_g1 I, II 
B2M Beta-2-microglobulin Hs99999907_m1 III 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase Hs99999905_m1 
I, II, 
III 
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4.8.3 Immunofluorescence 
Protein expression of the putative markers for the stem cells, definitive endoderm, 
and hepatocytes were evaluated in iPSCs, differentiating, immature and matured 
HLCs as well as in PHHs and HepG2 cells using immunofluorescence (Studies I 
and II). The primary and secondary antibodies are presented in Table 4. The staining 
protocol is described in detail in the original publication (Study I). 
 
Table 4.  Primary and secondary antibodies used in Studies I and II. 
Primary 
antibody 
Target Origin Dilution  Manufacturer 
OCT3/4 iPSCs Goat 1:400 R&D 
SOX17 Endoderm Mouse 1:200 R&D 
FOXA2 Endoderm Goat 1:300 Abcam 
LDL-R HLCs Rabbit 1:300 Cayman 
ASGPR1 HLCs Mouse 1:100 Novus Biologicals 
AFP Immature HLCs Rabbit 1:500 Dako 
ALB Mature HLCs Mouse 1:400 R&D 
Secondary 
antibody 
Target Origin Dilution  Manufacturer 
Anti Goat  OCT3/4, FOXA2 Donkey 1:800 Life Technology 
Anti rabbit  LDL-R, AFP Donkey 1:800 Life Technology 
Anti mouse  SOX17, ASGPR1, ALB Donkey 1:800 Life Technology 
Abbreviations: OCT, octamer-binding transcription factor; SOX17, (sex determining 
region Y)-box 17; FOXA2, forkhead box protein A2; LDL-R, low-density lipoprotein 
receptor; ASGPR 1, asialoglycoprotein receptor 1; AFP, alpha fetoprotein; ALB, 
albumin; iPSCs, induced pluripotent stem cells; HLCs, hepatocyte-like cells. 
4.8.4 Flow cytometry 
To determine the efficiency of the DE differentiation (Studies I and II), cells were 
stained by a DE surface marker, CXCR4 conjugated antibody (R&D Systems), and 
the number of CXCR4-positive cells were analysed using the AccuriTM C6 device 
(BD Biosciences, Franklin Lakes, NJ). The detailed protocol can be found in the 
original publications.  
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4.9 Biochemical methods 
HLCs were evaluated for their functionality during the differentiation (Study I) and 
maturation (Studies I and II) and the results were then compared with the data from 
the PHHs and HepG2 cells, which were cultured in parallel with the HLCs. PHHs 
were also evaluated for their functionality during the process of de-differentiation 
(Study III). The albumin, triacylglycerol (TAG), and urea content of the culture 
conditioned medium were determined, with the human albumin ELISA quantitation 
kit (Bethyl Laboratory, USA), the triglyceride quantification kit (BioVision Inc.), and 
the QuantiChromTM urea assay kit (BioAssay Systems), respectively, according to 
the manufacturers’ instructions. The values were normalised to the cell numbers.  
4.10 Mass spectrometry lipidomics 
Lipids (cholesterol, sphingolipids, glycerolipids, and glycerophospholipids) were 
extracted from iPSCs (Study I), DEs (Study I), immature HLCs (Study I), matured 
HLCs (Studies I and II), PHHs (Studies I, II, and III) and HepG2 cells (Study II) 
by Hamilton Microlab Star system (Hamilton Robotics AB, Kista, Sweden), and 
studied by using shotgun lipidomics.  
In the shotgun lipidomics, lipid extracts [cholesteryl ester (CE), diacylglycerol, 
(DAG), lysophosphatidylcholine (Lyso-PC), lysophosphatidylethanolamine (Lyso-
PE), lysophosphatidylglycerol (LPG), lysophosphatidylserine (LPS), 
lysophosphatidylinositol (LPI), and sphingomyelin (SM)] were examined on a hybrid 
triple quadrupole/linear ion trap mass spectrometer (QTRAP 5500) equipped with 
a robotic nanoflow ion source (NanoMate, Advion Biosciences Inc., Ithaca, NJ). 
Molecular lipids were analysed in positive ion mode using lipid class-specific 
precursor ion or neutral loss scans (Ekroos et al., 2002, 2003). Sphingolipids 
[ceramide (Cer), lactosylceramide (LacCer), glucosyl/galactosylceramide 
(Glc/GalCer), and globotriaosylceramide (Gb3)] and molecular phospholipids 
[phosphatidylcholines (PC), phosphatidylethanolamines (PE), and 
phosphatidylinositols (PI)] were analysed using ultra-high pressure liquid 
chromatography-mass spectrometry (UHPLC-MS) with a targeted approach (Merrill 
et al., 2005). Identified lipids were normalized against their respective internal 
standard (Ejsing et al., 2006) as well as their total protein concentrations in the cell 
samples. The total protein concentrations were determined by the Micro BCA™ 
Protein Assay kit (Thermo Scientific Pierce Protein Research Products) according to 
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the manufacturer’s instructions. The detailed procedure of analysis is described in 
the original publications.  
4.11 Fatty acid analysis by gas chromatography 
The FA composition and concentrations in the cell culture media used at iPSC-stage 
and at different stages of hepatocyte differentiation (Study I), as well as in the 
matured HLCs, PHHs, and HepG2 cells and their media (Study II) were analysed 
by gas chromatography. The calculations of the FA compositions and 
concentrations followed standard procedures and the FAs were named by using the 
abbreviations: [carbon number]:[number of double bonds] n-[position of the first 
double bond calculated from the methyl end] (e.g. 18:2n-6). The detailed analytical 
procedure is described in the original publications. 
4.12 miRNA analysis 
The expression profiles of all miRBase release v21 human miRNAs were determined 
using Agilent Sureprint G3 Human miRNA microarray slides. RNA was labelled and 
hybridized using the Agilent’s miRNA Complete Labelling and Hybridization Kit 
according to manufacturer’s protocol. After hybridization, the slides were scanned 
using Agilent’s High Resolution Microarray Dx Scanner. Data was normalised by 
quantile normalization (Bolstad et al., 2003) using the robust multi-array average 
(RMA) algorithm (Irizarry et al., 2003). Log2 fold change 1 was applied as a cut off 
value for determining the up- or downregulation of miRNAs in PHHs. 
4.13 Statistical analysis  
The results were compared using one-way ANOVA, followed by Bonferroni’s 
multiple-comparison test (Studies I and II). Data are presented as means ± SD 
with n representing the number of independent experiments. Analysis was carried 
out in GraphPad Prism version 5.02 software and results were considered significant 
if p-value <0.05. 
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5 SUMMARY OF THE RESULTS 
5.1 Hepatic differentiation 
5.1.1 Cell morphology during the hepatic differentiation 
The cells underwent a dramatic morphological changes during the hepatic 
differentiation process: round and dense iPSCs gradually lost their morphology and 
start migrating outwards from the colonies to form new network of DE cells. By 
second week, cells gradually increased in size, particularly in cytoplasm, and formed 
hepatoblasts/immature hepatocytes. During the third week of differentiation, 
immature hepatic cells became mature and formed polygonal cells with distinct 
canaliculated borders (Figure 7A). 
 
 
Figure 7.  The differentiation of iPSCs towards HLCs and their characterisations at different stages. 
A) Phase contrast images showing the morphological changes from iPSCs to definitive 
endoderm, hepatoblasts, and finally matured hepatocyte. B) Characterization of cells by 
immunocytochemistry at various stages of hepatic differentiation. OCT, octamer-binding 
transcription factor; SOX17, (sex determining region Y)-box 17; AFP, alpha fetoprotein; 
ASGPR, asialoglycoprotein receptor; DAPI, 6-diamidino-2-phenylindole. Scale bar 200 μm. 
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5.1.2 Gene and protein expression during the hepatic differentiation 
Consistent with the morphological changes, dramatic changes in gene expression 
was also observed during the differentiation process. The expression of OCT3/4 was 
downregulated at day 5, while the DE markers, SOX17 and FOXA2, were highly 
expressed. As the cells differentiated further, AFP started to be expressed around 
day 10 and the expression of mature liver marker, ALB, increased significantly 
around day 15 and peaked at day 20 or 25.  
Immunocytochemical staining further confirmed the results from gene 
expression. The cells at DE stage expressed only low levels of pluripotency marker 
OCT3/4 but were positive for the DE markers, SOX17 and FOXA2 (Study II, Fig. 
S2A). In addition, alpha-fetoprotein (AFP), albumin (ALB) as well as 
asialoglycoprotein receptor (ASGPR) were all expressed in differentiated HLCs, 
further confirming their hepatic phenotype (Figure 7B). 
5.1.3 Functionality assessment during the hepatic differentiation 
Several experiments were performed to evaluate the functionality of the 
differentiated HLCs. Our results showed that HLCs were able to synthesise and 
release albumin into the culture medium by the end of second week, with a maximum 
secretion at day 20 (Figure 8A). In addition, the expression of apolipoprotein B 
(APOB) and apolipoprotein A-I (APOA1) were measured as a surrogate for 
estimating VLDL and HDL production levels of the cells which further 
demonstrated that the cells are differentiating and maturing towards functional 
hepatocytes (Study II, Fig. 2C). Furthermore, HLCs showed to be able to efficiently 
uptake labelled LDL particles from the culture medium and produce and store lipid 
droplets in a FA rich medium supporting the role of functional LDL receptors and 
molecular machinery to generate lipid droplets (Figure 8 B&C).  
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Figure 8.  The assessment of functionality of HLCs during the differentiation. A) Albumin secretion by 
HLCs generated from three individual cell lines at 4 time points of days 14, 17, 20, and 23. 
Bars represent mean±SD of three biological replicates. B) Uptake of labeled LDL by HLCs 
at day 16 of differentiation generated by Method 1 and Method 2. C) Oil Red O staining of 
HLCs at day 16 of differentiation generated in low FA medium (Method 1) and FA rich 
medium (Method 2). HLCs were able to generate lipid droplets in FA rich medium. Scale bar 
200 μm. 
5.1.4 Fluctuation in the lipid species content of cells during hepatic 
differentiation 
We followed the changes in the cellular lipid content and composition during the 
entire differentiation process and overall, more than 160 molecular lipid species were 
detected using a shotgun mass spectrometry. Our results showed that the cellular 
lipid contents were constantly altered during the hepatic differentiation from iPSCs 
to matured HLCs and the alterations were mostly a reflection of the lipid or FA 
content of the culture medium (Figure 9A). At DE stage, the concentrations of the 
majority of lipid classes reduced in the cells, whereas three classes of SM, CE and PI 
were increasing independent of the lower or undetectable levels of those lipids in the 
DE medium. In hepatic commitment stage, a sudden increase in all lipid classes was 
evident, which mirrored the abundant lipid and FA in the medium at this stage. 
During the hepatic maturation, changes in the lipid levels were more subtle in 
agreement with the constant FA level of the medium during this stage. In addition, 
PCA showed that the cellular lipid composition of iPSC and DE cells clearly differ 
from that in hepatoblasts and HLCs (Study II, Fig. 2 C&D)  
Studying the lipids in molecular levels showed that the majority of CEs peaked at 
day 12. At later time points, however, the concentration of most CEs decreased 
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except those containing very-long chain unsaturated fatty acids (VLCUFA) such as 
CE 22:6, the concentration of which increased by maturation of HLCs (Figure 9B). 
In addition, we detected an overall increase in the FA chain length of SLs during 
hepatic differentiation and maturation. The largest changes in PLs occurred in 
polyunsaturated fatty acid (PUFA)-containing species such as PC 18:0/20:4 and PC 
18:0/22:6, and their concentration drastically increased in HLCs (Study I, Fig. 3C). 
On the other hand, PLs containing saturated or monounsaturated FAs (SFA or 
MUFA) were more constant during the differentiation. We detected, in total, 41 
molecular lipids that statistically significantly changed during the maturation stage 
(Figure 9B). 
 
 
 
Figure 9.  Alterations in the lipidome during the iPSC-HLC differentiation in Study I. A) Lines define 
the total concentration of different lipid classes in HLCs at seven time points during the 
differentiation. Bars show the total FA concentration of different media used for the hepatic 
differentiation. B) Lipidomic heat map showing the fold-increase of molecular lipid species 
that differed statistically significantly (p<0.05) between day 12 and day 28. CE, cholesteryl 
ester; Cer, ceramide; DAG, diacylglycerol; Gb3, globotriaosylceramide; Glc/GalCer, 
glucosyl/galactosylceramide; LacCer, lactosylceramide; Lyso-PC, lysophosphatidylcholine; 
Lyso-PE, lysophosphatidylethanoamine; PC, phosphatidylcholice; PC O, alkyl-linked 
phosphatidylcholice; PE, phosphatidylethanolamine; PE O, alkyl-linked 
phosphatidylethanolamine, PI, phosphatidylinositol; PS, glycerophosphoserine; SM, 
sphingomyelin. 
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5.1.5 Gene-lipid interactions 
In Study I, several SLs with very-long chain FAs increased during the hepatic 
maturation phase independent of the exogenous lipid supplies. Concurrently, a 
number of genes including CERS2, UGCG, SGMS1, and SGMS2 involved in the 
synthesis of SLs were upregulated in matured HLCs (Study I, Fig. 5A). In addition, 
positive correlations between several SLs and their corresponding genes (e.g. Cer 
d18:1/24:0 and CERS2; Glc/GalCer d18:1/26:0 and UGCG; and SM d18:1/24:1 
and SGMS2) were detected. Unlike SMs with very-long chain fatty acids (VLCFAs), 
the shorter-chain SMs (e.g. SM d18:1/18:0) decreased at hepatic maturation stage. 
SMs can be degraded by many different sphingomyelinase enzymes. The expression 
of two out of four studied sphingomyelinases, SMPD1 and SMPD3, were increased 
during the hepatic differentiation. On the other hand, the expression of several other 
genes such as CERS3, CERS5, ASAH2b, SMPD2, and SMPD4 remained constant 
during the hepatic differentiation.  
5.2 Comparison of hepatic differentiation methods 
5.2.1 Morphology 
In all five hepatic differentiation methods used in Study II, dramatic morphological 
changes happened during the differentiation, particularly at DE stage (Figure 4 
displays the five methods). In all methods except M5, migrating DE cells possessed 
a spiky morphology, while in M5, DEs were instead more square-shaped. 
Furthermore, the amount of cell death in M5 was considerably lower than in the rest 
of the methods. The choice of CHIR 99021 (used in M1) or Wnt3 (used in M2–4) 
seemed to have no effect on the morphology of the DE cells. At the hepatic 
specification stage, cells treated with BMP4, bFGF, and HGF (used in M1) 
possessed a different morphology compared to the cells treated with DMSO (used 
in M2–5). In addition, the HLCs differentiated by M4 showed the highest 
binuclearity (16%), the closest to the binuclearity observed in PHHs (Study II, Fig. 
2b). 
Initiating differentiation with single cells in M3 and M4 did not results in a higher 
efficiency of DE formation compared to M1 and M2, which were started with 
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colonies. However, DE cells were observed one or even two days earlier in methods 
initiated with single cells compared to methods initiated with colonies. 
5.2.2 Gene and protein expression  
SOX17 in M2-HLCs and FOXA2 in M4-HLCs were expressed lower than HLCs 
differentiated by other methods, however, this difference was not found statistically 
significant. On the other hand, the expression of AFP in the M2-HLCs was 
statistically significantly higher than in the M1-HLCs and the expression of ALB in 
the M5-HLCs was significantly higher than in the M1-HLCs and M3-HLCs (Study 
II, Fig. 2c).  
The analysis from flow cytometry showed that the expression of CXCR4, a 
surface DE marker, is higher in M1-, M2-, and M3- HLCs compared to that in M4- 
and M5-HLCs. Estimated by immunocytochemistry, matured HLCs differentiated 
by M4 contained the highest number of ALB positive cells (37.7%), while M1 
contained the lowest (9.8%). Additionally, in M2-, M3-, M4-, and M5-HLCs, more 
than 90% of cells showed to be positive for ASGPR, a mature hepatic marker. 
5.2.3 Functional assays 
The liver is responsible for producing albumin, the major protein in human serum. 
All the HLCs generated in Study II, were able to secrete albumin and no major 
differences were observed between the differentiation protocols. On the other hand, 
the levels of secreted urea by the M3- and M4-HLCs was significantly higher 
compared to the M1-, M2-, and M5-HLCs. Conversely, the TAG secretion in M1- 
and M2-HLCs was considerably higher than that in M3-, M4-, and M5-HLCs. The 
expression of both APOA1 and APOB in the HLCs was comparable in some points 
to HepG2 cells, PHHs, and hLTR, which further indicated the functionality of the 
HLCs (Study II, Fig. 2c). Interestingly, the expression of APOB in M2 correlated 
well with TAG secretion, whereas M5 showed high APOB expression but low TAG 
secretion. Unfortunately, the secreted apoB and apoA-I were not measured in the 
culture medium. All HLCs were able to uptake the fluorescently-labelled LDL from 
the culture medium, which was also supported by positive immunostaining of LDL 
receptors (LDL-R) by monoclonal antibody. 
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5.2.4 Lipid species profiles and fatty acid synthesis 
Since the HLCs differentiated by M3, M4, and M5 showed superior functionality, 
we selected the HLCs differentiated by those methods for the lipidomic analysis by 
a shotgun mass spectrometry. Overall, 15 major lipid classes – including CE, DAG, 
PC, Lyso-PC, PI, LPI, PE, Lyso-PE, SM, Cer, LacCer, Glc/GalCer, and Gb3 – were 
investigated, and altogether more than 150 molecular species were detected in Study 
II. The lipid profile of M3-, M4-, and M5-HLCs closely resembled each other with 
the exception of three PC species (PC 16:1–20:4, PC 17:0–18:1, and PC 17:0–20:4) 
(Study II, Fig. 3a). When the total levels of lipid classes were compared between 
the methods, only the concentration of Cer was at significantly lower levels in the 
M5-HLCs compared to the M4-HLCs (Study II, Fig. 5b).  
5.3 Comparison of hiPSC-HLCs with HepG2 and primary 
human hepatocytes 
5.3.1 Morphology 
The morphology of differentiated HLCs in Study I and II resembled the 
morphology of PHHs very well. HLCs possessed a polygonal structure with dense 
nuclei and high cytoplasm/nuclei ratio. In addition, similar to PHHs, it was common 
to observe binuclear HLCs. However, among all, M4-HLCs displayed the closest 
morphology and characteristic binuclearity to PHHs. 
5.3.2 Gene and protein expression 
All the HLCs expressed SOX17 higher than that in the PHHs and HepG2 but 
interestingly at the same levels as in the hLTR. In addition, the level of FOXA2 in 
the HLCs was comparable to those shown in PHH, hLTR, and HepG2. 
Furthermore, due to the immature characteristic of the HLCs, the expression of AFP 
was considerably higher while the expression of ALB was considerably lower in 
HLCs compared to those expression levels seen in the three studied reference 
samples. 
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5.3.3 Functional assays 
HLCs differentiated by all the methods displayed the hepatic functional aspects 
observed in PHHs. However, the levels of functionality varied in HLCs depending 
on the protocols and the functionality assays. For instance, all HLCs secreted lower 
amounts of albumin than the PHHs or even the HepG2 cells. M3- and M4-HLCs 
secreted TAG and urea in the same levels as those in PHHs. Additionally, the 
expression of APOA1 and APOB in M3- and M4-HLCs were the closest to the 
expression of those in the PHHs.  
5.3.4 Lipid species and fatty acid profiles  
The levels of PC and PI classes were similar among HLCs, PHHs, and HepG2 cells. 
The level of PE was, however, detected lower in the HLCs compared to the PHHs, 
mostly due to the lower levels of PE 18:0-18:2 and PE 18:0-20:4 in the HLCs. We 
observed that the concentration of PLs containing PUFAs were significantly lower 
in HLCs compared to the PHHs, particularly in the species that a SFA was coupled 
with 18:2 FA or its derivative 20:4. The concentrations of Lyso-PLs in the HLCs and 
the PHHs were in similar levels, whereas HepG2 cells contained considerably higher 
levels of Lyso-PLs compared to both HLCs and PHHs (Study II, Fig. 3). 
Similar to PLs, DAGs containing FA 18:2 were found in higher levels in the 
PHHs compared to HLCs. On the other hand, DAGs with FA 18:1 were lower in 
PHHs when compared to the HLCs. The CE concentration turned out to be lowest 
in PHHs, intermediate in HLCs, and the highest in HepG2 cells (Study II, Fig. 4).  
HLCs mimicked the SM profile of PHHs very well except that both the HLCs 
and HepG2 cells contained significantly higher levels of SM d18:1/16:0 compared 
to the PHHs. In addition, HepG2 also contained statistically significantly higher 
concentrations of SM d18:1/15:0 and SM d18:1/16:1 compared to both the HLCs 
and PHHs. In general, HLCs mimicked the ceramide profile in PHHs very well, 
however, the ceramide levels as total in HLCs were closer to HepG2 cells as PHHs 
contained higher levels of ceramides with long- and very-long chain SFAs (e.g. Cer 
d18:0/22:0, Cer d18:1/22:0, and Cer d18:1/24:0). Conclusively, HLCs contain lower 
levels of ceramide but higher levels of LacCer, Glc/GalCer, and Gb3 [members of 
glycosphingolipid (GSL) family] compared to the PHHs (Study II, Fig. 5).  
The FA analysis of HLCs, PHHs, and HepG2 cells in Study II (Fig. 6) showed 
that PHHs contained the highest and HepG2 cells the lowest amount of cellular 
PUFAs. In PHHs, this was mostly a reflection of high concentration of FA 18:2n-6 
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in their media. HLCs seemed to compensate the shortage of PUFAs receiving from 
their medium by efficiently synthesising VLCUFAs from the derivatives. For 
instance, the levels of 20:4n-6 (arachidonic acid), a bioactive metabolite of 18:2n-6, 
in HLCs was very close to that found in PHHs, while HepG2 did not show such 
efficiency. Comparing the MUFAs, the total levels of MUFAs in the HLCs were 
higher than in the PHHs, but lower than HepG2. FA 18:1n-9, generated from FA 
18:0 via stearoyl-CoA desaturase (SCD) function, was the major MUFA in the HLCs. 
HepG2 cells, on the other hand, contained high levels of 18:1n-7, clearly indicating 
a difference from the HLCs and the PHHs. Comparing the SFAs, the levels of SFAs 
in HLCs was also closer to PHHs than to HepG2 cells. In summary, the most 
abundant FAs detected in the studied cell types were as follows: HLCs: 18:1n-
9>16:0>18:0; PHHs: 16:0>18:0>18:2n-6; and HepG2: 16:0>18:1n-9>18:1n-7. 
5.3.5 Fatty acid metabolic regulation pathway 
In Study II, the expression of six key genes important in the synthesis of FAs were 
also studied by qPCR. GCK, FASN, ELOVL2, and ELOVL5 were expressed in 
HLCs mostly in similar levels as in PHHs. In half of the differentiated HLCs, the 
expression of FADS2 was similar to that in the PHHs, and the other half expressed 
FADS2 in the levels detected in HepG2 and hLTR samples. FADS1 was also 
expressed in HLCs at similar levels as in hLTR and the HepG2 cells but in 
significantly lower levels compared to the PHHs (Study II, Fig. 7). 
5.4 De-differentiation of primary human hepatocytes in culture 
5.4.1 The morphology, gene expression, and the functionality of de-
differentiating PHHs 
In Study III, the morphology of cultured PHHs remained unchanged for first two 
days of the culture but they started to lose their typical polygonal morphology from 
day 3 and presented weakly defined cell-to-cell borders (Figure 10A). The expression 
of FOXA2 and ALB, CYP1A2, and CYP51A1 was dramatically downregulated in 
PHHs within the first day of culture (Figure 10D), all confirming that the PHHs 
were going through the de-differentiation process. The secretion of TAG and urea 
by PHHs did not show any change between day2 and day 5. Interestingly, PHHs 
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seemed to slightly adapt to their new culture environment as their ability to secrete 
ALB was improved to some extent at day 5 compared to day 2, which correlated 
well with our observation from the expression of ALB at gene level. 
 
 
Figure 10.  Alteration in morphology, lipid profile, miRNAs, functionality as well as metabolism of FAs in 
de-differentiating PHHs. A) Phase contrast images displaying the morphology of the PHHs 
in the culture on days 1, 2, and 5. Scale bar 200 μm. B) Lines describe the detected total 
concentration of different class of lipids in cultured PHHs on days 1, 2, and 5. C) Heatmap 
presenting the expression changes of top 30 miRNAs in cultured PHHs on days 1, 2, and 5. 
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miRNAs that have already been associated with regulation of lipids are presented in Red. 
D) Real-time qPCR analysis of genes important in the functionality (CYP1A2 and ALB) or 
metabolism of FAs (ELOVL1, ELOVL2, ELOVL3, ELOVL6, ELOVL7, FADS2, FASN, and 
SCD) in PHHs on time points day 0, day 1, day2, and day5. The values are calculated 
relative to the human liver total RNA (hLTR) sample. Each sample was run in triplicate and 
bars represent mean±SD of the biological replicates. 
5.4.2 Lipid profile of de-differentiating PHHs 
The lipidomics data from Study III showed that the levels of ceramide, LacCer, 
Glc/GalCer, and Gb3 increased while the levels of PE and PI decreased in de-
differentiating PHHs (Figure 10B). In addition, the total CE content of PHHs was 
dramatically reduced after 1 day of the culture. The total PC and DAG, however, 
remained relatively constant during the culture of the PHHs.  
All the molecular SL species increased in PHHs-d5 particularly SLs containing 
LCFAs. The only exceptions were Glc/GalCer d18:1/23:0, SM d18:1/23:0, SM 
d18:0/23:0, SM d18:1/23:1 and SM d18:1/26:2, which decreased in PHHs-d5 
(Study III, Fig. 2B). Using qPCR, we carefully studied the expression of several 
genes related to the synthesis of SLs in the de-differentiating PHHs. In line with the 
lipidomics results, CERS5, CERS6, UGCG, SGMS1 and SGMS2 were all 
upregulated, while ASAH2 was downregulated in the cultured PHHs. CERS1 
expression was first elevated and then down-regulated during the culture of the 
PHHs. The expression of CERS2, ASAH1, SMPD1 remained relatively constant 
throughout the culture (Study III, Fig. 3).  
Lipidomics results also showed that the concentration of the PLs containing FA 
18:1 decreased during the first day of the culture of PHHs, while species containing 
FA 18:0 and FA 16:0 increased from day 0 to day 1. The PL species that contained 
PUFAs (specially 18:2) or highly unsaturated fatty acids (HUFAs with 4-6 double 
bonds) coupled with a SFA (e.g. PC 16:0-22:6) decreased in PHHs from day 2 to day 
5. On the other hand, the PCs consisting of SFAs and MUFAs (e.g. PC 16:0-18:1) 
mainly increased between day 2 and day 5.  
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5.4.3 Fatty acid and glucose metabolism in de-differentiating PHHs 
Studying the expression of key genes in metabolism of FAs showed an upregulation 
in the genes involved in de-novo lipogenesis of SFAs and MUFAs but downregulation 
in the genes synthesising the enzyme modifying PUFAs structures (Figure 10D). In 
fact, we observed an upregulation in the expression of ELOVL1, ELOVL3, 
ELOVL7, and FADS2. On the other hand, the expression of ELOVL2 was 
downregulated in the de-differentiating PHHs. FADS1 and ELOVL5 remained 
relatively unchanged. In addition, FASN, SCD, and ELOVL6 showed the same 
pattern of expression downregulated at days 1 and 2 but upregulated at day 5.  
Since the FA synthesis in hepatocytes is highly affected by glucose homeostasis, 
we also investigated 3 key genes involved in both glycolysis and gluconeogenesis in 
the liver. The expression of both glucokinase (GCK) and phosphoenolpyruvate 
carboxykinase 1 (PCK1) was constantly downregulated in cultured PHHs. Liver-type 
pyruvate kinase (PKLR) however, was temporally downregulated in PHHs-d1, but 
then upregulated in PHHs-d2 and recovered to its original level of expression of day 
0 at day 5 of the culture (Study III, Fig. 4B). 
5.4.4 miRNA profile of de-differentiating PHHs 
In total, 382 miRNAs were detected in the cultured PHHs. Our analysis showed 
major alterations in the expression of miRNAs in PHHs during the course of de-
differentiation. Comparing the miRNA profile of PHHs-d5 to that in PHHs-d0 it 
was demonstrated that 23 miRNAs were upregulated in de-differentiated PHHs 
from which miR-34a, miR-27a-3p, and miR-1246 were the most upregulated 
miRNAs. On the other hand, 22 miRNAs were downregulated in PHHs-d5 and 
miR-575, miR-4741, and miR-8069 were the most downregulated miRNAs. Those 
30 miRNAs that showed the largest temporal variations during the PHH de-
differentiation are presented in a heatmap (Figure 10C).
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6 DISCUSSION 
6.1 The differentiation of hiPSCs towards HLCs 
In Study I, we performed a comprehensive lipidomic fingerprint of differentiating 
HLCs in conjunction with transcriptional, biochemical and functional measurements 
and HLCs demonstrated the expected functionality and phenotype of hepatic cells. 
We observed that the concentrations of most lipid classes, including functionally 
important PLs and SLs increased after commitment of the cells to hepatic lineage. 
However, PCs and PEs, the main building blocks of bulk membrane, showed less 
variation. At the same time, the levels of storage lipids such as CEs were elevated. 
Similarly, DAGs that are intermediary lipid class between the storage and structural 
lipids were elevated indicating the enhanced lipid metabolism in the cells. 
Unfortunately, TAGs, which are the major lipids in hepatic LDs were not measured 
in the HLCs. Along with the significant influence of exogenous supplies of FAs and 
PUFAs, we also detected endogenous cellular responses in generating very-long 
chain and polyunsaturated FAs. Correlations were detected between the distinct SL 
species levels and their specific SL metabolism-regulating genes.  
Medium C (used in the hepatic commitment stage) contained high concentration 
of FAs which exceeded the sufficient amount needed for cells consumption. This 
excess amount of FAs resulted in formation of lipid droplets (LDs) during the 
second week of differentiation (see Figure 8C) in HLCs. LDs are the main reservoir 
for neutral lipids (majorly TAGs) in hepatocytes and can be used for e.g. membrane 
and steroid synthesis as well as for lipoprotein biosynthesis (Martin and Parton, 
2006). These observations were giving confidence that lipid metabolism in HLCs 
resembles that of genuine hepatocytes. 
It has been shown that the VLCFA-containing SLs are critical for the liver 
function (Park et al., 2014). During the HLCs differentiation and maturation, the 
concentration of several VLCFA-containing SLs increased, confirming that the 
stepwise hepatic differentiation protocol produced HLCs with a lipid phenotype 
resembling that of the PHHs. Ceramides can  be  degraded  to  sphingosine  and  
free  FA  by ceramidases (encoded by the ASAH genes) (Mao and Obeid, 2008). 
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Concurrent with increase in VLCFA-containing Cer in differentiating HLCs, the 
expression of ASAH2 was also upregulated, suggesting a balancing mechanism 
between Cer production and degradation during differentiation, which could partly 
explain why Cer levels remain constant during the late maturation stage.  
The expression of sphingomyelin synthases, SGMS1 and SGMS2, was 
upregulated in differentiating HLCs, correlating with increase in several molecular 
SM species (particularly those containing FAs C23-26). Simultaneously, SMPD1, a 
lysosomal acid sphingomyelinase, was upregulated during the differentiation. It is 
known that the SM coordinated breakdown is an essential part of membrane 
homeostasis (Kim et al., 2008) and ceramide as one of the products of SM catabolism 
is critical to the vital cellular processes (Delgado et al., 2006; Gault et al., 2010). 
Therefore, our data suggested that lysosomal degradation of SM might be crucial for 
balancing proper differentiation, maturation or functional structure of the HLCs.  
The levels of several VLCFA-containing GSLs were also increasing during the 
maturation of HLCs in Study I correlating with the expression of UGCG in HLCs.  
It has been shown that GSL products play critical roles in cell growth and 
differentiation, and mediate cell adhesion and modulate signal transduction (Gault 
et al., 2010). Our finding emphasizes the important role of active UGCG enzyme 
function in hepatic maturation. We also detected an overall increase in the FA chain 
lengths in the studied SLs classes during the differentiation. This might suggest that 
as the cells differentiate towards HLCs, SLs with longer chain FAs are incorporated 
in the lipid rafts affecting the membrane lateral lipid organisation. Complex SLs have 
various roles in lipid rafts for example for cell-cell contact and efficient membrane 
trafficking (Wassall et al., 2004). In addition, cell-adhesion and signalling molecules 
are localised in lipid rafts, implicating that these membrane domains may form 
platforms for cell adhesion and signal transduction.  
We detected a strong increase in PUFA-containing PL species during the hepatic 
differentiation in Study I. The increase in the polyunsaturated PLs affect the bulk 
membrane properties, such as flexibility, fluidity, and permeability (Rawicz et al., 
2008) and changing in these properties affects membrane vesicle formation and 
thereby lipid and protein trafficking, which needs to be efficient as the cells grow, 
differentiate and make more membranes (Van Meer et al., 2008). PC species 
containing FA 20:4 increased more drastically than PCs containing the other PUFAs. 
This increase was concurrent with the highest expression of apolipoprotein B-100 
and emergence of the lipid droplets in the cells. Studies showed that defects in 
efficient incorporation of 20:4n-6 into ER membranes, reduces TAG secretion from 
hepatic cells (Rong et al., 2015; Ruhanen et al., 2017). Thus, it appears that PC species 
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containing FA 20:4n-6 from the ω-6 FA pathway are crucial for the assembly and 
secretion of TAG containing lipoprotein particles, and likely needed for the proper 
function of the HLCs.  
Taken together, in Study I, it was demonstrated that how the lipidome of stem 
cells is remodelled in response to the external stimuli as they differentiate and mature 
towards functional HLCs. In addition, independent elevation in the production of 
VLCFA-containing SLs and PUFA-containing PLs during the hepatic maturation 
clearly showed that cells efficiently uptake FAs from the media, incorporate them, 
and modify simple lipids into more complex ones, which in turn can modify the 
membrane architecture mirrored in the altered cellular functions.    
6.2 hiPSCs-HLCs as cell models for investigating the lipid 
aberrations of the liver 
In Study II, we generated functional hiPSC-HLCs using five hepatic differentiation 
protocols and compared the differentiated HLCs comprehensively for their 
morphology, gene and protein expression, lipid composition, and functional traits to 
each other and to the two common hepatic cell models, PHHs and HepG2 cells. In 
this study, we performed a thorough characterisation of the metabolic features of 
HLCs and investigated their potential as a new cell model for lipid studies. 
First, we examined the effect of various conditions and stimuli on the phenotype 
of the cells during the hepatic differentiation. Determining the correct initial cell 
density for each cell line and method was found to be a key factor in success for the 
DE differentiation process. This was more critical than e.g. the type of the DE 
inducer such as CHIR 99021 or Wnt3. Furthermore, initiating the differentiation 
with single cells instead of colonies resulted in an earlier emergence of the DE cells 
but not the efficiency of the differentiation. In line with previous studies (Cameron 
et al., 2015), coating the culture plates with a mixture of Laminin 521/111 instead of 
GeltrexTM increased the number of ALB-positive cells by 82% and the binuclearity 
of the HLCs by 65%, however, this coating did not see any affect on the functionality 
of the HLCs. Conclusively, M3, M4, and M5 showed to differentiate HLCs with 
superior characteristics for studying the liver function and lipid metabolism 
compared to the M1 and M2 (see Figure 6). 
PUFAs and their bioactive derivatives play important roles during the cell 
proliferation and differentiation (Bieberich, 2012; Kim et al., 2009) and the PHHs 
possess an excellent capacity to metabolise diet-derived PUFAs (Sprecher, 2000). In 
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Study II, it was shown that the HLCs express the key enzymes in the metabolism 
of FAs at similar levels to those in the PHHs. In addition, HLCs showed to be 
superior cell models for studying the overall FA metabolism of the liver compared 
to HepG2 cells. 
FASN determines the de-novo synthesis of FAs in the cells by synthesising 
palmitate (FA 16:0) (Jensen-Urstad and Semenkovich, 2012). The relative activities 
of SCD and ELOVL dictate whether the metabolism of 16:0 follows the route 16:0 
– 16:1n-7 – 18:1n-7, or the route 16:0 – 18:0 – 18:1n-9 (Glück et al., 2016) (see 
Figure 2A). Our results showed that HepG2 cells may prefer the route forming 
18:1n-7 and this clearly distinguished them from HLCs and PHHs. HepG2 cells also 
significantly differed in the expression of most other genes involved in the synthesis 
of FAs such as FASN, ELOVL2, FADS1, and FADS2. The high expression of 
FASN in the HepG2 cells has also been reported elsewhere (Huang and Lin, 2012). 
Due to the rich supply of the FA 18:2n-6 in their medium, PHHs contained a 
considerably larger proportion of PUFAs, part of which was apparently converted 
to 20:4n-6 by the cells using the FADS1, FADS2, ELOVL2, and ELOVL5 enzymes. 
Consequently, the PLs composed of 16:0-18:2, 18:0-18:2, 16:0-20:4, and 18:0-20:4 
were abundant in the PHHs. HLCs, despite the very low supply of 18:2n-6 in their 
medium, were able to efficiently produce FA 20:4n-6, suggesting the proper function 
of corresponding enzymes in the HLCs. However, the presence of 2–3 mol% n-9 
PUFAs (produced from MUFAs) in both HLCs and HepG2 cells showed that both 
cell types suffered from essential PUFA deficiency (Kamada et al., 1999). It is 
considered that a high supply of n-6 PUFA to PHHs inhibits their endogenous 
MUFA synthesis from SFAs (Ntambi, 1999). Therefore, considering the important 
role of PUFAs in HLCs’ maturation shown in Study I, we speculate that 
reformulating the HLCs’ medium to a PUFA-rich medium may help to produce 
hepatic cells with improved functionality and a lipid profile better resembling that 
shown in the PHHs.  
The HLCs showed a mild accumulation of neutral lipids, which is likely due to 
their treatment with a FA-rich medium at the hepatoblast stage (discussed in Study 
I). The PHHs contained low levels of CE due to their low FA medium. HepG2 cells, 
on the other hand, were grown in FA rich medium and accumulated a large amount 
of the neutral lipids (preferentially TAGs). Therefore, results in the Studies I and II 
reveal the need to revise the generally overlooked FA content of culture media and 
to tailor it according to the cell’s needs. In addition, developing a standardised 
medium may bring added value in the accuracy of the results and prevent wrong 
interpretations particularly in the comparison studies.  
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In conclusion, data in Study II showed the detailed lipid profile of the HLCs in 
parallel to PHHs and HepG2 cells and evaluated their ability to metabolise FAs. 
iPSC-HLCs closely mimicked the lipid profile of PHHs and showed to be a more 
relevant liver cell model than HepG2 cells for studying cellular and molecular 
mechanisms that regulate lipid homeostasis in the liver.  
6.3 Lipids and the de-differentiation of the PHHs 
Hepatocytes undergo rapid de-differentiation in 2D culture and lose their phenotype, 
which particularly hampers their utility in long-term in vitro studies. In Study III, the 
mechanisms behind the de-differentiation and the possible role of lipids and 
miRNAs in the loss of the phenotype of PHHs were investigated. Here, a 
comprehensive lipidomic and lipid-related gene analysis as well as miRNA analysis 
on de-differentiating PHHs over 5 days of their culture was performed. Major 
alterations in both lipid and miRNA profiles of the cultured PHHs were observed. 
Despite the abundant PUFA 18:2-n6 in the culture medium of PHHs, the lipidome 
of PHHs showed increasing concentrations of SLs and MUFA-containing PLs and 
concurrently decreasing levels of PUFA-containing PLs. In line with this, the high 
expression levels of FASN, SCD, and ELOVL6 at day 0 created the prerequisite for 
de-novo synthesis of SFAs and MUFAs, although the genes related to the desaturases 
(FADS1, FADS2) and elongases (ELOVL2, ELOVL5), required for PUFA 
modifications were also expressed in the de-differentiating PHHs.   
It is previously reported that the viability of the PHHs decreases by 50% after 3 
days in culture (Ling et al., 2013). Conversely, we did not observe a dramatic cell 
death in 5 days culture of PHHs. One reason can be attributed to the density of the 
cultured PHHs. In our study, PHHs were cultured with high density, and therefore 
they formed a confluent monolayer, which could provide the cells with the critical 
cell-cell interactions. In Ling et al. study, however, the cell density was considerably 
lower. Alternatively, Ling et al. used RPMI+10% FBS medium for culturing the 
PHHs which differed from the defined medium used in the present study.  
Interestingly, as PHHs morphologically de-differentiated, they showed partial 
adaptation to the new 2D environment as the expression of both ALB and CYP 
genes were slightly improved at day 2 or 5. It is known that de-differentiation is an 
active, complex and differentially controlled process (Heslop et al., 2017) (Elaut et 
al., 2006; Gault et al., 2010). Therefore, while some features are diminishing, some 
other features might become over-expressed during the de-differentiation of the 
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PHHs. Therefore, even though the PHHs were de-differentiating, some functional 
features could still improve through adaptation to the new culture environment. 
We found that the concentration of almost all SL species increased during the de-
differentiation of PHHs. We confirmed this observation in gene expression levels 
and observed that several genes involved in the synthesis of SLs (such as UGCG and 
SGMS1) were upregulated, while the genes involved in the degradation of SLs (such 
as ASAH2) were downregulated in the de-differentiated PHHs. The concentration 
of SMs increased during the de-differentiation of PHHs. It is known that in the cells, 
approximately two-thirds of the total SM is located on the plasma membrane, 65% 
of which are found in the structure of the lipid rafts (Li et al., 2007). As discussed in 
chapter 2.3, lipid rafts are enriched with very-long chain and saturated SLs, 
surrounded with the bulk membrane containing unsaturated PLs (Ishibashi et al., 
2013; Simons and Gerl, 2010). We also observed a clear increase in very-long and 
saturated SLs (e.g. SLs with FA 22:0) and MUFAs containing PLs. These changes 
may implicate the alteration of the cellular membrane and the lipid rafts during the 
process of de-differentiation. This can subsequently affect lateral lipid packing 
membrane fluidity and permeability as well as cellular trafficking, signalling, and 
functionality. 
CERS1 and CERS5 were upregulated but CERS4 was downregulated in the 
cultured PHHs. Different Cers are known to be involved in regulating the balance 
between cell death and survival (Mesicek et al., 2010). We speculate that up- or down-
regulation of specific ceramides may be attributable to the activation of anti-
apoptotic or pro-survival mechanisms in PHHs (Cingolani et al., 2016; Heslop et al., 
2017; Saddoughi et al., 2008). These alterations could act as a double-edged sword, 
on one hand preventing the cell death, while on the other hand, causing the loss of 
the liver-specific functions in PHHs.  
In the de-differentiating PHHs, the de-novo synthesis of SFAs and MUFA 
synthesis (see Figure 2) was upregulated but the synthesis pathway of PUFAs was 
downregulated. FASN, ELOVL6, and SCD genes showed a tight co-regulation 
displaying similar pattern of expression: all downregulated on day1 and 2, but 
upregulated on day 5 suggesting that they regulated de-novo FA synthesis in a 
concerted manner during the prolonged culture of the PHHs. ELOVL1 and 
ELOVL3 were upregulated during the de-differentiation of the PHHs, matching 
with the observation from the increase in the lipids harbouring SFAs and MUFAs. 
On the other hand, ELOVL2 was downregulated in line with our observations of 
the reduced levels of PL species with a very-long PUFA chain in the de-
differentiating PHHs.  
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The increased degree of intrahepatic lipid saturation could affect the cell fate as 
SFAs may play an important role in “lipotoxic” mechanisms and in the initiation of 
apoptosis in hepatic cells. In addition, it could trigger the detrimental unfolded 
protein response (UPR) signalling pathways (Leamy et al., 2013). In the de-
differentiating PHHs, however, the reduction in the polyunsaturated PL content was 
compensated by an increase of PL species with MUFAs, which should balance the 
overall fluidity of the membrane bulk lipids (Ntambi, 1999). The MUFA production 
from SFA precursors may also have protected the cells from accumulation of high 
levels of toxic SFAs. Nevertheless, by reduction in PUFAs, PHH membrane 
dynamics, requiring polyunsaturated PE (van der Veen et al., 2017), and signalling 
pathways, requiring PI precursors (Balla, 2013), may have been hampered in de-
differentiating PHHs. 
6.4 The role of miRNAs in de-differentiation of PHHs 
Alongside the lipidomics, we analysed the miRNA profile in de-differentiating PHHs 
to identify the miRNAs that possibly regulate the lipid alterations during this process. 
We mainly focused on those miRNAs whose role in the regulation of lipids or FAs 
is already established or have been linked to the functionality of the cells (Novák et 
al., 2015; Takagi et al., 2010; Yang et al., 2015; Zhang et al., 2017). Several miRNAs 
were identified that were either up- or downregulated in the de-differentiated PHHs 
and which were connected to the regulation of lipid metabolism or PHHs 
functionality. miR-122 is a liver-specific miRNA and is the first miRNA reported to 
regulate lipid metabolism and its deletion results in the lower secretion of cholesterol 
and TG (Esau et al., 2006). This miRNA was downregulated in de-differentiated 
PHHs. On the other hand, miR-34a was upregulated in de-differentiated PHHs. It 
has been already shown that miR-34a plays multiple roles in the regulation of cell 
cycle, differentiation, migration and apoptosis (Yang et al., 2015). miR-34a can 
regulate bile acid-synthesizing enzymes such as CYP7A1, CYP26 family, and 
CYP3A4 (Goodwin et al., 2000; Oda et al., 2014; Takagi et al., 2010) as well as a 
series of genes and proteins involved in the lipid and glucose metabolism (Kim et 
al., 2013; Rodgers and Puigserver, 2007; Ye et al., 2017). In addition to miR-34a, 
miR-23a was another upregulated miRNA in the de-differentiated PHHs and 
reportedly it plays a role in suppression of gluconeogenesis in cells (Reyes et al., 2014; 
Wang et al., 2012). Therefore, it can be speculated that the upregulation of miR-34a 
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and miR-23a may be associated with the downregulation of GCK, PCK1, and CYP 
genes, and/or the loss of functionality observed in the de-differentiated PHHs. 
miR-27a was another upregulated miRNA in de-differentiated PHHs. It has been 
shown that miR-27a regulates several enzymes connected to the metabolism of lipids 
including adenosine triphosphate-binding cassette transporter A1 (ABCA1), FASN, 
SCD1, sterol regulatory element-binding proteins (SREBP-1 and SREBR-2), PPARα 
and PPARγ, APOA1, APOB100 and APOE3 (Ji et al., 2009; Shirasaki et al., 2013; 
Yang et al., 2015; Zhang et al., 2017). It has been suggested that miR-27a may 
regulate the metabolism of lipids by reducing lipid synthesis and increasing lipid 
secretion from the cells (Yang et al., 2015). The upregulation of miR-27a in Study 
III was simultaneous with the downregulation of both FASN and SCD in PHHs-
d1 and PHHs-d2, but not in PHHs-d5 where the expression of those genes was 
upregulated. This observation proposes the possible involvement of other 
miRNA(s) in the regulation of FASN and SCD. Interestingly, we found that miR-
30c, recently known to target FASN (Fan et al., 2017), was downregulated in PHHs-
d5 which suggests that miR27a and miR-30c may work together to regulate the 
synthesis, accumulation, and secretion of lipids in PHHs during their de-
differentiation. 
6.5 Limitations and future perspective 
iPSC-HLCs could serve as a powerful and functional cell model to study patient-
specific mechanisms of the lipid aberrations leading to pathological conditions, such 
as fatty liver disease or atherosclerosis. They provide a valuable platform for both 
academia and pharmaceutical industry for screening novel drugs in a truly patient-
specific manner and discovering the modes of action of molecules modulating the 
key lipids. Using iPSC-HLCs as a cell model, we can implicate the impact of genetic 
variations in developing metabolic diseases. iPSC-HLCs are also a promising cell 
source for regenerative medicine in hepatic replacement and managing of liver 
failure. However, more research is needed to improve the maturity of HLCs before 
they are widely applied in the clinic or drug screening. In fact, despite the huge 
progress, current efforts worldwide have not yet taken HLCs beyond a relatively 
immature phenotype (Baxter et al., 2015), and an integral part of this challenge is 
how we can capture the mature hepatic phenotype and prevent its deterioration. 
Crucially, increased understanding of both differentiation and de-differentiation 
process could be beneficial in developing a culture environment that improves the 
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maturity and maintains a hepatic phenotype from pluripotent cells in vitro. Our 
approach in Study I opens up new avenues in lipid-focused stem cell biology as it 
provides a novel tool in utilising the lipidome to follow the cell differentiation and 
maturation and how this is affected under altered conditions or stimuli. The stem 
cell lipidomic fingerprinting during HLC differentiation will assist in generating 
HLCs that more closely resemble the phenotype of primary human hepatocytes. 
Both Studies I and III illustrated the importance of VLC PUFAs in maturation 
and proper function of the hepatic cells. We showed that HLCs are capable of 
metabolising highly unsaturated FAs in order to fulfil the complex biological 
functions mediated by those FAs. In addition, we illustrated that the de-
differentiation of PHHs is accompanied by the reduction in their cellular PUFAs 
content. Therefore, it can be speculated that improving the PUFA homeostasis of 
hepatic cells either endogenously or exogenously, may help to improve their maturity 
and/or postpone their de-differentiation process in culture. In this respect, further 
studies in utilizing CRISPR-Cas9 technology to upregulate specific key genes 
important in synthesis of PUFAs could be applied in the future. In addition, 
improving the lipid formulation of the culture medium according to the HLCs need 
is worthwhile to be considered.  
It is well accepted that the 3D culture of hepatocytes enhances the organization, 
metabolic activity, and life-span of the hepatocytes. (Gieseck et al., 2014; Vellonen 
et al., 2014). However, the effect of 3D culture on the lipid profile of hepatic cells is 
not yet known. Therefore, further investigations using more physiologically relevant 
3D hepatic cell models are needed. 
 71 
7 CONCLUSIONS AND FUTURE ASPECTS 
This thesis provides a comprehensive study on iPSC-derived hepatic cells as a novel 
cell model for studying the lipid metabolism of liver. Here, the lipid profile of iPSC-
HLCs is characterised and compared to their native counterparts (PHHs) and the 
role of molecular lipid species and FAs in both differentiation and maturation as well 
as the de-differentiation of hepatic cells in 2D cell culture is investigated. The 
following conclusions can be drawn based on the three collective studies presented 
in this thesis: 
1. Three iPSC lines have been successfully differentiated to functional HLCs 
using various conditions described as five individual methods. HLCs 
resembled PHHs by expressing relevant hepatic markers as well as enabling 
secretion of lipoproteins, albumin, TAG and urea.  
2. iPSC-HLCs closely mimicked the lipid and FA profile of PHHs and thus 
they are a relevant cell model to investigate human lipid homeostasis at both 
molecular and cellular levels. 
3. The lipid profile of cells was dramatically altered during their differentiation 
from iPSC to HLCs, most of which was caused by exogenous supply of 
relevant lipids provided to the cells. However, several VLC SLs and PUFA-
containing PLs increased during the hepatic maturation phase independent 
of the exogenous lipid supplies, which is proposed to be important for 
proper inherent hepatic function.  
4. The de-differentiation of PHHs was accompanied with an upregulation in 
de-novo synthesis of SFAs and MUFAs, which was clearly mirrored in the 
increased levels of saturated and monounsaturated PLs and SLs. On the 
other hand, the levels of PLs containing PUFAs were reduced in the de-
differentiated PHHs. All these changes could dramatically affect the cellular 
membrane fluidity and functionality. 
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5. We found that collectively 45 miRNAs were either up- or downregulated in 
the cultured dedifferentiated PHHs from which miR-34a, miR-27a-3p, and 
miR-1246 were the most upregulated while miR-575, miR-4741, and miR-
8069 were the most downregulated miRNAs. Several up- or downregulated 
miRNAs in de-differentiating PHHs have been earlier associated with the 
regulation of genes involved in the lipid metabolism of hepatic cells. 
6. Although a 3D culture of hepatic cells would be more ideal, the 2D platform 
developed in this study can still facilitate the generation of HLCs resembling 
PHHs to a great extent.  
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ABSTRACT
Hepatocyte-like cells (HLCs) differentiated from human induced
pluripotent stem cells (iPSCs) offer an alternative model to primary
human hepatocytes to study lipid aberrations. However, the detailed
lipid profile of HLCs is yet unknown. In the current study, functional
HLCs were differentiated from iPSCs generated from dermal
fibroblasts of three individuals by a three-step protocol through the
definitive endoderm (DE) stage. In parallel, detailed lipidomic
analyses as well as gene expression profiling of a set of lipid-
metabolism-related genes were performed during the entire
differentiation process from iPSCs to HLCs. Additionally, fatty acid
(FA) composition of the cell culture media at different stages was
determined. Our results show that major alterations in the molecular
species of lipids occurring during DE and early hepatic differentiation
stages mainly mirror the quality and quantity of the FAs supplied in
culture medium at each stage. Polyunsaturated phospholipids and
sphingolipids with a very long FAwere produced in the cells at a later
stage of differentiation. This work uncovers the previously unknown
lipid composition of iPSC-HLCs and its alterations during the
differentiation in conjunction with the expression of key lipid-
associated genes. Together with biochemical, functional and gene
expression measurements, the lipidomic analyses allowed us to
improve our understanding of the concerted influence of the
exogenous metabolite supply and cellular biosynthesis essential for
iPSC-HLC differentiation and function. Importantly, the study
describes in detail a cell model that can be applied in exploring, for
example, the lipid metabolism involved in the development of fatty
liver disease or atherosclerosis.
KEY WORDS: Induced pluripotent stem cell, iPSC, Hepatocyte-like
cell, HLC, Differentiation, Cell model, Lipidomics, Fatty acid
INTRODUCTION
The liver is the main metabolic and synthetic organ in the human
body, carrying out more than 500 different functions. It is mainly
composed of hepatocytes, which constitute approximately 60% of
the cells in the liver and possess many important functions.
Hepatocytes produce the majority of circulating plasma proteins,
including transporters (such as albumin and lipoproteins), protease
inhibitors (α1-antitrypsin, antithrombin and α2-macroglobulin),
blood coagulation factors, and modulators of immune complexes
and inflammation (complement C3, C-reactive protein).
Hepatocytes also control the homeostasis of energy/fuel
molecules such as glucose/glycogen and fatty acids (FAs) as well
as other essential compounds of lipid metabolism such as
cholesterol and bile acids. Additionally, liver has a central role in
lipid metabolism as it is the major site for the generation of plasma
lipoproteins (Godoy et al., 2013).
The use of hepatocytes as in vitro models to explore different
aspects of liver function and metabolism has escalated in recent
years but primary human hepatocytes (PHHs), the key in vitro cell
type involved in e.g. cholesterol metabolism, are scarce because
they are obtained from organ donors. Furthermore, when in culture
the PHHs quickly dedifferentiate and lose their liver functions, thus
making them impractical for modelling the liver in vivo (Elaut et al.,
2006). Human induced pluripotent stem cell (iPSC)-derived
hepatocytes provide a good alternative to PHHs because iPSCs
can be easily reprogrammed from dermal fibroblasts and then
differentiated into hepatocyte-like cells (HLCs), which functionally
resemble PHHs (Hu and Li, 2015). iPSC-HLCs can recapitulate
metabolic variations observed in the population and have proved to
be potent in both short- and long-term drug screening and in
investigating hepatotoxicity or developing novel therapeutics
(Holmgren et al., 2014; Medine et al., 2013; Szkolnicka et al.,
2014). In addition, they have been utilised for studying fetal liver
exposure to harmful substances (Lucendo-Villarin et al., 2017) and
in identifying noncoding micro-RNAs regulating human liver
damage (Szkolnicka et al., 2016; Yang et al., 2016). Furthermore,
HLCs have been successfully used in developing in vitromodels for
studying hepatic diseases such as systemic amyloidosis (Leung
et al., 2013), liver-stage malaria (Ng et al., 2015) and hepatitis C
viral infection (Zhou et al., 2014). iPSC-HLCs could also offer a
good model for investigating basic mechanisms of e.g. lipid
metabolism as well as its dysregulation related to different diseases
such as fatty liver disease or atherosclerosis.
Lipids are a highly diverse class of biological molecules with
crucial roles in cellular energy storage (mainly in the form of
triacylglycerols), structure (e.g. key components of plasma and
nuclear membranes, endoplasmic reticulum and Golgi apparatus,
and trafficking vesicles like endosomes and lysosomes) and
signalling (as ligands that activate signal transduction pathways as
well as mediators of signalling pathways) (Van Meer et al., 2008).
Furthermore, de novo FA synthesis in the cells has a significant
impact on the acquisition and maintenance of cellular pluripotency
through increased mitochondrial fission (Wang et al., 2017).
Mammalian cells express tens of thousands of different lipid
species and use hundreds of proteins to synthesise, metabolise andReceived 30 May 2017; Accepted 10 July 2017
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transport them (Muro et al., 2014). Moreover, lipid defects are
central to the pathogenesis of many common diseases such as non-
alcoholic fatty liver disease (Ruhanen et al., 2017; Younossi et al.,
2016) or atherosclerosis (Meikle et al., 2011; Stübiger et al., 2012).
However, because the cellular lipidome is highly complex and very
dynamic, the study of lipids and identifying the precise underlying
defects has previously been hampered by analytical limitations.
This has been resolved by the emergence of advanced lipidomic
technologies. Lipidomics aims to precisely define and quantitate the
molecular profiles of lipids present in a cell, organism or tissue
(Watson, 2006; Wenk, 2005), and provides precise quantitative
snapshots of the lipidomes comprising hundreds of different
molecules (Llorente et al., 2013; Sales et al., 2016). This
technological advancement in conjunction with computational
technologies has made this field a promising area for biomedical
research (Ekroos, 2012).
In this study, we produced iPSCs from patient-derived dermal
fibroblasts and differentiated them into HLCs. In total, we
quantified 165 molecular species of lipids, and are the first to
report a comprehensive lipidomic profile of cells during the entire
differentiation process from iPSCs through the definitive endoderm
(DE) stage to HLCs. We assess the occurring lipidomic alterations
in relation to the variable supply of different FAs measured in the
cell culture media at each stage of the differentiation. Thus, we do
not overlook the comprehensive effects of the essential exogenous
metabolites the cells acquire from the culture medium. Additionally,
we present biochemical and functional measurements and
expression of sphingolipid (SL) metabolism-related genes during
HLC differentiation.
RESULTS
Characterisation of the iPSC lines
The three iPSC lines used in this study – UTA.10100.EURCAs,
UTA.11104.EURCAs and UTA.11304.EURCCs –were characterised
in detail for their pluripotency. All three iPSC lines expressed
characteristic markers of pluripotency at the protein (Fig. S1A) and
gene (Fig. S1B) level, and the virally transferred exogenous
pluripotency genes were silenced (Fig. S1C). The pluripotency of
iPSC lines was proven in vitro by embryoid body (EB) formation
and performing PCR to show the presence of all three germ layers
(Fig. S1D). The karyotypes of all three iPSC lines were normal
(Fig. S2).
Differentiation of iPSCs to HLCs through a DE stage
We used a previously described three-step protocol (Hay et al.,
2008) to produce HLCs from human iPSCs (Fig. 1A). During the
differentiation process, the cells underwent morphological changes:
iPSCs gradually lost their typical round and dense morphology and
after migration formed spiky-shaped DE cells. During the second
week of differentiation, at the hepatoblast stage, cells gradually
increased in size and, as they matured during the third week, formed
polygonal HLCs with distinct canaliculated borders (Fig. 1B). The
immunocytochemical staining at day 5 showed that cells expressed
only low levels of pluripotency marker OCT3/4 but were strongly
positive for the DE marker SOX17 (Fig. S3A). Furthermore, flow
cytometry analyses showed that 71-96% of the cells were positive
for the DE marker CXCR4 at day 5 of differentiation (Fig. S3B).
These results indicated that the iPSCs had efficiently differentiated
into DE during the endodermal induction step of the differentiation
protocol.
Consistent with the morphological changes observed during the
differentiation process (Fig. 1B), changes in gene expression were
detected (Fig. S3C). The expression of OCT3/4 was clearly
downregulated by day 5, whereas the DE marker SOX17 was
highly expressed at this stage. FOXA2, a transcription factor
involved in liver metabolism (Wolfrum et al., 2004), had a
continuous expression pattern starting around day 5 and
continuing until the end of differentiation. As the cells
differentiated further from DE towards HLCs, they started
expressing AFP (around day 10, which peaked around day 15-20
depending on the cell line). Expression of ALB, the gene for the
most abundant liver protein, increased strongly around day 15 and
peaked at day 20-25 (Fig. S3C). Immunocytochemical staining
further confirmed the expression of hepatic proteins at day 20 of
differentiation (Fig. 1C,D). Low-density lipoprotein receptor
(LDL-R), asialoglycoprotein receptor (ASGR), alpha fetoprotein
(AFP) as well as albumin (ALB) were all expressed in HLCs
(Fig. 1C,D). HLCs stained positive for ALB in 13, 18 and 19% of
the cells differentiated from UTA.10100, UTA.11104 and
UTA.11304, respectively. Both AFP and ASGR stained positive
in more than 90% of HLCs in all three cell lines.
Functionality assessment of mature HLCs
To assess the functionality of the iPSC-HLCs, we performed several
experiments. Because liver is the most important organ for LDL
catabolism and LDL-R activity, the ability of HLCs to uptake LDL
from the culture mediumwas evaluated. As shown in Fig. 1E, iPSC-
HLCs were able to efficiently uptake LDL. The level of secreted
albumin was measured from the cell culture medium at days 14, 17,
20 and 23 of differentiation, and all the iPSC-HLCs synthesised and
released albumin into the culture medium with maximum secretion
at day 20 (Fig. 1F).
Apolipoprotein B (APOB) and apolipoprotein A-I (APOA1) gene
expression levels of the iPSC-HLCs during the differentiation were
also measured as a surrogate for estimating very low-density
lipoprotein (VLDL) and high-density lipoprotein (HDL) production
levels of the cells. APOB is the main protein component of VLDL,
and the product of the APOA1 gene is the main protein component
of HDLs. The expressions of both APOB and APOA1 genes rose
around day 10, reached their peak at day 15 and then lowered
towards the levels of expression in PHHs (Fig. 1G,H). The
increasing expression of these liver-specific genes further
demonstrated that the iPSCs were differentiating and maturing
towards functional hepatocytes.
Lipidomic profiling of iPSC-HLCs
We performed lipidomic profiling of the cells during the entire
differentiation process from iPSCs to HLCs, and observed changes
in cellular lipid content and composition. Overall, more than 160
molecular species of lipids including cholesteryl esters (CEs),
diacylglycerols (DAGs), phospholipids (PLs) and SLs were
detected during the course of differentiation (Table S5). The
cellular contents of lipid classes (per protein) were constantly
altered during the differentiation. In the beginning, the protein-
normalised concentrations of the majority of lipid classes decreased
from day 0 to day 6, which mostly mirrors the low supply of lipids or
FAs from the culture media at this stage (Fig. 2A,B). However, clear
increases were observed in three classes – sphingomyelin (SM), CE
and phosphatidylinositol (PI) – independent of the lower or
undetectable levels of those lipids in medium B. This was
followed by a drastic increase in all lipid classes from day 6 to
day 12, which clearly reflected the abundant lipid and FA in
medium C (supplied to the cells from ∼day 7 to day 12). Thus, the
amount of FAs and lipids available in the media affects the lipid
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composition and content of the cells. The measured concentrations
of medium lipids and FAs were nicely in line with each other
(Fig. 2A,B). During the hepatic maturation, from ∼day 12 onwards,
changes in the lipid levels were more subtle, in agreement with the
constant FA level of medium D, which was given to the cells during
the hepatic maturation phase and contained on average 32.0 nmol
FA/ml of medium (Fig. 2A). Principal component analysis (PCA)
showed that the cellular lipid composition of iPSCs and DE stage
Fig. 1. See next page for legend.
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cells (days 0 and 6, respectively) clearly differs from the later time
points representing hepatoblasts (day 12) and HLCs (day 16-28)
(Fig. 2C). A similar PCA plot pattern was detected for the FA
composition of cell culture media (Fig. 2D).
To visualise the alterations occurring in the cellular lipidome
during the iPSC to HLCs differentiation in more detail, a heat map
was computed using day 0 as the reference and including all the
detected molecular lipids (Fig. S4A). Because the biggest alterations
in the cellular lipid content and composition happened before day 12
as observed in the PCA (Fig. 2C) and appeared mostly to reflect the
FA supply from the media, we computed another heat map using day
12 as the reference (Fig. S4B). From this heat map, the lipid
remodelling during the hepatocyte maturation phase became more
evident as the fluctuation from days 0 to 6 was excluded. We further
restricted the heat map to include only molecular lipids, the
concentration of which changed statistically significantly between
days 12 and 28 (P<0.05). In the resulting heat map, 41 molecular
lipids divided into two distinct clusters visible on the heat map
dendrogram (Fig. 2E). The upper cluster consists of mainly SLs with
very-long-chain FAs (C24-26), levels of which increased during the
maturation. Lipids that decreased after day 12 are clustered in the
lower part of the heat map consisting of several CE species as well as
lipids containing FA 18:2 [linoleic acid (LA)]. Similar phenomena
were observed in another heat map drawn separately for the 45 FAs
present in specific lipid classes in the cells (Fig. S5).
We detected 16 different CE species, the most abundant during
the iPSC to HLC differentiation being CE 18:1, CE 16:0 and CE
18:0 (Fig. 3A, lines), concurring with the higher level of FAs 16:0,
18:0 and 18:1 available in the medium C (Fig. 3A, columns).
Interestingly, CE 18:0 concentration was low in medium C whereas
CE 18:2 was detected the highest (Fig. 3A, insert). This CE 18:2
loading did not cause comparable accumulation of CE 18:2 in the
cells. The majority of CEs peaked at day 12, with the exception of
CE 20:1 (peak day 16) and CE 20:3, CE 22:5 and CE22:6 (peak day
24). The decrease of several CEs and the increase of CE 22:6 are
clearly visible in the heat maps, illustrating the statistically
significant lipid and FA changes between days 12 and 28
(Fig. 2E, Fig. S5). It is of note that only the last medium (medium
D, given to the cells from ∼day 13 onwards) provided the cells
abundantly with FA 22:6 (Fig. 3A).
During hepatic differentiation and maturation, we detected an
overall increase in the FA chain length of SLs (Fig. 3B). The C16-18
species predominated (64%) in the beginning of differentiation but
their relative abundance gradually decreased (to 44%) during the
hepatocyte maturation process. At day 6, a temporary increase in
the proportion of the C16-18 species was detected. Interestingly, as
the differentiation progressed, the SL chain length profile
approached that of PHHs, in which the very-long-chain species
(C20-26) predominate (Fig. 3B).
Closer examination of the PL molecular species revealed that the
largest changes occurred in polyunsaturated fatty acid (PUFA)-
containing lipid species, whereas lipids comprised of saturated or
monounsaturated FAs (SFA or MUFA, respectively) were more
constant throughout the entire differentiation (Fig. 3C, Table S5). The
polyunsaturated lipid species were essentially absent at the beginning
of differentiation and increased drastically until day 12 or 16, reflecting
the increasing concentrationofn-3 and n-6 PUFAs in themedia during
differentiation, as shown in Fig. 3C for the phosphatidylcholines
(PCs). On the other hand, the PCs containing FA 22:5 and 22:6
appeared later during the differentiation and at a lower concentration,
consistentwith their lowmediumconcentration aswell as a late and (as
compared to n-6 PUFAs) low level supply of n-3 PUFAs from the
medium (Fig. 3C). Lipids with different PUFA constituents mostly
peaked around day 12, after which they steadily decreased following
the pattern of medium FA 18:2 and 18:3 levels, which were at the
highest inmediumC (during∼days 7-13) and then dropped to a lower
level for the rest of the differentiation (Fig. 4). The molecular species
containing FA 20:3 and FA 20:4 peaked around day 12, reflecting the
media rich in their C18 precursors, and then their contents remained at
the fairly constant level due to the later moderate supply of FA 20:3
and 20:4 themselves (Fig. 4). The n-3 PUFA precursor, FA 18:3, and
the successors on the metabolic pathway, FA 20:5 and 22:5, were not
able to efficiently raise the levels of the 22:6-containing species,
which peaked only during days 16-24, i.e. after switching to 22:6-rich
medium (Fig. 4, lower row).
Gene–lipid interaction
Levels of several ceramides with very-long-chain FAs, e.g. Cer
d18:1/26:1 and Cer 18:1/26:0, increased statistically significantly
during the hepatic maturation phase (Fig. 2E). Ceramide synthesis
involves six different ceramide synthases (CerSs): CerS1-CerS6.
The CERS1 gene was the only highly expressed ceramidase gene at
the iPSC stage and it gradually reduced to the expression levels
detected in PHHs (Fig. 5A). The expression of the CERS2 gene, by
contrast, slowly increased during hepatocyte differentiation,
reaching the expression level in PHHs by day 20 of differentiation
(Fig. 5A). A statistically significant correlation was observed
between CERS2 expression and the very-long-chain ceramides Cer
d18:1/24:0 (r=0.83, P<0.0001), Cer d18:1/23:0 (r=0.78, P<0.001)
and Cer d18:1/26:0 (r=0.73, P<0.001) (Fig. 5B). A similar gene
expression pattern to CERS2 was observed for CERS3. CERS4
expression varied whereas that ofCERS6 gradually increased during
the differentiation, and CERS5 was ubiquitously expressed
throughout the differentiation (Fig. S6A).
Ceramides are degraded to sphingosine and free FAs by
ceramidases encoded by distinct genes such as ASAH1 and ASAH2.
The expression of ASAH1 increased during the differentiation (Fig.
S6B). ASAH2 expression peaked strongly at day 15 and then
gradually reduced towards the levels detected in PHHs. ASAH2b
expression was constant throughout the differentiation and at the
same level as in PHHs, only peaking slightly at day 15 (Fig. S6B).
Lactosylceramide (LacCer) and glucosyl/galactosylceramide
(Glc/GalCer) are members of the glycosphingolipid (GSL) family
and the UDP-glucose:ceramide glucosyltransferase (UGCG) gene
Fig. 1. Hepatic differentiation of iPSCs through the definitive endoderm
(DE) stage. (A) A schematic representation of the hepatic differentiation
protocol (modified from Hay et al., 2008) and cell culture media used at each
stage. See text for details of the media. (B) Phase-contrast images showing
sequential morphological changes from iPSCs (day 0) to DE (day 5) and finally
hepatocyte-like cells (HLCs) (day 20) during differentiation. (C,D)
Immunocytochemistry of the iPSC-HLCs differentiated from three patient lines
(UTA.10100.EURCAs, UTA.11104.EURCAs andUTA.11304.EURCCs) at day
20 showing the expression of (C) LDL receptor (LDL-R) and asialoglycoprotein
receptor (ASGR), as well as (D) α-fetoprotein (AFP) and albumin (ALB). Nuclei
are stained with DAPI. (E) The iPSC-HLCs were able to uptake LDL at day 20
of differentiation and (F) produce and secrete albumin during differentiation.
Values are normalised per 1 million cells per 24 h. Bars represent means±s.d.
of three biological replicates. Gene expression levels of (G) apolipoprotein B
(ApoB) and (H) apolipoprotein AI (ApoAI) at different time points during the
iPSC to HLC differentiation normalised to the housekeeping gene GAPDH,
and expressed relative to day 0. Each sample was run in triplicate and bars
represent means±s.d. of three studied cell lines. iPSC, induced pluripotent
stem cell; KO-DMEM, KnockOut Dulbecco’s modified Eagle medium; DMSO,
dimethyl sulfoxide; HGF, hepatocyte growth factor; OSM, oncostatin M; PHH,
primary human hepatocyte. Scale bars: 200 μm.
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encodes the enzyme that catalyses the first glycosylation step in
GSL biosynthesis. There was a statistically significant increase in
four different GSLs, including LacCer d18:1/26:0 and Glc/GalCer
d18:1/26:1, during the hepatic maturation phase (Fig. 2E).
Compatibly, UGCG expression increased during the iPSC-HLC
differentiation (Fig. 5A), and we observed a statistically significant
correlation between UGCG expression and the total level of Glc/
GalCer (r=0.54, P<0.05), particularly with Glc/GalCer d18:1/26:0
(r=0.84, P<0.0001) (Fig. S6C).
An almost fourfold increase in total SM level was detected from
day 0 to day 28 of the iPSC-HLC differentiation (Fig. 2A).
Specifically, an increase in the longer (C23-26) SM species was
observed (Fig. S7A). SM is metabolised from ceramides by SM
synthases (SMS1 and SMS2). The expression of the corresponding
Fig. 2. Changes in the lipidome during iPSC to hepatocyte-like cell (HLC) differentiation. (A) Lines describe the total concentration of different lipid classes
detected in the cells at seven timepoints during the iPSC toHLCdifferentiation.Bars represent the total FA concentration (nmol FA/ml ofmedium) of differentmedia
used during hepatic differentiation. Values at the top of bars and the top line show the total concentrations of FAs in the medium and PC in the cells, respectively.
(B) Total concentration (μM) of different lipid classes in culture medium A, B, C and D. (C) Principal component analysis (PCA) plot showing the separation of
samples based on lipid profiles. PCA analysis of the 165molecular lipids showed that the two first principal components constitute 63.2% of the variance. (D) PCA
analysis of the FA content of cell culture media used at different stages of hepatic differentiation. (E) Lipidomic heat map showing fold increase of molecular lipid
species at day 16, 20, 24 and 28 of iPSC to HLC differentiation as compared to day 12. Each horizontal row represents a molecular lipid and each vertical column
represents an individual time point of the differentiation. Lipid abundance ratios are coloured according to the fold changes and the colour key indicates the
magnitude of log2 fold change. Data shown are the lipids for which concentration differed statistically significantly (P<0.05) between day 12 and day 28. iPSC,
induced pluripotent stem cell; CE, cholesteryl ester; Cer, ceramide; DAG, diacylglycerol; Gb3, globotriaosylceramide; Glc/GalCer, glucosyl/galactosylceramide;
LacCer, lactosylceramide; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanoamine; PC, phosphatidylcholine; PCO, alkyl-linked phosphatidylcholine;
PE, phosphatidylethanolamine; PE O, alkyl-linked phosphatidylethanolamine; PI, phosphatidylinositol; PS, glycerophosphoserine; SM, sphingomyelin.
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genes, SGMS1 and SGMS2, increased during differentiation, reaching
the expression levels of PHHs by day 10 (Fig. 5A). A statistically
significant correlation was detected between SGMS2 expression and
levels of very-long-chain SMs (Fig. 5C) such as d18:1/24:0 (r=0.82,
P<0.0001), SM d18:1/24:1 (r=0.78, P<0.001) and SM d18:1/26:1
(r=0.67, P<0.01). Levels of these very-long-chain SMs increased
independently of the exogenous lipid supplies during the hepatoblast
phase, whereas the shorter-chain SMs such as SMd18:1/18:0 and SM
d18:1/18:1 decreased at the hepatic maturation stage (Fig. S7A,B).
Several different sphingomyelinase (Smase) enzymes degrade SMs.
The SMPD1 gene encodes a lysosomal acid Smase, the expression of
which increased during the hepatic differentiation (Fig. 5A) along
with the expression of another sphingomyelinase gene, SMPD3
(Fig. S7C). The expression of two other Smase genes, SMPD2 and
SMPD4, was fairly constant through the differentiation and similar to
that in PHHs (Fig. S7C).
DISCUSSION
In this study, we successfully produced functional HLCs from iPSCs
and describe a comprehensive lipidomic fingerprint of these cells in
conjunction with biochemical and functional measurements. We
quantitatively monitored a total of 165 molecular species of lipids
during the course of hepatic differentiation, as well as measuring the
concentrations of different lipids and FAs in the cell culture media at
each stage of differentiation. The analyses of lipids and FAs in the
media were complementary in characterising the supplies of the
cells. After commitment of the cells to the hepatic lineage (around
day 12), protein-normalised concentrations of most studied lipid
classes increased. These included functionally important specific
PLs and SLs but, as expected, the main building blocks of bulk
membrane, PC and PE, showed less variation. At the same time, the
levels of storage lipids were elevated, indicated by the increased CE
totals. DAGs were also analysed because they are an important
intermediary lipid class between the storage and structural lipids,
and their elevated levels at day 12 indicate enhanced lipid
metabolism (complex triacylglycerol molecular species were not
addressed in this study). These lipidome alterations mirror the large
increase in medium FA levels and improved supply of PUFAs to the
cells. Simultaneously, the cells grew in size and approached
hepatocyte cell morphology. Along with the influence of
Fig. 3. Changes in cholesteryl ester (CE),
polyunsaturated fatty acid (PUFA)-containing
phosphatidylcholine (PC) species and the chain length
of sphingolipids (SLs) during the iPSC to hepatocyte-
like cell (HLC) differentiation. (A) Lines represent the
concentration (pmol/μg total protein) of all detected CE
species at different time points of the iPSC to HLC
differentiation. Concentrations are presented on a
logarithmic scale. Bars represent concentration of all
different FAs (nmol FA/ml of medium) detected in different
cell culture media used during hepatic differentiation. The
insert on the lower right shows the concentration (μM) of CE
species detected in culture medium A, B, C and D. No CE
species were detected in medium B. (B) The distribution of
SLs with different FA chain lengths at different time points
shows that, during hepatic differentiation and maturation,
the relative abundance of C16-18 species gradually
decrease, whereas C23-24 species increase. At the end of
the hepatic maturation phase, the distribution closely
resembles that of primary human hepatocytes (Hu8209 and
Hu8210). All SLs detected were included in the
calculations. (C) Lines represent the concentrations (pmol/
μg total protein) of selected PC species at different time
points. The levels of saturated/monounsaturated FA (in
blue)-containing species remain rather constant, whereas
levels of PUFA-containing lipid species (20:4 in red; 22:5/
22:6 in orange) emerge/increase considerably at day 6 and
12. Bars represent the total n-3 FA, n-6 FA and FA 22:6
concentration (nmol FA/ml of medium) in cell culture media
at each stage of differentiation. The insert on the lower right
shows the concentration (μM) of PC species detected in
culture mediumA, B, C andD. PCs 18:0/22:5 and 18:0/22:6
were not detected in the media. Values at the top line show
the concentration of PC 16:0/18:1 in the cells during
differentiation.
1146
RESOURCE ARTICLE Disease Models & Mechanisms (2017) 10, 1141-1153 doi:10.1242/dmm.030841
D
is
ea
se
M
o
d
el
s
&
M
ec
h
an
is
m
s
exogenous supplies, we also found endogenous cellular responses:
specific SL-metabolism-related genes correlated with distinct SL
species levels, which showed that, during the differentiation,
changes in gene expression levels were reflected in the levels of
specific lipid species at a given time point.
Cholesterol biosynthesis is one of the important functions of
hepatic cells. Interestingly, the three most abundant storage forms of
CEs detected during the differentiation of iPSCs to HLCs, i.e. CE
18:1, CE 16:0 and CE 18:0, have previously been shown to be
among the most abundant CEs in the human liver (Nestel and
Couzens, 1966). Despite the level of CE 18:2 being very high in
media C and D, when analysing cellular CE levels, this species was
not among the highest species but the essential 18:2n-6 [linoleic
acid (LA)] was apparently incorporated into structural PLs, priming
these PUFAs for signalling. This gives confidence that lipid
metabolism of this cell model resembles that of genuine
hepatocytes. Most CE species were at their highest levels at day
12 and then, along with decreasing medium CE and FA levels, CEs
in the cells decreased during hepatocyte maturation. Compared to
medium A and B, medium C (provided to the cells from ∼day 7 to
∼day 13) contained a very high total concentration of FAs,
exceeding the sufficient amount for a cell’s consumption. This is
also consistent with our observation of lipid droplet (LD) formation
during the second week of differentiation (results not shown),
suggesting that the excess amount of FAs provided in medium C are
stored as LDs in the cells. LDs are the main reservoir for neutral
lipids in the cells and can be used for metabolism, membrane
synthesis (PLs and cholesterol) and steroid synthesis (Martin and
Parton, 2006).
SLs form a class of lipids defined by their C18 amino-alcohol
backbones, which are synthesised in the ER from non-SL
precursors. Modification of this basic structure gives rise to the
vast family of SLs such as ceramides, SMs and GSLs, which are
structural components of biological membranes and bioactive
molecules participating in diverse cellular activities such as cell
division, differentiation, gene expression and apoptosis (Gault et al.,
2010). SLs also participate in cell signalling and modulate
inflammation (Hannun and Obeid, 2008; Maceyka and Spiegel,
2014). Furthermore, increasing evidence shows that SLs contribute
to the pathogenesis of metabolic diseases including atherosclerosis
(Borodzicz et al., 2015; Haus et al., 2009; Hornemann and Worgall,
2013) and that SL metabolism is affected by dyslipidemia (Holland
and Summers, 2008). Because the liver is heavily involved in lipid
metabolism, hepatocytes offer a good cell model for studying the
basic mechanisms of lipid metabolism and its dysregulation.
The precursor of all SLs is ceramide, which primarily consists of
a sphingoid long-chain base (sphingosine) and one FA chain, the
length of which typically ranges from C14 to C26, the ceramide
species with FAs 16:0, 24:0 and 24:1 being predominant in most
mammalian tissues. Ceramide synthesis is a complex process and
orchestrated by six mammalian CerSs, each of which produces
ceramides with distinct FA chain lengths (Cingolani et al., 2016;
Levy and Futerman, 2010; Park et al., 2014). The expression pattern
of CerS is cell specific, which is reflected in the different SL acyl
chain composition in a given tissue (Levy and Futerman, 2010).
CerS2, the dominant CerS isoform found in the liver, utilises C20-
C26 acyl-CoA species as substrate and is one of the major CerSs
responsible for the synthesis of long-chain ceramide species
Fig. 4. The levels of polyunsaturated fatty acid (PUFA)-containing lipids during iPSC to HLC differentiation. Lines in the graphs show concentrations
(pmol/μg total protein; logarithmic scale on the left) of lipids containing the given PUFA moiety at different time points. Each line represents the lipid species with
the specific PUFA in a particular lipid class; line colour refers to lipid class (colour key depicted on the right). The bars represent the concentration of FA 18:2, 20:3,
20:4, 18:3, 20.5, 22:5 and 22:6 (nmol FA/ml of medium, scale on the right) in the cell culture media during hepatic differentiation. CE, cholesteryl ester; PC,
phosphatidylcholine; PC O/PC P, ether-linked PC; PE, phosphatidylethanolamine; PE O/PE P, ether-linked PE; PS, phosphatidylserine; FA, fatty acid.
1147
RESOURCE ARTICLE Disease Models & Mechanisms (2017) 10, 1141-1153 doi:10.1242/dmm.030841
D
is
ea
se
M
o
d
el
s
&
M
ec
h
an
is
m
s
(C20-C26) (Laviad et al., 2008). In our study, the concentration of
several very-long-chain (C22 to C26) SLs increased statistically
significantly between days 12 and 28, which indicates an increase in
CerS2 activity as the cells matured towards functional HLCs. This
was supported by a clear and statistically significant increase
of CERS2 gene expression during iPSC-HLC differentiation.
Furthermore, a statistically significant positive correlation between
CERS2 expression and very-long-chain ceramides (e.g. Cer d18:1/
24:0) was found. The very-long-chain ceramides produced by
CERS2 are essential for liver function (Park et al., 2014); thus, the
increase in their levels acts as evidence of hepatocyte functionality.
Admittedly, we have not measured CERS2 enzyme activities but
only the level of CERS2 gene expression. Still, both the increased
CERS2 gene expression as well as the increase in long-chain
ceramides and other long-chain SLs showed that the stepwise
hepatic differentiation protocol produced iPSC-HLCs with a lipid
phenotype resembling that of PHHs. Ceramide can be degraded to
sphingosine and free FA by ceramidases (Mao and Obeid, 2008).
Acid ceramidase (encoded by the ASAH1 gene) most efficiently
hydrolyses ceramide with medium-chain FA components (C12 to
C14), whereas the neutral ceramidase (ASAH2) prefers long-chain
to very-long-chain components (C16 to >C24) (Gault et al., 2010).
In the current study, expression of ASAH1 and ASAH2b was rather
constant, whereas, concurrent with the increase in very-long-chain
ceramide, the expression of ASAH2 peaked at day 15 and then
gradually decreased towards levels in PHHs. These findings suggest
that there is a balance between ceramide production by CerS and
degradation by ceramidases during differentiation, which could
partly explain why ceramide levels stay constant towards the end
of the differentiation. The C26 FAs were not detected in any of the
culture media and the C26 species of ceramides and SLs
(synthesised from their precursor) were still found in the cells,
with increasing amounts towards the end of the differentiation
process. Thus, the levels and molecular species composition of
ceramide and the successor SLs seemed to be endogenously
regulated.
Total SM levels increased during iPSC-HLC differentiation. We
showed that the corresponding genes for SM synthases – SGMS1 and
SGMS2 – were expressed in the iPSC-HLCs throughout the
differentiation at levels approaching those in PHHs. It has
previously been shown that both SGMS1 and SGMS2 positively
correlate with levels of cellular SM (Li et al., 2007). Our study
supports this because the expression of SGMS1 and SGMS2 correlated
well with several molecular SM species, especially the long-chain
ones (C23 to C26). Furthermore, during the DE differentiation stage, a
sharp increase in total level of SM was observed, whereas PC and
ceramide decreased. SM synthases use ceramide and PC as substrates
to produce SM (Liu et al., 2009), offering an explanation for the
transient decreases of ceramide and PC in the beginning of the hepatic
differentiation. However, this still requires further studies owing to the
Fig. 5. Expression levels of
sphingolipid (SL) metabolism-related
genes during hepatic differentiation
and in primary human hepatocytes
(PHHs). (A) The expression of CERS1,
CERS2, UGCG, SMPD1, SGMS1 and
SGMS2 during hepatic differentiation from
iPSCs at day 0, 5, 10, 15, 20 and 25 as
well as in PHHs. The expression of each
gene was normalised to the endogenous
control gene, GAPDH, and presented
relative to day 0 (iPSCs). Each sample
was run in triplicate and bars represent
means±s.d. of three studied cell lines or
two PHH donors. **P≤0.01; ***P≤0.001.
(B) The expression of CERS2 correlates
positively with Cer d18:1/24:0 (Spearman
r=0.83, P<0.0001), Cer d18:1/23:0
(r=0.78, P<0.001) and Cer d18:1/26:0
(r=0.73, P<0.001). (C) SGMS2 expression
correlates positively with levels of SM
d18:1/24:0 (r=0.85, P<0.0001), SM d18:1/
24:1 (r=0.78, P<0.001) and d18:1/26:1
(r=0.67, P<0.01). Cer, ceramide; CERS,
ceramide synthase; SGMS, sphingomyelin
synthase; SMPD, sphingomyelin
phosphodiesterase; UGCG, UDP-glucose
ceramide glucosyltransferase; SM,
sphingomyelin.
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very complex and dynamic nature of the cellular lipidome, and strong
influence of the culturemedia. Because SM is themost abundant SL in
human cells, its coordinated breakdown is an essential part of
membrane homeostasis. It occurs by the Smase family and results in
the production of ceramide and free phosphocholine. The SMPD1
gene encodes a lysosomal acid Smase, whereas SMPD2, SMPD3 and
SMPD4 are neutral Smases localised to different cellular
compartments (Kim et al., 2008). SMPD2 is located in ER, and
SMPD4 in both ER and Golgi. The expression of SMPD1 increased
during the hepatic differentiation as early as at DE stage, suggesting
that lysosomal degradation of SM might be crucial for differentiation,
maturation or functional structure of the HLCs because ceramide, as
one of the products of SM catabolism, is considered crucial to the
above-mentioned vital cellular processes, as are its derivatives
(Delgado et al., 2006; Gault et al., 2010). Pharmacological
inhibition of SM de novo synthesis decreases not only SM levels
but also ceramide and sphingosine (Liu et al., 2009). This clearly
emphasises that the metabolic conversions among the SLs in the cell
are tightly interconnected. In linewith this, we observed a similar gene
expression pattern between SMPD1, ASAH1 and UGCG during the
entire hepatic differentiation.
GSLs are complex carbohydrate-containing SLs and
characteristic components of plasma membranes, residing
specifically in the membrane microdomains called lipid rafts.
GSL metabolism and composition are altered during the
proliferation and differentiation of various types of cells
(Iwabuchi et al., 2010). LacCer is a precursor in the biosynthesis
of complex GSLs, and known to activate a signal transduction
pathway leading to cell proliferation. In our study, LacCer d18:1/
26:0 as well as three different very-long-chain Glc/GalCer increased
during hepatic maturation. There was also a trend of increased
expression of UGCG (responsible for glycosylation) during the
iPSC-HLC differentiation, correlating with the levels of Glc/
GalCer. This suggests that active UGCG enzyme function is vital
in hepatic maturation because its GSL products are essential players
in cell growth, development and differentiation, and mediate cell
adhesion and modulate signal transduction (Gault et al., 2010).
We detected an overall increase in the FA chain lengths in the
studied SL classes during the differentiation. This might suggest
induction of membrane lateral heterogeneity with more lipid rafts
incorporating SLs with longer chain lengths as the cells differentiate
towards HLCs. The lipid rafts are regarded as small (from 10 to
200 nm) specialised regions of plasma membrane enriched in
cholesterol and SLs with very-long and saturated acyl chains. The
lipid rafts are more ordered and slightly thicker lipid domains than
the surrounding bulk membrane, which contains unsaturated PL
molecules. In line with this, we found significant increase in very-
long and saturated SLs (24:0 and 26:0) (Fig. S5), as well as high
levels of unsaturated PLs provided by medium C from day 7
(Fig. 3C). Signalling and cell-adhesion molecules are localised in
lipid rafts, implicating that these domains may form platforms for
signal transduction and cell adhesion. Complex SLs are needed in
the lipid rafts for example for cell–cell contact and efficient
membrane trafficking (Wassall et al., 2004). However, besides
cholesterol and SLs, the emergence of the raft domains from bulk
membrane also involves unsaturated PLs.
Enrichment of n-3 PUFA in the plasma membrane alters the
lateral organisation of lipids. Polyunsaturated PLs, especially those
with highly unsaturated n-3 PUFAs, are sterically incompatible with
cholesterol and lipids with long saturated acyl chains, and thus the
incorporation of these PUFAs into the membrane PLs forces the raft
lipids out of the bulk membrane, inducing raft formation (Wassall
and Stillwell, 2009). However, supplementing cells in excess with
highly unsaturated FAs, consequently inserted into the membranes,
may disturb raft integrity (Turk and Chapkin, 2013). By regulating
the sizes and properties of the raft versus non-raft domains, the n-3
PUFAs regulate raft-mediated downstream signalling,
transcriptional activation and cytokine secretion (Turk and
Chapkin, 2013). We detected a strong increase in PUFA-
containing PL species during hepatic differentiation. In addition
to driving raft formation, the polyunsaturated PLs affect bulk
membrane properties, such as fluidity, flexibility and permeability
(Rawicz et al., 2008). The changing of these properties affects
membrane vesicle formation and thereby lipid and protein
trafficking, which needs to be efficient as the cells grow,
differentiate and make more membranes (Van Meer et al., 2008).
Very recently, Ghini and co-workers showed that supplementing
culture medium with 22:6n-3 [docosahexaenoic acid (DHA)]
affected both the lipidome and metabolome of HepG2 hepatoma
cells. Owing to the supplement, the total contents of cholesterol,
SFAs andMUFAs decreased, whereas the PUFA and TAG contents
of the cells increased (Ghini et al., 2017). In our study, 22:6n-3 was
present at a very low level in media A, B and C, and present mainly
in medium D, used during the late hepatic maturation. The
precursors of 22:6n-3 (e.g. 18:3n-3), given to the differentiating
cells at an earlier phase, did not immediately give rise to 22:6n-3,
which is likely owing to the required multistep synthetic pathway.
Compared to the synthesis of 20:4n-6 from its precursor 18:2n-6, the
metabolism of 22:6n-3 from 18:3n-3 requires two additional chain
elongations and a desaturation in the ER followed by a peroxisomal
chain-shortening step, the process thus requiring more time and
being less efficient than the synthesis of 20:4n-6 (Tigistu-Sahle
et al., 2017). The HLCs, however, were able to produce some 22:6n-
3 from its precursors, as can be seen from the rising levels of e.g.
22:6-containing PC-P (plasmalogen) during hepatic maturation.
Incorporating 22:6n-3 into PS is crucial to activate protein kinase C
pathways (Aires et al., 2007; Giorgione et al., 1995) and, apparently,
this type of signalling is actively recruited only at late stages of the
differentiation.
PC is the major component of eukaryotic cell membranes and the
major PL component of all plasma lipoprotein classes (Cole et al.,
2012), and is currently the only known PL class to be required for
lipoprotein assembly and secretion (Castro-Gómez et al., 2015). PC
molecules contain a range of FA chains with varying lengths and
double-bond positions (Yamashita et al., 1997). We saw a more
drastic increase (at ∼day 12) of PC species containing FA 20:4, the
precursor of which is an essential FA (18:2n-6), than PCs containing
other PUFAs. This can partly be explained by the concurrent strong
rise of n-6 PUFAs in the medium. When the cells get enough 18:2n-
6 from the medium, they are able to synthesise all the other members
of the n-6 PUFA family (Russo, 2009). However, cellular
remodelling processes prefer producing PC species with 20:4n-6
in the sn-2 position of the molecule: such PC species are the
preferred substrates for cytosolic phospholipase A2 type IV
(PLA2IV), cleaving 20:4n-6 for synthesis of eicosanoids, which
modulate immune responses, cell growth and differentiation
(Astudillo et al., 2012; Fujishima et al., 1999). Apparently, the
capacity of the differentiating cells to produce these lipid mediators
arises along with the appearance of 20:4n-6-containing PC species.
It is especially interesting that, in our cells, APOB expression
peaked and LD were observed at 2 weeks, soon after the maturing
HLCs reached their highest levels of 20:4n-6-containing PC. It was
recently revealed that defects in proteins such as Lpcat3 and
Tm6sf2, needed for efficient incorporation of 20:4n-6 into ER
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membranes, reduce TAG secretion from hepatic cells (Rong et al.,
2015; Ruhanen et al., 2017). Thus, it appears that the 20:4n-6-
containing PC species are crucial for the assembly and excretion of
TAG-containing mature lipoprotein particles, and are likely needed
for the proper function of our cell model, the HLCs. Because these
specific PC species regulate both immune functions and lipid
metabolism of the cells, it is understandable that, when the levels of
these 20:4-containing PCs first increased in the 18:2n-6-rich
medium, they did not peak very high (as happened for many
18:2-containing lipids) but remained at a constant level to the end of
the experiment, independent of the latest switch of the medium. The
levels of 20:4n-6-containing PCs were apparently efficiently
regulated to avoid excessive eicosanoid signalling and to adjust
the rate of lipid secretion from the cells.
Taken together, we show how the lipidome of stem cells is
remodelled in response to supplies available in the cell culture
media and as a result of changing lipid-gene expression as the cells
differentiate and mature towards functional HLCs. The lipidome
and expression of lipid-related genes in HLCs resemble those of
the PHHs, and the HLCs display the expected morphology and
cellular functions of a functional hepatocyte. The observed
elevations in the production of very-long-chain SLs and PUFA-
containing PLs during hepatic maturation clearly show that cells
efficiently take up FAs from the media, incorporate them and
modify simple lipids into more complex ones, which in turn can
change the membrane architecture, causing the alterations in
cellular functions.
Conclusions
Here, we show an efficient differentiation of iPSCs to HLCs and
demonstrate their functionality determined by their cellular
lipidomic fingerprint in conjunction with biochemical and
functional measurements and lipid-metabolism-focused gene
expression. To our knowledge, this is the first time a lipidomic
profile has been acquired of stem cells during the course of their
maturation into functional HLCs. We anticipate that the described
approach will open up new avenues in lipid-focused stem-cell
biology and medicine as it provides detailed maps of the underlying
lipid content and metabolism of a cell at a given time point, taking
into account the cell culture environment and FA components
available in the culture media. This provides a novel tool in utilising
the lipidome to follow cell differentiation and maturation and how
this is affected under different conditions or stimuli. Thus, we
expect that the stem-cell lipidomic fingerprinting through HLC
differentiation will facilitate the production of target cells that more
closely resemble the primary human hepatocytes, helping to
improve our understanding of many hepatocyte-related diseases
and their treatments.
MATERIALS AND METHODS
iPSC culture
iPSC lines were maintained at 37°C in 5% CO2 on mitotically inactivated
mouse embryonic fibroblasts (MEFs; Applied StemCell, cat. no. ASF-
1223). Cells were treated with KnockOut Dulbecco’s modified Eagle
medium (KO-DMEM) supplemented with 20% KnockOut Serum
Replacement (Ko-SR), 2 mM GlutaMAX, 0.1 mM 2-mercaptoethanol (2-
ME) (all from Gibco), 1% nonessential amino acids (NEAA) and 50 U/ml
penicillin/streptomycin (both from LONZA). Medium was supplemented
with 4 ng/ml human basic fibroblast growth factor (bFGF; R&D System).
To generate HLCs, iPSCs were adapted to feeder-free condition on pre-
coated plates with Geltrex (Gibco®, 1:100 dilution) in mTeSR medium
(=medium A) before hepatic differentiation. Cell lines were checked for
mycoplasma contamination.
iPSC reprogramming
Three iPSC lines (UTA.10100.EURCAs, UTA.11104.EURCAs and
UTA.11304.EURCCs) were used in this study. The lines were derived
directly from the fibroblast of three individual patients. The study was
approved by the Ethical Committee of Pirkanmaa Hospital District
(R12123) and written consent was obtained from all fibroblast donors.
The collected fibroblasts were induced to pluripotency using the Sendai
reprogramming kit (OCT4, SOX2, KLF4, C-MYC; CytoTune; Life
Technologies) based on the protocol described by Takahashi et al. (2007).
Cell lines were induced according to the manufacturer’s instructions and
cultured on MEF feeders until characterisation.
iPSC characterisation
All the iPSC lines were characterised in detail as described before (Manzini
et al., 2015). In short, we used PCR to study the expression of endogenous
pluripotency genes (NANOG, REX1, OCT3/4, SOX2 and c-MYC) and the
absence of virally imported exogenes (OCT4, SOX2, c-MYC and KLF4).
Immunocytochemistry was performed to study the protein expression of
pluripotency markers (Nanog, OCT-3/4, SOX2, SSEA-4, TRA 1-60 and
TRA 1-81) (Table S1). The normal karyotype of the iPSC lines was
confirmed by performing genome-wide screening for gross chromosomal
abnormalities with KaryoLite BoBs (product number 4501–0010, Perkin
Elmer) in the Finnish Microarray and Sequencing Centre, as described
elsewhere (Lund et al., 2012).
The pluripotency of the iPSCs was verified in vitro by the formation of
embryoid bodies (EBs) from which RNA was extracted and reverse
transcription performed as described previously (Manzini et al., 2015).
The expression of marker genes characteristic of endoderm (SOX17 or
AFP), mesoderm (KDR or ACTC1) or ectoderm (nestin or musashi) were
studied from EBs by PCR and GAPDH was used as an endogenous control.
The primer sequences for pluripotency genes and virally imported exogenes
as well as for marker genes of the three germ layers are presented in
Table S2.
Hepatic differentiation
Hepatic differentiation was performed according to the protocol developed
by Hay et al. (2008). After the colonies became 60-70% confluent,
differentiation was initiated by culturing the cells in RPMI1640+GlutaMAX
medium (Gibco) supplemented with 100 ng/ml Activin A (R&D Systems),
75 ng/ml Wnt3, 1 mM sodium butyrate (NaB) on the first day and 0.5 mM
from day 2, and 2% B27 (Gibco) (=medium B) for 5-6 days to DE stage.
Hepatic differentiation was initiated by switching the medium to KO-
DMEM+20% Knockout Serum Replacement, 1 mM GlutaMAX, 1%
NEAA, 0.1% 2-ME and 1% dimethyl sulfoxide (DMSO) (=medium C)
for 7 days. From this point cells were cultured in Leibovitz’s L-15 medium
(Invitrogen), supplemented with 8.3% fetal bovine serum (FBS) (Biosera),
8.3% tryptose phosphate broth (Sigma-Aldrich), 10 μM hydrocortisone
21-hemisuccinate, 1 mM insulin (both from Sigma-Aldrich), 2 M
GlutaMAX, 25 ng/ml hepatocyte growth factor (HGF) and 20 ng/ml
oncostatin M (R&D Systems) (=medium D) (Fig. 1A).
Hepatic characterisation
Flow cytometry
DE cells were detached at day 5 by a 7- to 8-min incubation with Gentle Cell
Dissociation Reagent (StemCell Technologies) at 37°C and then suspended
in 3% FBS before being stained by CXCR4 conjugated antibody (R&D
Systems) for 15 min at room temperature (RT). The percentage of CXCR4-
positive cells were assessed using a BD Accuri C6 cytometer.
Real-time quantitative PCR (RT-qPCR) analyses
RNA samples were collected at days 0, 5, 10, 15, 20 and 25 using the
RNeasy kit (Qiagen, cat. no. 74106). cDNAs were generated using the High
Capacity cDNA Reverse Transcription kit (Applied Biosystems, USA)
according to the manufacturer’s instructions in the presence of RNase
inhibitor. The PCR reaction was performed by using Power SYBR Green
PCR Master Mix (Life Technologies, cat. no. 1408470) and the cDNAwas
multiplied using the Applied Biosystems 7300 Real-time Sequence
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Detection system. CT values were determined using 7300 SDS software
(Applied Biosystems) and relative quantification was calculated by the
2−ΔΔCT method (Livak and Schmittgen, 2001). The primer sequences are
presented in Table S3.
The expression of 18 genes involved in lipoprotein formation or SL
metabolism was studied by RT-qPCR with the Biomark HD system
(Fluidigm Corp., San Francisco, USA) and using TaqMan assays. cDNA
was prepared and pre-amplified according to the manufacturer’s
instructions, as were the RT-qPCR reactions. TaqMan assays (Life
Technologies) used in the RT-qPCR are presented in Table S4. The levels
of mRNA expression were normalised to the endogenous control gene,
GAPDH, and expressed as relative expression compared to the
undifferentiated iPSCs (at day 0). Each sample was run in triplicate.
Immunocytochemistry
Cultured cells were fixed in 4% paraformaldehyde (PFA) for 20 min at RT.
Permeabilization and blocking was performed at the same time by 10%
normal donkey serum (NDS), 0.1% Triton-X 100 and 1% bovine serum
albumin (BSA) for 45 min. Cells were incubated overnight with primary
antibodies (Table S1) in the above solution with reduced NDS to 1%.
Antigens were visualised using Alexa Fluor 488- and 568-conjugated
secondary antibodies (Table S1). Finally, the cells were mounted with
Vectashield (Vector Laboratories Inc., Burlingame, CA, USA) containing
40,6-diamidino-2-phenylindole (DAPI) for the nuclei staining and imaged
with an Olympus IX51 phase-contrast microscope equipped with
fluorescence optics and an Olympus DP30BW camera (Olympus
Corporation, Hamburg, Germany).
Functionality of the differentiated iPSC-HLCs
The ability of the iPSC-HLCs to both uptake LDL and secrete albumin was
studied using the LDL Uptake Assay kit (Cayman Chemicals, USA) and
Human Albumin ELISA Quantitation set (Bethyl Laboratories, USA),
respectively, according to the manufacturers’ instructions. Secreted albumin
was measured from 24-h conditioned medium and normalised to the cell
number.
Lipidomic profiling of cells and FA analyses of cell culture media
Lipid sample preparation and extraction
Lipids [CEs, SLs, glycerophospholipids (GPL) and polar glycerolipids] were
extracted at days 0, 6, 12, 16, 20, 24 and 28 of differentiation from PBS-
resuspended cells by a modified Folch lipid extraction, using chloroform
[high-performance liquid chromatography (HPLC) grade], methanol and
acetic acid [both liquid-chromatography–mass-spectrometry (LC-MS) grade]
for liquid−liquid extraction (Ståhlman et al., 2009), which was performed on
96-well plates employing a Hamilton Microlab Star system (Hamilton
Robotics AB, Kista, Sweden). All solvents were purchased from Sigma-
Aldrich. Samples were spiked with known amounts of lipid-class-specific
non-endogenous synthetic internal standards. After lipid extraction, samples
were reconstituted in chloroform:methanol (1:2, v/v) and synthetic external
standards were post-extract spiked to the extracts (Heiskanen et al., 2013).
Quality control samples (QCs) were prepared along with the actual samples
for all lipidomic analyses to monitor the extraction and MS performance. In
addition, calibration lines were prepared to determine the linear dynamic
range of the MS analyses. QCs and calibration lines were prepared in fresh
frozen plasma (FFP) samples (Veripalvelu, Finland).
Mass spectrometric analyses and data processing
In shotgun lipidomics, lipid extracts were analysed on a hybrid triple
quadrupole/linear ion trap mass spectrometer (QTRAP 5500) equipped
with a robotic nanoflow ion source (NanoMate, Advion Biosciences Inc.,
Ithaca, NJ, USA) as described (Heiskanen et al., 2013). Molecular lipids
were analysed in both positive and negative ion modes using either
multiple precursor ion or neutral loss scans (Ekroos et al., 2002, 2003).
The molecular species of lipids were identified and quantified in absolute
[CE; PC; phosphatidylethanolamine (PE); phosphatidylserine (PS);
lysophosphatidylcholine (LPC); lysophosphatidylethanoamine (LPE);
DAG; SM] or semi-absolute [PI; alkyl-linked phosphatidylcholine (PC-
O); alkenyl-linked phosphatidylcholine (PC-P); alkyl-linked PE (PE-O);
alkenyl-linked PE (PE-P)] amounts (Ejsing et al., 2006) by normalising
to their respective synthetic internal standard and the sample amount.
SLs were analysed as described before (Merrill et al., 2005), using an
Acquity BEH C18, 2.1×50 mm column with a particle size of 1.7 μm
(Waters, Milford, MA, USA). A 25 min gradient using 10 mM ammonium
acetate in water with 0.1% formic acid (mobile phase A) and 10 mM
ammonium acetate in acetonitrile:2-propanol (4:3, v/v) containing 0.1%
formic acid (mobile phase B). SLs were analysed on a hybrid triple
quadrupole/linear ion trap mass spectrometer (4000/5500 QTRAP)
equipped with an ultra-high-pressure liquid chromatography (UHPLC)
system (CTC HTC PAL autosampler and Rheos Allegro pump or
Shimadzu Nexera X2) using a multiple reaction monitoring (MRM)-
based method in negative ion mode.
Molecular lipids were normalised to the total protein concentration in the
cell samples. Total protein concentrations were determined using the Micro
BCA Protein Assay kit (Thermo Scientific Pierce Protein Research
Products) according to the manufacturer’s instructions. Data processing
was performed by MultiQuant, LipidProfiler/LipidView (AB Sciex)
softwares and SAS.
FA analysis
FA composition and concentrations in the cell culture media (mediumA,B, C
and D, see above for details) used at iPSC stage and at different stages of
hepatocyte differentiation were analysed by gas chromatography. First, the
lipid residues of nitrogen-dried media were subjected to transmethylation in
1% methanolic H2SO4 at a temperature of 96°C and under nitrogen
atmosphere for 120 min, according to the recommendations of Christie
(1993). The FA methyl esters (FAMEs) formed were recovered with hexane
and their quantitative analysis was performed using a Shimadzu GC-2010
Plus gas chromatograph with ﬂame-ionization detector (GC-FID). The
FAME structures were identiﬁed by Shimadzu GCMSQP2010 Ultra with
mass selective detector (GC-MSD). Both GCequipments were equippedwith
ZB-wax capillary columns (30 m, 0.25 mm ID, 0.25 μm film, Phenomenex,
USA). When calculating the composition, the FID responses were corrected
according to the theoretical response factors (Ackman, 2007) and, when
calculating the concentrations in medium, the FAME 13:0 (not present in the
samples) was used as an internal standard. In the Results, the FAs were
marked by using the abbreviations: [carbon number]:[number of double
bonds] n-[position of the first double bond calculated from the methyl end]
(e.g. 22:6n-3).
Statistical analyses
Gene expression data
GraphPad Prism version 5.02 software was used for the data analysis. The
standard deviation (s.d.) was calculated from the average of three
independent samples. Statistical analyses comparing gene expression
levels in more than two groups was performed with one-way ANOVA
and P<0.05 was considered statistically significant.
Lipidomic data
Statistical analyses for lipidomic data was performed with R (version x64
3.2.1). Zero values in the data were imputed with a value corresponding to
half of the minimum value of the corresponding lipid across all the samples.
PCA was performed for the log2-transformed data applying centering and
scaling. Heat maps were generated with gplots package by calculating the
mean log2 fold change to samples at day 0 or 12.
Correlation analyses
Correlation analyses (Spearman) were performed to study whether the
expression of SL metabolism genes pairs with relevant lipid parameters and
how strong the potential correlation is.
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Stübiger, G., Aldover-Macasaet, E., Bicker, W., Sobal, G., Willfort-Ehringer, A.,
Pock, K., Bochkov, V., Widhalm, K. and Belgacem, O. (2012). Targeted
profiling of atherogenic phospholipids in human plasma and lipoproteins of
hyperlipidemic patients using MALDI-QIT-TOF-MS/MS. Atherosclerosis 224,
177-186.
Szkolnicka, D., Farnworth, S. L., Lucendo-Villarin, B., Storck, C., Zhou, W.,
Iredale, J. P., Flint, O. andHay, D. C. (2014). Accurate prediction of drug-induced
liver injury using stem cell-derived populations. Stem Cells Transl. Med. 3,
141-148.
Szkolnicka, D., Lucendo-Villarin, B., Moore, J. K., Simpson, K. J., Forbes, S. J.
and Hay, D. C. (2016). Reducing hepatocyte injury and necrosis in response to
paracetamol using noncoding RNAs. Stem Cells Transl. Med. 5, 764-772.
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K. and
Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human
fibroblasts by defined factors. Cell 131, 861-872.
Tigistu-Sahle, F., Lampinen, M., Kilpinen, L., Holopainen, M., Lehenkari, P.,
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Abstract
Hepatocyte‐like cells (HLCs) differentiated from human‐induced pluripotent stem cells
offer an alternative platform to primary human hepatocytes (PHHs) for studying the
lipid metabolism of the liver. However, despite their great potential, the lipid profile of
HLCs has not yet been characterized. Here, we comprehensively studied the lipid
profile and fatty acid (FA) metabolism of HLCs and compared them with the current
standard hepatocyte models: HepG2 cells and PHHs. We differentiated HLCs by five
commonly used methods from three cell lines and thoroughly characterized them by
gene and protein expression. HLCs generated by each method were assessed for their
functionality and the ability to synthesize, elongate, and desaturate FAs. In addition,
lipid and FA profiles of HLCs were investigated by both mass spectrometry and gas
chromatography and then compared with the profiles of PHHs and HepG2 cells. HLCs
resembled PHHs by expressing hepatic markers: secreting albumin, lipoprotein
particles, and urea, and demonstrating similarities in their lipid and FA profile. Unlike
HepG2 cells, HLCs contained low levels of lysophospholipids similar to the content of
PHHs. Furthermore, HLCs were able to efficiently use the exogenous FAs available in
their medium and simultaneously modify simple lipids into more complex ones to fulfill
their needs. In addition, we propose that increasing the polyunsaturated FA supply of
the culture medium may positively affect the lipid profile and functionality of HLCs. In
conclusion, our data showed that HLCs provide a functional and relevant model to
investigate human lipid homeostasis at both molecular and cellular levels.
K E YWORD S
fatty acid (FA), gas chromatography, hepatocyte‐like cell (HLC), HepG2, human‐induced pluripotent
stem cell (hiPSC), lipidomics, mass spectrometry (MS), primary human hepatocyte (PHH)
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1 | INTRODUCTION
The liver plays an important role in the regulation of many
physiological functions of the body, including lipid and carbohydrate
metabolism, glycolytic/urea metabolism, plasma protein synthesis,
and the detoxification of a wide variety of molecules (Si‐Tayeb et al.,
2010). Hepatocytes, which comprise about 70% of the liver’s mass,
originate from the anterior portion of the definitive endoderm (DE),
one of the three embryonic layers (Blouin, Bolender, &Weibel, 1977).
Hepatocytes handle many crucial metabolic functions of the
liver, including the synthesis of lipoproteins, triacylglycerols
(TAGs), cholesterol, and phospholipids (PLs; Gordillo, Evans, &
Gouon‐Evans, 2015).
Primary human hepatocytes (PHHs) are currently considered the
“gold standard” in cell modeling for studying, for example, liver
physiology, toxicity, and lipid homeostasis. Typically, PHHs are
obtained from cadaveric donors, but they are scarce and functionally
heterogeneous, and it is hard to maintain them in a culture. When
cultured, PHHs loose functionality relatively fast, and their liver‐
specific features progressively deteriorate, which particularly ham-
pers long‐term studies (Elaut et al., 2006; Godoy et al., 2013). To
address these limitations, various human hepatoma cell lines,
including HepG2 and Huh7, have been used due to their ease of
handling, unlimited life span, and stable phenotype. Nevertheless,
they do not faithfully mirror the metabolic activities of healthy liver
cells. In fact, the expression levels and profiles of genes involved in
liver‐specific functions are poorly presented in these systems
(Olsavsky et al., 2007). As a result, hepatoma cell lines have failed
to predict the numerous adverse hepatotoxic side effects of new
drugs (Castell, Jover, Martínez‐Jiménez, & Gómez‐Lechón, 2006).
Alternatively, animal models, such as rats and mice, or animal primary
hepatocytes have been widely used to study lipid metabolism and
lipoprotein production in the liver (Kvilekval, Lin, Cheng, & Abumrad,
1994). However, the information gained from murine cells is not fully
translatable to humans, and there are significant differences in lipid
metabolism between the species. Animal models are also expensive
and unsuitable for large‐scale screening. Furthermore, due to
growing ethical concerns, there is an urgent need to reduce the
use of rodents and other animal models in research.
Human‐induced pluripotent stem cells (hiPSCs) provide an
unlimited supply of tissue‐specific differentiated cell types for
disease modeling and cell therapy. Hepatocytes differentiated from
pluripotent stem cells circumvent the problem of the limited
availability of cells faced when working with PHHs. They show very
similar characteristics to PHHs; for instance, they secrete albumin as
well as urea, and to some extent express drug transporters and
cytochrome P450 enzymes (Kia et al., 2012). Unlike rodent
hepatocytes and some human hepatoma cells, these hepatocyte‐like
cells (HLCs) are sensitive to hepatitis C virus infection and support
viral replication similar to PHHs (Schwartz et al., 2012).
Patient‐specific iPSC lines provide us with an advantageous system
of HLCs from patients of different genetic backgrounds, a
prerequisite for the development of personalised medicine.
The generation of hiPSC‐derived HLCs (hiPSC‐HLCs) in large
quantities enables their use in modeling inborn errors of hepatic
metabolism, understanding the molecular basis of liver cell differ-
entiation, studying disease mechanisms, and facilitating drug
discovery and safety. HLCs have already proven to be of great value
in developing novel therapeutics (Medine et al., 2013; Szkolnicka
et al., 2014) and identifying the noncoding micro‐RNAs regulating
human liver damage (Szkolnicka et al., 2016; Yang et al., 2016). HLCs
have also been successfully used as in vitro cell culture systems, for
example, to recapitulate the pathophysiology of familial hypercho-
lesterolemia (Cayo et al., 2012) and human cholesterol homeostasis
(Krueger et al., 2013). Lipid defects are central to the pathogenesis of
many common diseases, such as atherosclerosis (Meikle et al., 2011;
Stübiger et al., 2012) and nonalcoholic fatty liver disease (Ruhanen
et al., 2017; Younossi et al., 2016). Therefore, hiPSC‐HLCs offer a
great platform for investigating the basic mechanisms of lipid
metabolism and its dysregulation in a patient‐specific manner.
However, to date, no detailed studies have yet been performed on
the lipid profile and fatty acid (FA) metabolism of HLCs. To better use
HLCs as a cell model to study the role of molecular lipids in liver
diseases, it is essential to know their lipid profile in relation to actual
human adult liver tissue and to the currently used cell models,
namely PHHs and hepatoma cell lines.
Hepatic differentiation methods have greatly improved over
the last decade, enabling the efficient generation of high quality
HLCs from pluripotent stem cells (Cameron et al., 2015; Hannan,
Segeritz, Touboul, & Vallier, 2013; Hay et al., 2008; Kajiwara et al.,
2012; Si‐Tayeb et al., 2010). Nevertheless, the experimental
details and some differentiation factors differ between the
current protocols, which might affect the phenotype of the HLCs.
To reproduce the physiological conditions of the human liver, it is
crucial to generate functional HLCs that are as similar as possible
to PHHs. In this study, we describe five protocols for generating
HLCs from hiPSCs and comprehensively compare the morphology,
genetics, biochemistry, and functional traits of the HLCs pro-
duced. In addition, we compare the HLCs with the two most
common cell models currently used—PHHs and HepG2 cells—as
well as human liver tissue. Most importantly, the lipid profiles of
HLCs, PHHs, and HepG2 cells are analyzed by both mass
spectrometry (MS) and gas chromatography, and the similarities
and main differences between the cell types are discussed in light
of selected key genes involved in FA metabolism. Finally, the lipid
profile of HLCs is fully characterized, and the potential and
limitations of HLCs as a model for studying lipid metabolism are
evaluated.
2 | MATERIAL AND METHODS
2.1 | Ethical issues
The study and patient recruitment have been approved by the Ethics
Committee of Tampere University Hospital (approval number:
R12123). All participants providing skin biopsies were adults more
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than 18 years old who had signed an informed consent form after
receiving both oral and written descriptions of the study.
2.2 | hiPSC reprogramming and cell culture
Three hiPSC lines (UTA.10100.EURCAs, UTA.11104.EURCAs, and
UTA.11304.EURCCs) were generated directly from the fibroblasts of
three individuals. Pluripotency was induced with the Sendai
reprogramming kit (OCT4, SOX2, KLF4, C‐MYC; CytoTune; Life
Technologies, USA) based on the protocol described by Ohnuki,
Takahashi, Yamanaka, (2009) and Takahashi & Yamanaka, (2006).
hiPSCs were then maintained as described before (Kiamehr et al.,
2017). Details of the hiPSC cell culture are also described in the
Supporting Information.
2.3 | Hepatic differentiation
In all methods except Method 4 (M4), hiPSCs were transferred
from mouse embryonic fibroblasts to GeltrexTM (USA; Cat: A14133‐
01, 1:50 dilution), kept in mTeSR1TM medium, and adapted to the
changed culture conditions for a few passages before commencing
the differentiation. In M4, hiPSCs were adapted on Laminin 521
(BioLamina, Lot: 80104) first, and the differentiation was completed
on Laminin mix 111/521‐coated plates (3:1 ratio, 10 μg/ml). The
hiPSCs used in all methods were at passage 20 or higher before
commencing the differentiation. Three lines were differentiated using
each method, except Method 5 (M5), which was applied to two cell
lines. Figure 1 shows a schematic view of all five methods used in the
study. Details of the five differentiation methods are described in
detail in the Supporting Information.
2.4 | PHHs and HepG2 cells
Cryopreserved PHHs (Cat. No. HMCPIS, Lot. HU8210, USA) were
purchased from Gibco®, and hepatocellular carcinoma cells (HepG2,
ATCC‐HB‐8065, Lot. No. 59947519) were purchased from ATCC™.
Both cells were plated according to the manufacturer’s instructions.
PHHs were cultured in William’s E medium (A1217601, Gibco, USA)
supplemented with cocktail B (Gibco, CM 4000) and dexamethasone,
whereas the HepG2 cells were cultured in Dulbecco’s modified Eagle
medium supplemented with 10% FBS.
2.5 | RT‐polymerase chain reaction
RNA extraction and polymerase chain reaction (PCR) for pluripo-
tency markers (OCT4, NANOG, SOX2, and SSEA4) were performed as
published before (Manzini, Viiri, Marttila, & Aalto‐Setälä, 2015).
2.6 | Quantitative PCR (qPCR) analysis
RNA samples were collected at the hiPSC, DE, and HLC stages, and
RNA was extracted using an RNeasy kit (Qiagen, Germany, Cat. No.
74106). Complementary DNA (cDNA) was generated using a high
capacity cDNA Reverse Transcription kit (Applied Biosystems)
according to the manufacturer’s instructions in the presence of an
RNase inhibitor. cDNA was multiplied either by the Power SYBR
Green PCR Master Mix (Life Technology, Cat. No. 1408470, Austin,
TX) and gene‐specific primers (OCT4, SOX17, FOXA2, AFP, ALB) or by
the TaqMan Universal Master Mix (Applied Biosystems, 4304437,
Austin, TX) and gene‐specific TaqMan probes (APOA1, APOB, FADS1,
FADS2, ELOVL2, ELOVL5, FASN) using the BioRad CFX384 Real‐Time
PCR Detection System. Values were normalized to GAPDH, which
was used as an endogenous control, and relative quantification was
calculated by the ΔΔCT method (Livak & Schmittgen, 2001). PHH
was used as the reference sample.
First Choice® Human Liver Total RNA (hLTR, Cat. No.
AM7960), purchased from Ambion®, was used as an extra control.
The results from qPCR were compared for the HLCs and the three
reference samples (PHHs, hLTR, and HepG2 cells).
2.7 | Immunostaining
Cells were fixed, stained, and visualized as described before (Kiamehr
et al., 2017). Details are also provided in the Supporting Information.
F IGURE 1 A schematic representation of the five hepatic
differentiation protocols used for generating hepatocyte‐like cells
(HLCs). Differentiation in Method 1 and Method 2 (M1 and M2) were
started with hiPSC colonies, in Method 3 and Method 4 (M3 and M4)
with dissociated iPSC single cells, and in Method 5 (M5) with 24 hrs
post‐cultured hiPSCs. Plates in Method 4 (M4) were coated with a mix
of Laminin 111/521 (3:1 ratio) instead of the GeltrexTM used in the
remainder of the methods. hiPSC: human‐induced pluripotent stem
cell [Color figure can be viewed at wileyonlinelibrary.com]
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The percentage of ALB‐positive cells and binuclear HLCs were
calculated manually by counting HLCs in 3–5 stained areas and
calculating the average.
2.8 | low‐density lipoprotein uptake
The ability of the cells to uptake low‐density lipoprotein (LDL) was
evaluated by incubating the HLCs with labeled LDL (Cell‐based assay
kit, Cayman, USA, Cat. No. 10011125) for 4 hr, after which the cells
were imaged by fluorescent microscopy.
2.9 | FACS analysis
To analyze the number of CXCR4‐positive cells, endodermal cells
were detached with Versene (Gibco®, UK), suspended in 3%–5%
bovine serum albumin buffer, stained with a PE‐conjugated CXCR4
antibody (R&D Systems FAB173P, Minneapolis, 10 μl for 106 cells)
for 15min at RT, washed three times, and analyzed using the
AccuriTM C6 device (BD Biosciences).
2.10 | Albumin, urea, and TAG secretion
At the late stage of hepatic differentiation, HLCs were evaluated for
their functionality. The albumin, urea, and TAG content of the
conditioned medium were determined, respectively, with the Human
Albumin ELISA Quantitation kit (Bethyl Laboratory), the Quanti-
ChromTM Urea Assay Kit (BioAssay Systems, USA), and the
Triglyceride Quantification Kit (BioVision Inc., Cat. No. K622‐100,
USA) according to the manufacturers’ instructions. The values were
normalized to cell numbers. The results were then compared with the
data from the PHHs and HepG2 cells, which were cultured in parallel
with the HLCs.
2.11 | Lipid mass spectrometry
2.11.1 | Lipid sample preparation and extraction
Lipids (sphingolipids [SL], cholesterol, glycerolipids, and glyceropho-
spholipids) were extracted from the HLCs by Hamilton Robotics AB
and studied by shotgun lipidomics. The detailed procedure is
described by Kiamehr et al., (2017).
2.11.2 | Mass spectrometric analyses and data
processing
In the shotgun lipidomics (cholesteryl ester [CE], diacylglycerol
[DAG], sphingomyelin [SM], lysophosphatidylcholine [LPC], lysopho-
sphatidylethanolamine [LPE], lysophosphatidylserine, lysophosphati-
dylglycerol, and lysophosphatidylinositol [LPI]), lipid extracts were
analyzed on a hybrid triple quadrupole/linear ion trap mass spectro-
meter (QTRAP 5500) equipped with a robotic nanoflow ion source
(NanoMate, Advion Biosciences Inc., Ithaca, NJ) as described by
Heiskanen, Suoniemi, Ta, Tarasov, & Ekroos, (2013). Molecular lipids
were analyzed in positive ion mode using lipid class‐specific
precursor ion or neutral loss scans (Ekroos, Chernushevich, Simons,
& Shevchenko, 2002; Ekroos et al., 2003).
Sphingolipids (ceramide [Cer], glucosyl/galactosylceramide [Glc/
GalCer], lactosylceramide [LacCer], and globotriaosylceramide [Gb3])
and molecular PLs (phosphatidylcholines [PC], phosphatidylethano-
lamines [PE], and phosphatidylinositols [PI]) were analyzed with a
targeted approach using ultra‐high‐pressure liquid chromatography‐
mass spectrometry (UHPLC‐MS; Merrill, Sullards, Allegood, Kelly, &
Wang, 2005). An analytical Acquity BEH C18, 2.1 × 50mm column
with a particle size of 1.7 μm (Waters, Milford, MA) heated to 60°C
was used. Mobile phases consisted of 10mM ammonium acetate in
water with 0.1% formic acid (solvent A) and 10mM ammonium
acetate in acetonitrile:isopropanol (4:3, v/v) containing 0.1% formic
acid (solvent B). The flow rate was set to 500 μl/min. Sphingolipids
were separated with a 15min linear gradient from 75% B to 100% B,
while molecular PLs were analyzed using a 10min gradient from 75%
B to 80% B. Both sphingolipids and PLs were analyzed on a hybrid
triple quadrupole/linear ion trap mass spectrometer (5500 QTRAP)
equipped with an UHPLC system (CTC HTC PAL autosampler and
Rheos Allegro pump or Shimadzu Nexera X2) using a multiple
reaction monitoring based method in positive ion mode for
sphingolipids and negative ion mode for molecular PLs. Curtain gas
was set at 25; the ion spray voltage was set at 5000 V in positive ion
mode and −4500 V in negative ion mode, and the ion source was
heated to 400°C in positive mode and to 300°C in negative ion mode.
The collision energy was optimized for each lipid class. Identified
lipids were quantified by normalizing against their respective internal
standard (Ejsing et al., 2006) and total protein concentrations in the
cell sample. Total protein concentrations were determined using the
Micro BCA™ Protein Assay Kit (Thermo Scientific Pierce Protein
Research Products) according to the manufacturer’s instructions.
Data processing was performed by MultiQuant, LipidView (AB Sciex)
software and SAS.
2.12 | FA gas chromatography
To confirm our observations from the MS analysis of molecular lipids
and to investigate the effect of the medium on the FA profile of the
cells, the FA composition of HLCs, PHHs, and HepG2 cells and their
media was analyzed by gas chromatography as described in detail
by Kiamehr et al., (2017). Briefly, the acyl chains in the cell pellet
lipids or the lipid residues of the nitrogen‐dried media were
converted to FA methyl esters (FAMEs) in a transesterification
reaction with 1% methanolic H2SO4. The quantitative analysis of the
FAMEs, which were extracted into hexane, was performed using a
Shimadzu GC‐2010 Plus gas chromatograph with a flame‐ionization
detector, and the FAME structures were identified by Shimadzu
GCMSQP2010 Ultra with a mass selective detector. In both systems,
the components of the FAME mixtures were separated in ZB‐wax
capillary columns (30m, 0.25mm ID, 0.25 μm film; Phenomenex). The
calculations of the FA compositions and concentrations followed
standard procedures (Kiamehr et al., 2017), and the FAs were
marked by using the abbreviations: [carbon number]:[number of
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double bonds] n‐[position of the first double bond calculated from
the methyl end] (e.g., 22:6n‐3).
2.13 | Statistical analysis
GraphPad Prism version 5.02 software was used for the data
analysis. Data are presented as means ± standard deviation with n
representing the number of independent experiments. The results
were compared using one‐way analysis of variance, followed by
Bonferroni’s multiple‐comparison test. A p value < 0.05 was con-
sidered statistically significant.
3 | RESULTS
3.1 | Cell morphology during hepatic
differentiation
In all methods, dramatic morphological changes were observed,
particularly during the first few days of DE differentiation. In all
methods except M5, migrating DE cells possessed a spiky morphol-
ogy, whereas in M5, migrating cells were instead more round or
square‐shaped (Supporting Information Figure S1a). In addition, the
amount of cell death in M5 was considerably lower than in the other
methods. No morphological differences were observed between the
DE cells treated with CHIR 99021 (Method 1, M1) or Wnt3 (Methods
2–4, M2–4). Initiating differentiation with single cells in M3 and M4
did not yield a higher efficiency of DE formation compared with M1
and M2, which were started with colonies (Supporting Information
Figures S1a and S3). However, we did observe cells with a DE
morphology appearing one or even two days earlier in methods
initiated with single cells compared with methods initiated with
colonies (Supporting Information Figure S1a). At the hepatic
specification stage, cells treated with basic fibroblast growth factor,
bone morphogenic protein 4 (BMP4), and hepatocyte growth factor
(HGF; M1) clearly had a different morphology compared with the
cells treated with DMSO (M2–5; Supporting Information Figure S1b),
which might imply different pathways toward hepatoblasts in those
protocols.
Binucleation is a feature of adult hepatocytes and generally
considered a sign of terminal differentiation (Miyaoka & Miyajima,
2013). We found 29% of the PHHs and on average 10% of the HLCs
to be binuclear ( Figures 1b and 2a). The HLCs differentiated by M4
showed the closest binuclearity (16%) to the PHHs. No individual cell
line was shown to be more potent in generating binuclear cells.
3.2 | Characterization of DE and HLCs at the
protein level
hiPSCs expressed OCT4 protein, which was lost during the DE stage,
while the expression of DE markers SOX17 and FOXA2 was
upregulated (Supporting Information Figure S2a). The efficiency of
the DE differentiation, estimated by measuring the CXCR4 expres-
sion by flow cytometry, did not differ across M1, M2, and M3
(Supporting Information Figure S2b). In M4 and M5, the amount of
CXCR4‐positive cells was lower than in the other methods.
The immature hepatic marker AFP was expressed in hepatic
progenitor cells and remained expressed until the later stages in all
five methods (Figure 2a). In addition, ALB, LDL receptor (LDL‐R), and
asialoglycoprotein receptor (ASGR) were all expressed in mature
HLCs (Figure 2a and Supporting Information Figure S5). The average
of the ALB‐positive cells in M1 to M5 was 9.8%, 16.6%, 20.8%, 37.7%,
and 31.5%, respectively, and the percentage in M4 was significantly
higher than in M1, M2, and M3, but not in M5 (Figure 2b). More than
90% of M2‐ to M5‐HLCs were positive for ASGR (data not shown).
3.3 | Gene regulation
As expected, OCT4 was highly expressed at the iPSC stage, whereas
at the DE stage, OCT4 was dramatically downregulated in most of the
cell lines, and SOX17 and FOXA2 were highly expressed (Supporting
Infomation Figure S6). Further differentiation toward HLCs resulted
in significant downregulation of SOX17, whereas FOXA2 remained
upregulated during the rest of the differentiation and maturation of
the HLCs (Figure 2c and Supporting Infomation Figure S7). The HLCs
expressed SOX17 at the same levels as hLTR. The level of FOXA2 in
the HLCs was comparable to those in the reference samples PHH,
hLTR, and HepG2. AFP was upregulated during the early and late
hepatic differentiation stages, indicating the immature characteristic
of the HLCs. The expression of AFP in the M2‐HLCs was statistically
significantly higher than in the M1‐HLCs. ALB was dramatically
upregulated in mature HLCs, up to 2 × 105‐fold compared with that in
the hiPSCs, and its levels remained close but below those found in
the PHHs. The expression of ALB in the M5‐HLCs was significantly
higher than in the M1‐HLCs (p < 0.01) and M3‐HLCs (p < 0.05). The
levels of ALB expression were comparable between the HepG2 and
the PHHs; however, ALB expression was about 19‐fold higher in the
hLTR when compared with the PHHs.
3.4 | Hepatic maturation and functionality
The liver is responsible for producing serum albumin. Therefore, we
evaluated the ability of HLCs to secrete albumin into the conditioned
medium. All HLCs were able to secrete albumin (Figure 2d). Albumin
secretion by UTA.11304 differentiated by M3 was about fourfold
higher compared with the same cell line differentiated by M1 or M2,
and twofold higher compared with M4 (data not shown), but no other
statistically significant differences were observed between the
differentiation protocols. However, PHHs secreted significantly
larger amounts of albumin than the HLCs or even the HepG2 cells.
The level of secreted urea by the cell lines differentiated by M3
and M4 was considerably higher compared with same lines
differentiated by M1, M2, and M5 and relatively closer to the
amount of urea secreted by the PHHs (Figure 2d). In fact, the level of
urea secreted by the HLCs differentiated by M1, M2, and M5 was
comparable to the HepG2 cells, which secreted 6.5‐fold less urea
than the PHHs.
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TAG secretion in the cell lines differentiated by M3, M4, and M5
was at similar levels as in the PHHs (Figure 2d). However, cell lines
differentiated by M1 and M2 secreted, on average, 5.9‐ and 3.8‐fold
more TAG than the PHHs. We were not able to detect secreted TAG
in the HepG2 culture medium due to medium interference.
Apolipoprotein A‐I (APOA1) encodes for apoA, which is the main
protein component of high‐density lipoproteins (HDL). The product
of apolipoprotein B (APOB) is the main protein component of
very‐low‐density lipoprotein (VLDL) and LDL. The expression of both
APOA1 and APOB in the HLCs was comparable to the HepG2 cells,
PHHs, and hLTR, which further indicated the functionality of the
HLCs (Figure 2c). Interestingly, both APOA1 and APOB were
expressed almost 5.5‐fold more in hLTR compared with the PHHs.
All the cell lines were able to uptake the labeled LDL from the
culture medium (Supporting Information Figure S5). This was
confirmed by staining the LDL‐R by monoclonal antibody (Supporting
Information Figure S4).
3.5 | Lipid profiles of HLCs differentiated by
different methods
The HLCs differentiated by M3, M4, and M5 showed superior
functionality as for TAG and urea secretion when compared with M1
and M2. In addition, the M5‐HLCs expressed higher ALB compared
with the HLCs differentiated by M1 and M3. Therefore, we selected
the HLCs differentiated by M3, M4, and M5, analyzed their lipid
profile by MS, and compared their lipid profile. In addition, the lipid
contents of their unconditioned media were studied to investigate
the influence of culture media lipids and their FAs on the cells.
Overall, 15 major lipid classes—including CE, DAG, PC, LPC, PI, LPI,
PE, LPE, SM, Cer, LacCer, Glc/GalCer, and Gb3—were investigated,
and altogether more than 150 molecular species were detected and
studied (Supporting Information Tables S2 and S3).
The lipid profile of the HLCs differentiated by M3, M4, and M5
closely resembled each other ( Figures ). In fact, only the levels of
three PC species (PC 16:1–20:4, PC 17:0–18:1, and PC 17:0–20:4)
were slightly, but statistically significantly, lower in M4 (Figure 3,
marked by blue arrows) compared with the other methods. No other
significant differences were found in any of the molecular species
between the methods. When comparing the total levels of lipid
classes, only Cer was found at significantly lower concentrations in
the cells produced by M5 compared with those produced by M4
(Figure 5b). However, at the molecular species level, none of the Cer
species differed significantly between M4 and M5 (Figure 5a and
Supporting Information Table S2).
3.6 | Lipid profiles of HLCs, PHHs, and HepG2 cells
Next, we compare the lipidomes of the HLCs with the PHHs and
HepG2 cells and describe our findings for each lipid class separately.
In addition, we highlight the differences and similarities between the
PHHs and HepG2 cells.
3.6.1 | Phospholipids
In the HLCs, the molecular species of PC, PE, and PI containing
saturated FAs (SFAs) and monounsaturated FAs (MUFAs) were
mostly similar to those in the PHHs, with the exceptions of PC 18:1/
18:1 (p < 0.05), PC 17:0–18:1 (p < 0.001), and PE 18:0–18:1 (p < 0.05),
which were statistically significantly higher in the HLCs (Figure 3,
marked by red arrows). When the PHHs were compared with the
HepG2 cells, a large number of species showed statistically
significant differences, particularly the species containing 14:0,
16:0, and 18:1 FAs. In PC and PE, the molecular species containing
polyunsaturated FAs (PUFAs) were present in significantly higher
concentrations in the PHHs compared with both the HLCs and
HepG2 cells. This difference was especially pronounced for the
species containing an SFA coupled with FA 18:2 or its derivative 20:4
(e.g., 16:0–18:2, 18:0–18:2, 16:0–18:2, and 18:0–20:4). The HepG2
cells, however, contained more of the species where an MUFA was
coupled to a PUFA (or another MUFA). The total levels of PC and PI
classes were similar among all three compared cell types. Total PE
was, however, detected at lower levels in the HLCs compared with
the PHHs (statistically significant in M4 and M5 vs the PHHs). This
was mostly due to the higher levels of PE 18:0–18:2 and PE 18:0–
20:4 in the PHHs. The concentration of PC, PE, and PI in the HLC and
PHH media was either zero or negligible, while the HepG2 medium
contained high amounts of PC (12.9 μM) but only minimal amounts of
PE and PI (Supporting Information Figure S7 and Table S3). The
profile and concentration of molecular lysophospholipids (LPLs)—
such as LPC, LPE, and LPI—in the HLCs were very close to those of
the PHHs (Figure 3a). Consequently, the total LPL levels of the HLCs
F IGURE 2 Characterization and functionality of hiPSC‐derived hepatocyte‐like cells (hiPSC‐HLCs) differentiated from three cell lines by five
methods and their comparison to primary human hepatocytes (PHHs), HepG2 cells, and human liver total RNA (hLTR). (a) Immunostaining of
cells for AFP (red) and ALB (green). Nuclei are stained with DAPI (blue). The red inset on the lower right shows the comparison of the
morphology and binuclearity (red arrows) of M5‐HLCs and PHHs. The scale bar represents 200 μm for the HLCs and 100 μm for the PHHs and
HepG2 cells. (b) The graph on the left shows the average percentage of binuclear HLCs in each method and their comparison to PHHs. The
graph on the right shows the average percentage of ALB‐positive HLCs in each method. Each bar represents the mean ± SD of the manual
counts from the immunostaining image analysis of at least five areas. (c) Real‐time qPCR analysis of the SOX17, FOXA2, AFP, ALB, APOA1, and
APOB genes at the hiPSC and hepatic stage and their comparison to the reference samples. Each sample was run in triplicate and the bars
represent the mean ± SD of three biological replicates from three individual cell lines. The gene expression data were normalized to the
housekeeping gene GAPDH and are presented relative to the PHHs. (d) Biochemical analysis of the conditioned media from the HLCs for
albumin, urea, and triacylglycerol. Values are normalized as 1 million cells per 24 hr. The bars represent the mean ± SD of three biological
replicates of the three cell lines. *p < 0.05, **p < 0.01, ***p < 0.001. DAPI: 6‐diamidino‐2‐phenylindole; n.s.: not significant; qPCR: quantitative
PCR; SD: standard deviation [Color figure can be viewed at wileyonlinelibrary.com]
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and PHHs were also similar (Figure 3b). The HepG2 cells, however,
contained considerably higher levels of LPL as total levels and
strikingly high levels of the molecular lyso‐species, with the 18:1 acyl
residue in each LPL class (Figure 3 and Supporting Information
Table S2).
3.6.2 | Neutral lipids
CE concentration was the highest in the HepG2 cells, intermediate in
the HLCs, and the lowest in the PHHs. The CE species profile of the
HLCs and HepG2 cells was different because 16 CE species showed
statistically significantly higher concentrations in the HepG2 cells
(Figure 4). When interpreting these differences, the effect of medium
CE concentration was considered. The HepG2 medium contained
154 μM of CE, whereas the CE concentrations were negligible in the
HLC and PHH media (Supporting Information Figure S7 and
Table S3).
Similar to PLs, the HLCs contained higher levels of DAG species
with FA 18:1 when compared with the PHHs. However, the level of
major DAG species 16:0–18:1 detected in the HLCs was clearly
closer to that detected in the PHHs compared with what was found
in the HepG2 cells. The PHHs, on the other hand, contained higher
levels of DAG species with FA 18:2 (the minor species DAG 18:
1–18:2 being an exception with its equally low levels in the HLCs,
F IGURE 3 Lipidomic analysis of phospholipids (PLs) and lysophospholipids (LPLs) in the HLCs differentiated by M3, M4, and M5, and their
comparison to PHH and HepG2 cell lipids. (a) Protein‐normalized concentration of molecular species detected in each class of PLs
(Phosphatidylcholine [PC], phosphatidylinositol [PI], and phosphatidylethanolamine [PE]) as well as LPLs (lysophosphatidylcholine [LPC],
lysophosphatidylinositol [LPI], and lysophosphatidylethanolamine [LPE]). The arrows refer to species that were found to be statistically significantly
different between HLCs in M3, M4, and M5 (blue arrows) or between the HLCs and PHHs (red arrows) by one‐way analysis of variance. (b) Total
concentrations of PLs and LPLs calculated from the sum of all the molecular species in those specific classes. Each sample was run in triplicate and the
bars represent the mean ± standard deviation of the studied cell lines [Color figure can be viewed at wileyonlinelibrary.com]
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PHHs, and HepG2 cells). As also observed in PC, the DAG species
with relatively short chain FAs (e.g., 14:0, 16:0, and 16:1) were
detected at higher concentrations in the HepG2 cells than in the
HLCs and PHHs (Figure 4A).
3.6.3 | Sphingolipids
Despite higher total SM concentration, HLCs mimicked the SM
profile of PHHs and HepG2 cells, except that SM d18:1/15:0 and SM
d18:1/16:1 were present at statistically significantly higher concen-
trations in the HepG2 cells (Figure 5a). Both the HLCs and HepG2
cells contained significantly higher levels of SM d18:1/16:0 compared
with the PHHs. The level of SM in the HLC and PHH media was
undetectable, whereas the HepG2 medium contained 6.5 μM of SM
(Supporting Information Figure S7 and Table S3).
In terms of the overall SL profile, the HepG2 cells situated
between the PHHs and HLCs. In fact, lipid class data showed that the
HLCs contained lower levels of Cer but higher levels of LacCer, Glc/
GalCer, and Gb3 (members of glycosphingolipid [GSL] family)
compared with the PHHs (Figure 5b). Closer examination showed
that Cers and, particularly, the saturated species with long‐ and very‐
long‐chain FAs (e.g., Cer d18:0/22:0 and Cer d18:1/24:0) were higher
in the PHHs (Figure 5a), in fact, the Cer species profile of the HLCs
resembled more that of the HepG2 cells. On the other hand, the
HLCs contained more GSLs—especially the species d18:1/16:0,
d18:1/24:0, and d18:1/24:1—and the differences were the most
pronounced in the Glc/GalCer class. The HepG2 medium contained
trace amounts of SLs, and the concentration of SLs in the HLC and
PHH media was either negligible or undetectable (Supporting
Information Figure S7 and Table S3).
3.7 | FA analysis
The HLCs contained 15 mol% PUFAs versus 29 mol% and 10.5 mol
% in the PHHs and HepG2 cells, respectively (Figure 6a). The FA
18:2n‐6 was, in proportion, the highest PUFA detected in the
PHHs (14 mol%); it was also the highest PUFA detected in the PHH
medium (89 mol%; Figure 6b and Supporting Information Table
S3). Both the HLCs and HepG2 cells had a low supply of 18:2n‐6 in
their media and, hence, lower relative levels of 18:2n‐6 in their
cellular FA profile. Interestingly, the HLCs seemed to be able to
compensate for the shortage of supply better than the HepG2
cells, and the levels of 20:4n‐6, a bioactive metabolite of 18:2n‐6,
were only 1.4‐fold lower in the HLCs compared with the PHHs,
indicating an active biosynthesis of 20:4n‐6 from its precursor in
the HLCs.
F IGURE 4 Lipidomic analysis of cholesteryl ester (CE) and diacylglycerol (DAG) in the HLCs differentiated by M3, M4, and M5, and their
comparison to PHH and HepG2 cell lipids. (a) Protein‐normalized concentration of molecular species detected for the CE and DAG lipid class. (b)
Total concentrations of CE and DAG calculated from the sum of all the molecular species in those specific classes. Each sample was run in
triplicate and the bars represent the mean ± standard deviation of the studied cell lines [Color figure can be viewed at wileyonlinelibrary.com]
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The total levels of MUFAs in the HLCs (43mol%) were higher
than in the PHHs (25mol%), but they were still lower than in the
HepG2 cells (52 mol%) (Figure 6a). FA 18:1n‐9 (with its 31mol% of all
FAs) was the major MUFA in the HLCs, a reflection of the high
concentration of 18:1n‐9 in their medium. FA 16:1n‐7 (an SCD
Δ9‐desaturation product of 16:0) had the lowest values in the HLCs
(0.6‐fold the PHH level) and the highest values in the HepG2 cells
(1.4‐fold the PHH level). Consequently, the relative concentration of
18:1n‐7 (an fatty acid elongase (ELOVL)5/6 chain elongation product
of 16:1n‐7) was the highest in the HepG2 cells (14mol%) and lower
in HLCs and PHHs (4 mol% and 2mol%, respectively). This implies
that the high 18:1n‐7 is a specific feature of HepG2 cells, marking a
clear distinction from the HLCs and PHHs, which appeared similar in
having 18:1n‐9 as their main MUFA component.
The total SFAs in the HLCs, PHHs, and HepG2 cells were 40mol
%, 46mol%, and 37mol%, respectively (Figure 6a). Relative to the
PHHs, the lower SFAs in the HLCs were attributable to the slightly
lower proportion of all major individual FAs (14:0, 16:0, and 18:0).
The lower amount of total SFAs in the HepG2 cells, however, was
mainly due to the considerably lower percentage of 18:0 compared
with the PHHs (2.2‐fold less).
3.8 | Gene expression of key enzymes in FA
metabolism
To further investigate the metabolism of FAs in the HLCs, PHHs, and
HepG2 cells, we studied the expression of five key genes involved in
the synthesis pathways of FA by qPCR. Lipogenesis is highly affected
F IGURE 5 Lipidomic analysis of sphingolipids (SLs) in the HLCs differentiated by M3, M4, and M5, and their comparison to the PHHs and
HepG2 cells. (a) Protein‐normalized concentration of molecular species detected for the sphingomyelin (SM), ceramide (Cer), glucosyl/
galactosylceramide (Glc/GalCer), lactosylceramide (LacCer), and globotriaosylceramide (Gb3) lipid classes. (b) Total concentrations of SLs
calculated from the sum of all the molecular species in those specific classes. Each sample was run in triplicate and the bars represent the
mean ± standard deviation of the studied cell lines. *p ≤ 0.05 [Color figure can be viewed at wileyonlinelibrary.com]
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F IGURE 6 Fatty acid (FA) analysis (mole% in total FAs) of the M3‐HLCs, PHHs, and HepG2 cells versus their media. (a) Total proportions of
saturated fatty acids (SFAs), monounsaturated fatty acids (MUFAs), polyunsaturated fatty acids (PUFAs), and dimethyl acetals (DMAs, derived
from plasmalogen PL alkenyl chains) in the studied cell types and their media. The ratio of total unsaturated FAs (UNFAs) to total SFAs is shown
on the top bar. (b) Mirrored bar chart presenting the FA profiles in the M3‐HLCs, PHHs, and HepG2 cells (red bars) in comparison to their media
(blue bars). Each bar represents the mol% of the detected FAs. Error bars in the HLCs are calculated from the mean ± standard deviation of
three biological replicates. (c) Schematic image of the metabolic pathways of SFAs, MUFAs, and PUFAs, including the responsible genes (FASN,
SCD, ELOVL, FADS). The figure is adapted from the work by Glück et al., (2016). HLC: hepatocyte‐like cell; PHH: primary human hepatocyte;
PL: phospholipid [Color figure can be viewed at wileyonlinelibrary.com]
KIAMEHR ET AL. | 11
by glucose homeostasis in the liver. Therefore, the expression of
Glucokinase (encoded by GCK), the key enzyme involved in glycolysis,
was also studied. The results revealed that FA synthase (FASN), a key
gene in de novo FA synthesis, was expressed in the HLCs mostly at
similar levels as in the PHHs (Figure 7a). The FASN expression level of
the HepG2 cells was higher than that of the PHHs. The expression of
GCK in HLCs was at similar levels as in the PHHs (Figure 7b).
Comparing the methods, M3‐HLCs and M4‐HLCs expressed GCK at
statistically significantly higher levels than M1‐HLCs. FA desaturase
1 (FADS1) was expressed at a statistically significantly lower level in
all the HLCs (p < 0.001) when compared with the PHHs, but at similar
levels as in hLTR and the HepG2 cells. In the HepG2 cells, hLTR, and
almost half of the HLCs, FADS2 was expressed at lower levels than in
the PHHs. In the other half of the studied HLCs, the expression of
FADS2 was similar to that in the PHHs (Figure 7a). In addition to the
FADSs, FA elongases ELOVL2 and ELOVL5, working in sequence with
the desaturases, are essential for the metabolism of long‐chain and
highly unsaturated FAs (Figure 6c). ELOVL2 was expressed in most of
the HLC lines at similar levels to the PHHs, but some lines produced
by M2, M3, and M5 showed statistically significantly higher
expression levels (Figure 7a). The expression of ELOVL2 was
statistically significantly higher in the HepG2 cells than in the PHHs.
ELOVL5, on the other hand, was expressed at roughly similar levels in
all analyzed cells types (PHHs, HepG2 cells, hLTR, and HLCs).
4 | DISCUSSION
hiPSC‐HLCs are a promising cell culture platform for studying lipid
homeostasis and its aberrations related to metabolic syndromes
manifested, for example, in atherosclerosis and fatty liver disease. In
the current study, we successfully generated functional HLCs from
hiPSCs using five hepatic differentiation protocols. We then
compared these HLCs comprehensively for gene and protein
expression, lipid composition, and functional traits. Similar compar-
isons were also made with the two common hepatic cell models,
F IGURE 7 Expression levels of genes involved in the metabolism of fatty acids (FAs) (a) and glucose (b). (a) Real‐time qPCR analysis of
ELOVL2, ELOVL5, FADS1, FADS2, and FASN in the HLCs (differentiated by five methods), PHHs, HepG2 cells, and human liver total RNA (hLTR).
(b) Real‐time qPCR analysis of GCK in HLCs (differentiated by five methods), PHHs, HepG2 cells, hiPSCs, and human liver total RNA (hLTR). The
expression of each gene was normalized to the endogenous control gene GAPDH and is presented relative to the PHHs. Each sample was run in
triplicate, and the bars in the HLCs represent the mean ± standard deviation of three biological replicates. PHHs were used as reference group
to calculate the statistical significance. *p < 0.05, **p < 0.01, ***p < 0.001. HLC: hepatocyte‐like cell; PHH: primary human hepatocyte;
qPCR: quantitative PCR
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PHHs and HepG2 cells. All five differentiation protocols produced
HLCs capable of expressing ALB, uptaking LDL, and secreting
albumin, urea, and TAG. The lipid profiles of the HLCs, PHHs, and
HepG2 cells were analyzed by both MS and gas chromatography. In
addition, the effects of FA supply from the culture media on the cells’
lipid profile were examined. In this study, we performed, to our
knowledge, the most thorough characterization of the metabolic
traits of HLCs and investigated their potential as a new cell model for
lipid studies in parallel with PHHs and HepG2 cells.
4.1 | Hepatic differentiation
Most protocols for differentiating HLCs from pluripotent stem cells
follow a three‐step differentiation through the DE phase, continuing to
the hepatoblast stage, and finally to mature HLCs. Various growth
factors and cytokines known to be necessary for liver development are
used through these procedures (Cameron et al., 2015; Chen et al.,
2012; Gerbal‐Chaloin et al., 2014; Hannan et al., 2013; Hu & Li, 2015;
Mallanna & Duncan, 2013; Schwartz, Fleming, Khetani, & Bhatia, 2014;
Si‐Tayeb et al., 2010; Sullivan et al., 2010; Takayama et al., 2012). We
observed that at the DE stage, the initial density of the hiPSCs played a
more critical role than the type of DE inducer (e.g., CHIR 99021 or
Wnt3). In fact, high initial cell density in M1, M2, and M5 leads to
remaining undifferentiated colonies, whereas inM3 and M4, this results
in the formation of new dense and undifferentiated areas. On the other
hand, very low initial cell density could lead to highly sparse cells and
consequently unsuccessful differentiation. Hence, it is fundamental to
find the optimal cell density for each cell line in each method.
At the hepatoblast stage, cells in M1 were supplemented with
FGF2 and BMP4, mimicking the stimuli present during liver
development (Rasmussen, 2015). However, in other methods, DMSO
was used instead of FGF2 and BMP4. DMSO has histone deacetylase
inhibitor activity and significantly increases the expression levels of
BMP2 and BMP4 while decreasing the expression levels of stem cell
markers, such as Oct4 (Behbahan et al., 2011; Choi et al., 2015;
Czysz, Minger, & Thomas, 2015; Santos, Figueira‐Coelho, Martins‐
Silva, & Saldanha, 2003). At Day 10, the cells in M1 had clear borders;
they had also formed sinusoidal canaliculi‐like structures (Supporting
Information Figure S1b). However, at the end of the hepatoblast
stage and the beginning of the maturation stage, the cells in M2, M3,
M4, and M5 also eventually gained sinusoidal canaliculi‐like
structures (Supporting Information Figure S3). In addition, small lipid
droplets were clearly visible in the cells in the culture medium
containing DMSO, which could be due to excess of FA supplies in
that medium (Kiamehr et al., 2017).
For the maturation of hepatocytes, HGF and oncostatin M were
used. Epidermal growth factor (EGF) was present only in M3, M4, and
M5. It has been shown that HGF and EGF—two tyrosine kinase
receptor ligands—together decrease the expression of several genes
involved in the metabolism of FAs (Michalopoulos, Bowen, Mulè, &
Luo, 2003). In our study, EGF seemed to affect urea and TAG
secretion but not the albumin secretion of the HLCs. In fact, M3‐,
M4‐, and M5‐HLCs secreted both urea and TAG similarly to the
PHHs, but clearly different from the levels secreted by the M1‐ and
M2‐HLCs (Figure 2D).
It has been proposed that the unnatural microenvironment provided
by current culture systems is partly responsible for the immature
features of HLCs (Godoy et al., 2015), and that coating the culture
plates with a mixture of Laminin 521/111 could further promote HLC
maturation (Cameron et al., 2015). Hence, in M4 we replaced the
Geltrex coating with Laminin 521/111. Even though we did not observe
this coating to improve functionality, it increased the number of ALB‐
positive cells by 82% and the binuclearity of HLCs by 65% compared
with those in M3. In the adult liver, 15%–30% of hepatocytes are
binuclear, and binucleation is usually considered a sign of terminal
differentiation in hepatocytes, even though binuclear hepatocytes are
still able to divide (Miyaoka & Miyajima, 2013). One study suggested
that polyploid cells are more resistant to stressful conditions (Anatskaya
& Vinogradov, 2007). However, the effect of size and number of nuclei
on the hepatocyte function is an intriguing question yet to be answered.
It is well established that the levels of lipoproteins in the serum
have a clear correlation with the risk of atherosclerosis (Moss, 1991).
It has been shown that HLCs produce, secrete, and uptake
cholesterol in vitro and that they robustly express apoprotein genes,
for example, APOA1, APOA2, APOB, APOC, and APOE (Rasmussen,
2015). HLCs also respond to statin treatment in vitro by reducing the
amount of secreted cholesterol (Krueger et al., 2013). Here, we
confirmed that HLCs are capable of uptaking labeled LDL (Supporting
Information Figure S5) as well as expressing APOA1 and APOB at
similar levels compared with PHHs (Figure 2c), which is in line with
findings in other studies (Godoy et al., 2015). APOA1 and APOB gene
expression levels were studied as a surrogate for estimating the HDL
and LDL production levels of HLCs.
Overall, the HLCs differentiated by M3, M4, and M5 showed
superior characteristics for studying the liver function and lipid
metabolism compared with the HLCs differentiated by M1 and M2.
The M3‐, M4‐, and M5‐HLCs secreted TAG at similar levels as the
PHHs. In addition, the M3‐ and M4‐HLCs secreted urea at levels closer
to the PHHs when compared with the HLCs differentiated by other
methods. M4 and M5 produced the most albumin‐positive HLCs, and
the M4‐HLCs showed the highest binuclearity compared with the HLCs
differentiated by the other methods. Furthermore, we observed that
the cell lines differentiated by M5 showed the least variation. This could
be attributed to the application of the STEMdiffTM DE kit at the DE
stage, which resulted in uniform DE differentiation. Because the DE
stage is the key phase in hepatic differentiation, evenly differentiated
DE cells could result in more uniform hepatic differentiation, reducing
possible variation between cell lines. Nevertheless, it should be
considered that the Laminin coating applied in M4 and the STEMdiffTM
DE kit used in M5 adds to the overall costs of the differentiation and
makes these methods more expensive than, for example, M3.
4.2 | Lipid profiling
PUFAs and their bioactive derivatives play important roles during
cell proliferation and differentiation (Bieberich, 2012; Kim, Kim, Kim,
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Kim, & Han, 2009). It has previously been shown that the addition of
certain FAs, such as docosahexaenoic acid (22:6 n‐3) or eicosapen-
taenoic acid (20:5 n‐3), to the media could promote neuronal
differentiation in neuronal stem/progenitor cells through the regula-
tion of the cell cycle (Katakura et al., 2013). Furthermore, a definite
mixture of FAs induces adipocyte‐like differentiation of osteosarco-
ma cells through the activation of peroxisome proliferator‐activated
receptors (Diascro et al., 1998). It is known that the endogenous
capacity of cultured cells to modify PUFAs for their needs can
partially compensate for suboptimal supply from the microenviron-
ment and culture medium (Zhang, Kothapalli, & Brenna, 2016). A
simplified schematic figure of the metabolic pathways of SFAs,
MUFAs, and PUFAs and the genes involved is presented in Figure 6c.
PHHs possess an excellent capacity to metabolize diet‐derived
PUFAs (Sprecher, 2000). Most of our HLC lines expressed the key
enzymes in the metabolism of FAs at similar levels to the PHHs. The
HepG2 cells, however, varied significantly in most of the studied
enzymes compared with the PHHs. This indicates that HLCs are
superior cell models for studying the FA metabolism of the liver
compared with HepG2 cells.
Our analysis revealed that PHHs contain a considerably larger
proportion of PUFAs compared with HLCs and HepG2 cells. The high
percentage of 18:2n‐6 in the PHHs reflects the very rich supply of
18:2n‐6 from the medium, part of which was apparently converted to
20:4n‐6 by the cells using the FADS2, ELOVL5, and FADS1 enzymes.
Even though the 18:2n‐6 level in the HLCs medium was very low,
these cells were able to efficiently produce 20:4n‐6, suggesting the
proper expression of FADS2, ELOV5, and FADS1. Interestingly, the
main n‐3 PUFA, 22:6n‐3, was also detected in the HLCs with levels
only 1.8‐fold lower than in the PHHs, despite only trace amounts of
n‐3PUFAs in their medium. This result means that either the n‐
3PUFAs of HLCs originate from previous conditions (hepatoblast
stage), or alternatively, these cells selectively and efficiently take up
and incorporate 22:6n‐3 into their lipids. The HepG2 cells received
22mol% PUFAs from their medium, whereas the HLCs received only
6mol%. In addition, the HepG2 medium was rich in the total FA
content. Despite this, the relative levels of PUFAs in the HepG2 cells
remained low (11mol%) compared with the levels in the PHHs
(29mol%) and HLCs (15mol%). The overloading of the HepG2 cells
with the medium lipids and the consequent high content of neutral
lipids (harboring fewer PUFAs than the structural PL) of the cells may
have resulted in a relatively PUFA‐poor FA composition in their total
lipids.
In deficient states, endogenous synthesis of the 20:3n‐9 from
18:1n‐9 occurs (Kamada et al., 1999). It is of note that the HLCs and
HepG2 cells both contained 2–3mol% of n‐9 PUFAs (20:2n‐
9 + 20:3n‐9), which means that the cells suffered from essential
PUFA deficiency. The large supply of 18:2n‐6 in the PHH medium,
however, prevented them from producing any significant amounts of
n‐9 PUFAs. PUFAs have been shown to be important in the
maturation and functionality of HLCs (Kiamehr et al., 2017).
Therefore, we propose that providing HLCs with a PUFA‐rich
medium may help to produce HLCs with a lipid profile even closer
to PHHs. A high supply of PUFA to PHHs inhibits their endogenous
MUFA synthesis from SFAs (Ntambi, 1999). Likewise, in our study,
the total MUFA in the PHHs remained low compared to the HLCs
and HepG2 cells. The lower the PUFA totals, the higher the MUFA
totals were at the expense of the SFAs.
Hepatocytes can uptake FAs from the cell culture medium.
Simultaneously, hepatocytes are able to produce FAs by hydro-
lyzing glucose to pyruvate, which links glycolysis to lipogenesis
where pyruvate is used to synthesize FAs through de novo
lipogenesis (Rui, 2014). Glucokinase (encoded by GCK gene) is
central to the glucose homeostasis and is the key enzyme involved
in the first step of glycolysis. Changes in hepatocyte GCK
expression represent an adaptive action to impaired glucose/lipid
metabolism to maintain glucose homeostasis (Massa, Gagliardino,
& Francini, 2011). In our study, there were no significant
differences in the expression of GCK between the HLCs and the
PHHs. However, the HepG2 cells expressed GCK at statistically
significantly lower levels than the PHHs, which is in line with
previous findings at protein level (Wiśniewski, Vildhede, Norén, &
Artursson, 2016). FASN is a major determinant of the capacity of a
tissue to synthesize FAs de novo, and palmitate (16:0) is its
primary product (Figure 6c; Jensen‐Urstad & Semenkovich, 2012).
Again, most HLC lines expressed FASN equally to the PHHs,
whereas the HepG2 cells had clearly higher expression levels. The
high expression of FASN in the HepG2 cells has also been observed
earlier (Huang & Lin, 2012). The relative activities of SCD and
ELOVL dictate whether the metabolism of 16:0 follows the route
16:0–16:1n‐7–18:1n‐7 or the route 16:0–18:0–18:1n‐9 (Glück,
Rupp, & Alter, 2016). In the former route, the SCD activity is
higher than the ELOVL activity, and in the latter route, the ELOVL
activity is higher than the SCD activity. Clearly, among the cells
analyzed, the route forming 18:1n‐7 was the most active in the
HepG2 cells. This feature differentiates the HLCs and HepG2 cells
and shows that the MUFA‐producing pathway in HLCs resembles
that found in PHHs. The elevated cellular contents of 16:1n‐7 and
high SCD activity appear to promote de novo lipogenesis, which
could partially explain the large neutral lipid stores of the HepG2
cells (Hodson & Fielding, 2013).
4.3 | FAs mirrored in molecular species
We observed that the PL species profile of cells was highly affected
by the culture medium. The PHHs’ lipid profile reflected the high
medium supply of 18:2n‐6, which after uptake was metabolized to
20:4n‐6 and incorporated into the PLs. Consequently, the PLs
composed of 16:0–18:2, 18:0–18:2, 16:0–20:4, and 18:0–20:4 were
abundant in the PHHs. The much lower supply of 18:2n‐6 to the
HLCs and HepG2 cells kept the levels of the above‐mentioned PL
species low. However, the HLCs could still actively synthesize 20:4
and couple this PUFA with SFAs and MUFAs. To compensate for the
overall PUFA deficiency, the HepG2 cells produced more MUFAs
(observed in high levels of 18:1n‐7), which is reflected in species such
as 16:0–18:1 and 18:1/18:1. The HLCs instead compensated for the
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PUFA shortage by uptaking 18:1n‐9, which was abundant in their
medium.
In general, the HLCs and HepG2 cells contained lower concen-
trations of Cer and higher concentrations of LacCer, Glc/GalCer, and
Gb3 when compared with the PHHs. Cer synthesis is a complex
process orchestrated by six CerSs (CerS1–CerS6), each of which
synthesizes Cers with distinct FA chain lengths (Cingolani, Futerman,
& Casas, 2016). Cer has important structural and signaling roles
(Gault, Obeid, & Hannun, 2010). It has been shown that at time of
cellular stress, the generation of C16:0‐ceramide via CerS5 is
proapoptotic, whereas synthesis of C24:0‐ceramides via CerS2 is
prosurvival (Mesicek et al., 2010), and the balance between these
long‐ and very‐long‐chain Cers is critical for cellular homeostasis. In
our study, similar levels of d18:1/16:0 were observed in all three cell
types, but the PHHs had significantly higher levels of d18:1/24:0
(Figure 5a). Transferring the PHHs from a physiological environment
to an artificial 2D system could be stressful for them. Therefore, it is
intriguing to speculate whether the survival or antiapoptosis
mechanism is turned on in PHHs. On the other hand, HepG2 cells
might suppress the apoptotic Cer signal by converting Cer to
complex GSLs, leading to lowered levels of Cer in HepG2 cells.
Overall, the interpretation of the observed Cer profile of the studied
cell types is very complicated and demands further studies.
The UDP‐glucose ceramide glucosyltransferase (UGCG) gene
encodes the enzyme UDP‐glucose Cer glucosyltransferase, which
catalyzes the first glycosylation step in the biosynthesis of GSLs. The
product of this reaction is glucosylceramide, which is the core
structure of many GSLs, including Glc/GalCer (Tokuda et al., 2013).
We have previously reported a higher expression of UGCG in HLCs
compared with PHHs (Kiamehr et al., 2017), which correlates well
with our lipidomics findings of high Glc/GalCer in HLCs. In the C24
species of every sphingolipid class, the ratio of the 24:0 species to the
24:1 species was higher in the PHHs than in the HLCs or HepG2 cells.
This may reflect the dominance of 24:1n‐9 over 24:0 in both the HLC
and HepG2 media and the reversed ratio of these trace MUFAs in the
PHH medium.
The PHHs were cultured in a low FA medium. As a result, the
PHHs contained low levels of CE in their cellular lipid profile. Unlike
the PHH cells, the HepG2 cells—which were grown in FA‐rich
medium—accumulated a large amount of the neutral storage lipids
CE and TAG, the latter being represented via its hydrolysis product
DAG. As is normal for cultured cells, the highest CE species was 18:1,
followed by 16:0 and 16:1, and there were also traces of various
other species. In line with the CE profile, the HepG2 cells contained
large amounts of DAG, chiefly 16:0–18:1 and 18:1/18:1. The HLCs
also showed an accumulation of neutral lipids (although milder than
in the HepG2 cells), which is likely due to their treatment with an FA‐
rich medium at the hepatoblast stage (Day 6 to Day 12; Kiamehr
et al., 2017). Therefore, our work reveals the need to revise the
generally overlooked FA content of culture media and to tailor it
according to the HLCs’ needs. In addition, we propose that increasing
the supply of PUFA in the culture medium may positively affect the
lipid profile and functionality of the HLCs.
To our knowledge, this is the first comparative study that
considers the effects of various stimuli from different protocols on
the differentiation and phenotype of HLCs. We are also the first to
show the detailed lipid profile of HLCs and to evaluate their ability to
metabolize FAs. Taken together, HLCs differentiated from hiPSCs
provide the advantage of direct studies of cellular and molecular
mechanisms that regulate lipid homeostasis in the liver. They also
facilitate a novel platform for the discovery, optimization, and study
of the modes of action of molecules modulating key lipids. This
platform would allow the functional assessment of the impact of
genetic variations in developing metabolic diseases, such as athero-
sclerosis.
5 | CONCLUSIONS
HLCs mimicked the lipid profile of PHHs very well and, thus, showed
to be a better liver cell model than HepG2 cells, especially in terms of
their low LPL content. HLCs were capable of metabolizing FAs to
produce C20–22 highly unsaturated FAs to fulfill the complex
biological functions mediated by those FAs. By improving the PUFA
supply in the medium, we can produce HLCs, which can serve as a
powerful and functional cell model to study patient‐specific
mechanisms in lipid aberrations leading to pathological states, such
as atherosclerosis or fatty liver disease.
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